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With 33.4 million people infected with human immunodeficiency virus (HIV) in 2008, HIV
infection has developed into a serious global pandemic. The impact of the epidemic is most
severe in developing countries, such as the countries in Sub-Saharan Africa, where social and
economic conditions in these regions affect the availability of antiretroviral treatments. The
control of the epidemic in these regions could be achieved with an effective HIV vaccine. The
urgent need for an efficacious HIV vaccine as well as the requirement for vaccine vectors for
other infectious diseases, provide the rationale for research into novel vaccine vectors that are
both safe and efficacious.
Lumpy skin disease virus (LSDV) Neethling strain, a capripoxvirus with host range limited to
ruminant animals, is unable to complete its replication cycle in human cells. LSDV has been
demonstrated to be a safe and effective veterinary vaccine vector for lumpy skin disease as well
as a vaccine vector for other infectious diseases of animals. In this thesis LSDV was
investigated to determine if it would be a suitable HIV vaccine vector. As no data was available
on the safety profile of LSDV in immunocompromised hosts, the safety of wtLSDV was
evaluated in two strains of immunocompromised mice in this study. This study also describes
the construction of a recombinant LSDV, rLSDV-Grttn, expressing an HIV-1 subtype C
polyprotein, Grttn, (comprised of Gag (G), reverse transcriptase (RT), Tat and Nef) and the
testing of this recombinant for immunogenicity to Grttn in BALB/C mice.
Immunocompromised mice (RAG and CD4 knockout) survived during a 30 day observation
period after vaccination with wtLSDV (104 ffu and 106 ffu/mouse) and did not experience any
significant weight change or change in well being compared to naïve control mice during this
period.
rLSDV-Grttn was constructed through introduction of the Grttn gene into the ribonucleotide
reductase gene of LSDV. Stable Grttn expression (from the VVmH5 promoter) was confirmed
by Western Blot analysis and PCR analysis showed the final rLSDV-Grttn preparation to be free
from wild type LSDV.
Immune responses to this candidate vaccine were investigated using female BALB/c mice.
rLSDV-Grttn was investigated as an individual vaccine and in prime/boost combinations with a
DNA vaccine,  pVRCgrttnC, or a recombinant MVA, MVA-Grttn, vaccine. Both vaccines











immune responses induced by these regimens were evaluated with IFN-γ and IL-2 ELISPOT
assays and CD8+ T cell MHC-I peptide pentamer binding assays. The presence of Gag-specific
antibodies in the sera of vaccinated mice was assessed using the LAVBlot I assay. (NO RT data
given)
rLSDV-Grttn alone was shown to induce low cumulative Gag- and RT-specific IFN-γ (131 net
SFU/106 splenocytes) and IL-2 (50 net SFU/106 splenocytes) ELISPOT responses. These
responses were enhanced when rLSDV-Grttn was used as a boost after a prime with
pVRCgrttnC (607 and 110 net IFN-γ and IL-2 SFU/106 splenocytes respectively).  However the
IFN-γ and IL-2 ELISPOT responses induced by pVRCgrttnC primed/ rMVA-Grttn boosted
mice were 2.2-2.5 times higher (1529 and 245 net SFU/106 splenocytes respectively) than
pVRCgrttnC primed/rLSDV-Grttn boosted mice. When rLSDV-Grttn was evaluated in
heterologous prime/boost vaccination regimens with rMVA-Grttn, Gag- and RT-specific
cumulative IFN-γ and IL-2 ELISPOT responses were higher than that of the pVRCgrttnC
prime/rMVA-Grttn boost regimen. A rLSDV-Grttn prime and rMVA-Grrtn boost induced Gag-
and RT-specific cumulative IFN-γ and IL-2 ELISPOT responses of 3067 and 449 net SFU/106
splenocytes respectively. The reverse regimen i.e. rMVA-Grrtn  prime/ rLSDV-Grttn boost,
induced similar Gag- and RT-specific cumulative IFN-γ and IL-2 ELISPOT responses of 2593
and 748 net SFU/106 splenocytes respectively. Binding of pentameric H-2Dk complexes folded
with the Gag AMQMLKDTI peptide and the RT peptide VYYDPSKDLIA to CD8+ T cells in
the spleens of the mice was used to assess the total number of HIV-specific CD8+ T cells
generated by the heterologous poxvirus vaccination regimens. When rLSDVGrttn was the
booster vaccine the sum of Gag- and RT- specific CD8+ T cells reached a frequency of 4.6% of
the CD8+ T cells while this frequency was 7% of the CD8+ T cells when rMVAGrttn was the
booster vaccine. Approximately 98% of these HIV-specific CD8+ T cells for both vaccination
regimens expressed CD44 confirming these cells to be antigen experienced. The degranulation
marker CD107a/b was also expressed on the majority of these HIV-1 specific CD8+ T cells
(>75%). Comparison of this direct enumeration of HIV-specific CD8+ T cells with the
enumeration of HIV-specific CD8+ T cells producing IFN-γ and IL-2 using ELISPOT assays,
suggested that these vaccine regimens also induce HIV-specific CD8+ T cells that produce
cytokines other than IFN-γ and IL-2. Gag-specific antibody was also produced in all rLSDV-
Grttn/rMVA-Grttn heterologous prime-boost vaccination regimens.
In summary, LSDV Neethling strain has been shown to be a safe vaccine vector, even in in vivo
immunocompromised settings. rLSDV-Grttn that was constructed was immunogenic in BALB/c











vaccination regimens with rMVA-Grttn. These observations indicate that rLSDV-Grttn could be
a novel and safe candidate HIV-1 subtype C vaccine, to be used in combination with
recombinant MVA vaccine to induce HIV-1 immune responses that could be superior to the
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1.1.1 The need for an HIV-1 vaccine
Since the initial isolation of the Human immunodeficiency virus (HIV) in 1983 (Barre-Sinoussi
et al., 1983; Gallo et al., 1983), HIV infection has developed into a serious global pandemic.
According to the UNAIDS 2009 reports (UNAIDS, 2009), the numbers of people infected with
HIV and who have died from HIV-related causes are estimated to be 60 million and 25 million
people respectively since the discovery of the virus. In 2008, it was estimated that 33.4 million
people were infected with HIV and there were 2 million HIV-related deaths globally.  According
to the estimated data from UNAIDS, there is a trend of stabilisation of the HIV pandemic,
reflecting the impact of antiretroviral treatment and changes in sexual behaviour of certain
population groups; however, high numbers of newly infected individuals (2.7 million) and cases
of Acquired immune deficiency syndrome (AIDS) related deaths (2 million) were still observed
in 2008. Although anti-retroviral therapy has a significant impact on limiting HIV transmission
and controlling disease progression, it has had limited impact on developing countries where
resources of antiretroviral drugs are limited (Giuliano & Vella, 2007; UNAIDS, 2009) . It is
these regions which are worst affected by the HIV pandemic, in particular, Sub-Saharan Africa,
which is the most affected region by the pandemic (Figure 1.1).  This region accounts for 67%
of the global HIV infected population and 70% of the AIDS related deaths globally.  HIV-1
infections have lowered the average life expectancy in Sub-Saharan Africa to below 50 years
and, up until 2008, HIV-1 related deaths have orphaned nearly 14 million children in Sub-
Saharan Africa (UNAIDS, 2009) . Consequently, huge social and economic burdens have been
created in this region (Mosam & Dlova, 2006). Although there has been an increase in the
availability of anti-retroviral therapy within this region and a significant reduction in HIV-
related deaths over the past six years (UNAIDS, 2009), the HIV pandemic remains uncontrolled
in the region. Drawbacks of antiretroviral treatment including cost, diagnosis of stages of HIV-
associated clinical disease, toxicity and drug resistance have limited the effect of the treatment











Figure 1.1 Schematic representation of global HIV-1 prevalence in 2008 (UNAIDS, 2009). The different
shades of blue represents different prevalence population categories in millions people.
An effective prophylactic or therapeutic HIV vaccine that can either prevent HIV infection or
delay disease progression to AIDS is urgently needed. Vaccination has been demonstrated to be
the most effective preventative measure against infectious diseases, as was shown in the
successful eradication of smallpox (Henderson, 1980) and the ongoing polio and measles
vaccination campaigns (de Quadros et al., 1998; Rey & Girard, 2008).
1.1.2 Evidence supporting the use of a vaccine to control the HIV-1 epidemic
1.1.2.1 Evidence from control of natural HIV-1 infection in humans
The potential ability to control the HIV-1 epidemic by vaccination is supported indirectly by
what has been observed to occur in the natural course of infection with HIV-1, with respect to
the specific immune response elicited by the host and its ability to control HIV-1 replication and
disease progression.
The typical clinical progression of HIV-1 infection is illustrated in Figure 1.2. During the early
stage of HIV-1 infection there is a burst of viraemia approximately 3 weeks post exposure. The
viral load decreases until it reaches the viral set point 2 to 6 months post exposure. The
reduction of viral load is believed to be attributed to the HIV-1 specific immune responses
elicited by mainly the cytotoxic CD8+ T lymphocyte response (CTL) (Johnston & Fauci, 2007;











Figure 1.2 Schematic representation of typical clinical progression of HIV-1 viral RNA and HIV-1 specific CTL in
HIV-1 infected individuals (Johnston & Fauci, 2007).
Long term control of HIV-1 replication and disease progression exist in small groups of
individuals in the general population. These individuals, termed HIV-1-infected elite controllers,
exhibit spontaneous control of HIV-1 infection (Buchbinder et al., 1994; Pereyra et al., 2008).
Despite the absence of antiretroviral treatment, these individuals were able to control the HIV-1
plasma viral load to <50 copies/ml for at least 12 months. The immune correlation to the control
of disease progression remains unclear; however, studies have indicated that most of these
individuals preferentially exhibit  HIV-1 Gag-specific CTL responses and enhanced
polyfunctional T cell functions (by cytokine secretions), which may contribute to their ability to
contain HIV-1 replication (Miura et al., 2009; Pereyra et al., 2008).
Human leukocyte antigen class 1 (HLA-1) molecules are known to be associated with antigen
presentation to cytotoxic CD8+ T lymphocytes. Certain HLA class I molecules, such as HLA-
B57, B5801 and B27 are over-represented in elite controllers (Migueles et al., 2000; Pereyra et
al., 2008) and are associated with control of HIV-1 related disease progression. These HLA class
I molecules recognize unique Gag epitopes and exert selection pressure for escape variants with
compromised viral fitness (Miura et al., 2009). A large percentage of the elite controllers also
express other HLA class I molecules that are not associated with viraemic control (Pereyra et al.,
2008). CD8+ T cell responses preferentially targeting Gag epitopes have been observed in most
of the elite controllers, while the CD8+ T cell responses of progressors were found to be more
broadly distributed across the different HIV-1 proteins (Pereyra et al., 2008). Elite controllers











(Pereyra et al., 2008). Strong CTL responses against the escape variants help to delay the
disease progression (Miura et al., 2009). A strong HIV-1 neutralizing antibody response was not
observed in the elite controllers, demonstrating that neutralizing antibody may not be critical to
HIV-1 viraemic control (Pereyra et al., 2008). It must be noted that the responses observed in
the individuals in the elite controller groups were heterogeneous and none of the observations
can be used to accurately predict the clinical outcome of HIV-1 infection.
These findings not only provide evidence that immunological control of HIV-1 replication is
possible with the use of a vaccine; they also provide direction for future HIV-1 vaccine design.
1.1.2.2 Evidence from vaccine induced protection in non-human primates
More direct evidence indicating the effectiveness of the use of vaccines in the prevention and
control of HIV-1 replication has been presented in several pre-clinical studies using simian
immunodeficiency virus (SIV) or chimeric SIV expressing HIV-1 Env (SHIV) in non-human
primate (NHP) models (Genesca et al., 2008; Jia et al., 2009; Reynolds et al., 2008; Whitney &
Ruprecht, 2004; Yankee et al., 2009).
Neutralizing antibodies have been demonstrated to be effective in preventing infection and for
control of viral replication (Chaudhri et al., 2006; Hessell et al., 2009; Johnson et al., 2009;
Mack et al., 1972; Panchanathan et al., 2006; Panchanathan et al., 2008; Trkola et al., 2008).
However, no HIV-1 vaccine candidate has yet successfully elicited broadly neutralising antibody.
Nevertheless, the protective property of neutralising antibody has been demonstrated in NHP
models; by passive introduction of SIV- or SHIV-specific neutralizing antibodies into rhesus
macaques, the viral set point was reduced, CD4+ T cells were preserved and the macaques were
protected against pathogenic SIV (SIVmac239) and SHIV infection respectively (Nishimura et
al., 2003; Ruprecht, 2009; Yamamoto et al., 2007).
Complete or partial protection from lentivirus infection afforded by live attenuated SIV
vaccination was also demonstrated in NHPs (Genesca et al., 2008; Jia et al., 2009; Reynolds et
al., 2008; Whitney & Ruprecht, 2004; Yankee et al., 2009). Rhesus Macaques vaccinated with
live attenuated SIV were completely protected from a challenge of the pathogenic wild-type SIV
(the strain from which the vaccine was derived) (Daniel et al., 1992). Partial protection, which
resulted in lower plasma viral load, was also achieved in the attenuated SIV vaccinated
macaques challenged with heterologous strains of pathogenic SIV and SHIV (Jia et al., 2009;
Wyand et al., 1996; Wyand et al., 1999). Investigation into the NHPs immune responses











macaques, which correlated with that observed in human elite controllers. This may be
attributed to the timing of HIV-1 specific gene expression. Presentation of Gag epitopes by
infected CD4+ T cells to CD8+ T cells occurred approximately 2 hours post infection, while the
presentation of Env epitopes only occurred after the de novo synthesis of the Env protein much
later in the course of infection (Mansfield et al., 2008; Sacha et al., 2007). This implies that the
Gag in the virus may be presented before de novo synthesis of the protein.
The protection against human or simian lentiviruses afforded by the host immune responses or
vaccination provides proof of principle that the control or even prevention of HIV-1 infection is
possible with the appropriate vaccine.
1.1.2.3 Evidence from the RV144 Phase 3 efficacy trial in Thailand
Currently there has only been one HIV vaccine efficacy trial that has shown moderate protection
from HIV infection (Rerks-Ngarm et al., 2009). The vaccine regimen used in the trial was
comprised of 4 priming vaccinations of recombinant canarypox virus ALVAC-HIV and two
boosting vaccination of recombinant gp120 protein AIDSVAX B/E. The vaccine regimen
efficacy analysis was evaluated in 8197 test subjects who received vaccination and 8198 test
subject who received placebo. The analysis has shown that the vaccine regimen has a moderate
protective efficacy of 31% when the number of HIV-1 infections in the vaccinated group and the
placebo group were compared. However the vaccine regimen did not induce a reduction in HIV-
1 viremia or CD4+ T cell loss in those vaccinated subjects who later became infected with HIV-
1. The correlates of protection from this trial are still being determined (Rerks-Ngarm et al.,
2009).
1.1.3 Challenges of HIV-1 vaccine development
Twenty-five years have passed since HIV-1 was described (Barre-Sinoussi et al., 1983; Gallo et
al., 1983); there has been only one clinical trial that has shown a low level of protection from
HIV infection (Rerks-Ngarm et al., 2009). This vaccine is not good enough to market and so
there is still no efficacious HIV-1 vaccine commercially available, despite numerous studies and
clinical trials carried out in the field of HIV-1 vaccine research (Corey et al., 2009; Flynn et al.,
2005; McElrath et al., 2008; Pitisuttithum et al., 2006). The absence of an ideal HIV-1 vaccine
may be attributed to various scientific obstacles and the natural immune evasive mechanism of
HIV-1. An ideal HIV-1 vaccine would be able to prevent HIV-1 infection by stopping the
systemic establishment of the virus and would protect individuals against a wide range of HIV-1
isolates. This would most probably be achieved by a vaccine eliciting both cellular and humoral











et al., 2005; Pitisuttithum et al., 2006; Robertson et al., 2008).
1.1.3.1 HIV diversity
HIV is thought to be derived from SIV, a virus of chimpanzees, which crossed species and
became adapted to humans (Gao et al., 1999). There are two types of HIV, HIV-1 and HIV-2.
For the purpose of this thesis, only HIV-1 will be discussed as this is the prevalent HIV type in
South Africa. HIV-1 is subdivided into three different groups, Major (M), Outlier (O) and Non-
major and non- outlier (N) (Korber et al., 2000), based on the differences in their genomes.
Most of the circulating HIV-1 belongs to the group M. Group M is further divided into different
subtypes or clades - A, B, C, D, F, G, H, J and K. Genetic variability between these subtypes are
not evenly distributed throughout the genome. Genetic sequence variability within a subtypes is
approximately 15%–20%, and between the subtypes 25%-35%, with the highest variability
found in the Env sequences (Hemelaar et al., 2006; McCutchan, 2000). The diversity in HIV-1
is mainly due to the high mutation rate resulting from the lack of proof-reading activity in the
viral reverse transcriptase (RT) enzyme (Mansky & Temin, 1995). Genetic recombination also
occurs between subtypes, as demonstrated by phylogenetic analysis of certain HIV-1 isolates
(Hemelaar et al., 2006; Robertson et al., 1995). Genetic analysis has revealed clustering of
differences within the genome. These clusters are found in different HIV-1 subtypes suggesting
that recombination occurred between different subtypes, probably in individuals infected with
multiple subtypes of HIV-1. These mosaic HIV-1 isolates are termed circulating recombinant
forms (CRFs) (Robertson et al., 1995).
The epidemiology of HIV-1 has shown that subtypes are not evenly distributed throughout the
world, but that different HIV-1 subtypes dominate specific geographical regions (Figure 1.3).
The predominating subtype in a region is determined either by a founder effect or by the
transmission route common in the region. The most predominant subtypes are A, B and C
(McCutchan, 2000; Peeters & Sharp, 2000). Subtype A predominates in regions such as eastern
and central Africa and eastern European countries. Subtype B predominates in western and
central Europe, America and Australia. Subtype C predominates in Sub-Saharan Africa, Russia
and China. Several CRFs are becoming increasingly prevalent in certain areas - CRF01-AE and
CRF02-AG are the recombinant isolates predominantly found in South East Asia and the
western part of Central Africa respectively (McCutchan et al., 1999; Motomura et al., 2000;











Figure 1.3 Global distributions of HIV-1 subtypes and recombinant forms (Taylor et al., 2008).
The evolving diversity of HIV-1 presents a major obstacle and a moving target for developing an
ideal HIV-1 vaccine that will be effective against most circulating strains. Although intra- and
inter-subtype CTL cross-reactivity has been observed in HIV-1 infected patients (Brown et al.,
2006b; Thakar et al., 2005), the magnitude and breadth of these responses are generally limited
(McKinnon et al., 2005). Most of the vaccine candidates designed to date have targeted single
HIV-1 subtypes that dominate a specific region. However, two strategies have been deployed in
the field of vaccine antigen design to try and overcome the problems of HIV-1 diversity. The one
strategy entailed designing vaccine antigens from inter-subtype consensus or ancestral
sequences, so that an immune response could be elicited to conserved and common epitopes
within these subtypes (Bansal et al., 2006; Malm et al., 2005; Santra et al., 2008). The other
strategy entailed co-administering a mixture of vaccine vectors expressing antigens derived from
different HIV-1 subtypes. Both strategies induced broad immune responses in mice and NHPs
against multiple clades of HIV-1 (Brave et al., 2007; Seaman et al., 2005)
1.1.3.2 HIV-1 immune evasive mechanisms
The HIV-1 genome consists of nine open reading frames encoding structural proteins (Gag and
Env), enzyme (Pol) and regulatory (Tat and Rev) and accessory (Vpr, Vpu,Vif and Nef) proteins
(Tripathi & Agrawal, 2007). The structure of the HIV-1 virion is shown in Figure 1.4. The
envelope proteins are positioned on the outside of the HIV-1 virion. The precursor env protein











protease. gp120 is non-covalently associated with gp41 to form heterodimers. These
heterodimers are organized into trimeric “spikes” that are anchored on the viral surface
membrane (Kowalski et al., 1987; Weiss et al., 1990). These glycoproteins are essential for
binding to membrane receptors on the target cells and facilitating the fusion between viral
membrane and cell plasma membrane, allowing the entry of the HIV-1 virion into the cells
(Chan & Kim, 1998; Weissenhorn et al., 1999; Wyatt & Sodroski, 1998). The interaction
between gp120, CD4 receptor and co-receptors such as chemokine receptors CCR5 and CXCR4
on CD4+ T cells (Berson et al., 1996; Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996),
triggers a change in conformation of the trimeric complex and exposes the hydrophobic binding
surface of gp41 to the host plasma membrane (Hart et al., 1991; Jones et al., 1998).
Because of the positioning of Env proteins on the surface of the virus and the critical role of
these glycoproteins in viral entry into the target cells, they serve as primary targets for
neutralizing antibody and CTL responses of the host to prevent and clear HIV-1 infection.
However HIV-1 exhibits several evasive mechanisms to escape the host immune responses. The
outer surface of gp120 is heavily glycosylated with N-linked glycan (Leonard et al., 1990), and
forms a glycan shield that blocks the binding of neutralizing antibody. The glycosylation on Env
protein is an evolving mechanism. Mutation in the Env gene can shift the glycosylation sites on
this protein and thus change the organization pattern of the glycan shield. The conformational
change in glycan shield pattern can mask neutralizing antibody binding sites and allow the virus
to escape without compromising the viral fitness (Wei et al., 2003). Certain critical neutralizing
antibody epitopes are buried within the trimeric structure of gp120 and masked by variable
regions such as V1 and V2, and can only be exposed during the conformational changes
triggered by gp120-cellular receptor binding (Kwong et al., 1998; Wyatt et al., 1998).











Gp120 consists of variable regions such as V1-V5, which form loops on the surface of the
glycoprotein and shield the conserved core region of gp120 (Kwong et al., 1998). These
hypervariable regions direct the host antibody responses to these regions, so allowing escape-
mutations to  occur without compromising viral fitness (Burton et al., 2004).
HIV-1 specific CTL responses have been shown to correlate with successful HIV-1 replication
control during acute and chronic phase of the infection. However, because of the lack of proof
reading ability of the RT of HIV-1, mutations are generated at a remarkably high rate of
approximately 3 x 10-5/ nucleotide bases per cycle of replication (Mansky & Temin, 1995). The
fast-mutating HIV-1 genome enables the virus to escape the CTL responses. The HIV-1 specific
CTL response creates a selection pressure favouring mutated virus variants that could escape the
existing CTL response without compromising the viral fitness significantly. These variants
exhibit mutations that are involved in alteration of antigen processing and presentation of the
CTL epitopes which leads to the inability of CD8+ T cells to recognize these epitopes presented
on infected cells (Tripathi & Agrawal, 2007). This selection pressure for CTL escape variants is
further supported by the more frequent occurrence of mutations within the CTL epitopes (Moore
et al., 2002b).
HIV-1 also evades immune control by modulating the immune components of the host via  HIV-
1 proteins such as Vpr, Env and p24 (Luzzati et al., 1994; Piguet et al., 1999). The most well
investigated mechanism is that of immunosuppression mediated through HIV-1 Nef. HIV-1 Nef
protein has been documented to downregulate the expression of surface molecules such as CD4,
CD28 and MHC class I on the surface of T lymphocytes and antigen presenting cells (Atkins et
al., 2008; Swigut et al., 2001; Yang et al., 2002). The downregulation of these surface
molecules affects the interaction of the antigen presenting cell with T lymphocytes and enables
the virus to evade HIV-1 specific immune control.
During the early course of  HIV-1 infection, CD4+ T cell depletion in the gut could result in
dysfunction of the cellular and humoral responses and prevent effective HIV-1 specific immune
responses being induced (Fukazawa et al., 2008; Guadalupe et al., 2003).
These evasive mechanisms exhibited by HIV-1 create great obstacles for vaccine development
and seriously compromise the effectiveness of vaccination.
1.1.3.3 HIV-1 latency and the short window of opportunity for vaccine elicited control











transcriptase (RT) and integrase. RT reverse transcribes the HIV-1 RNA genome into double
stranded DNA (Gotte et al., 1999; Jonckheere et al., 2000; Miller et al., 1997) . The HIV-1 DNA
is then incorporated into the human genome through integrase activity (Miller et al., 1997). The
ability of HIV-1 to integrate into the genomic DNA of infected resting CD4+ T cells, enables the
provirus to remain latent and undetected from immune surveillance of CTL responses. A latent
reservoir of provirus can be established in resting CD4+ T cells (Chun et al., 1998) and
complete eradication of the virus can not be achieved, even with extensive antiretroviral therapy
which reduces plasma viral load to an undetectable level (Siliciano et al., 2003). HIV-1
establishes this latent reservoir in the early course of the infection (Chun et al., 1998). Therefore
the window of opportunity for vaccine induced HIV-1 specific immunity to prevent HIV-1
infection is relatively short, within hours to days post infection (Chun et al., 1998; Johnston &
Fauci, 2007). This further complicates vaccine development, as the ideal HIV-1 vaccine would
have to induce a systemic and mucosal memory response that could be recalled within this short
period of time to prevent the establishment of a HIV-1 latent reservoir.
1.1.3.4 Inadequate immune correlates of protection
The precise mechanisms involved in the control of HIV-1 replication in certain individuals and
the types of responses needed to be induced by vaccines to achieve this control has not been
completely defined to date. Information on the immune correlates of protection against HIV-1
infection is critical for the design of HIV-1 vaccines and the development of immunological
assays to accurately predict vaccination outcome. The lack of this information has seriously
delayed the development of an efficacious HIV-1 vaccine.
The present data available on possible immune correlates of protective responses against HIV-1
infections was obtained from studies on elite controllers (Miura et al., 2009; Pereyra et al., 2008;
Walker, 2007a; Walker, 2007b) and  rhesus macaques, which were protected from SIV infection
by live attenuated SIV vaccination (Genesca et al., 2008; Jia et al., 2009; Reynolds et al., 2008;
Whitney & Ruprecht, 2004; Yankee et al., 2009) as mentioned in section 1.1.2.
With further elucidation of the immune mechanisms involved in the protective efficacy observed
in the RV144 trial (Rerks-Ngarm et al., 2009), critical questions such as relevant immune
correlates and the effectiveness of the prime-boost vaccine regimen can be answered and used to
improve future HIV-1 vaccine designs. Presently observations such as the absence of significant
difference in HIV-1 viremia and CD4+ T cell preservation between the vaccinated and placebo
group may suggest that the immune correlate of protection may not be the same as the immune











the priming and boosting vaccinations in the trial was envelope protein gp120. This may suggest
that humoral immune response may be the immune correlate responsible for the moderate
protection efficacy observed in the RV144 trial (Rerks-Ngarm et al., 2009).
1.1.4 HIV-1 vaccine research and delivery strategies
1.1.4.1 T-cell and B-cell vaccines
HIV-1 vaccines are generally designed to elicit either a B- or a T-cell immune response, or a
combination of both. It is commonly recognized that both arms of the immune response are
essential for achieving optimum protection through vaccination against HIV-1 infection
(Gauduin et al., 1997; Humbert et al., 2008; Jin et al., 1999; Mascola et al., 2005; Pantaleo et
al., 1995; Parren et al., 2001; Rowland-Jones et al., 1998; Schmitz et al., 1999). B-cell vaccines
usually carry envelope proteins as the vaccine antigen in order to induce neutralizing antibodies
whereas T-cell vaccines usually carry HIV-1 Gag and RT or other regulatory proteins against
which a cell mediated immune response can be elicited.
1.1.4.1.1 B-cell vaccines
The ability to elicit broadly neutralizing antibodies that could neutralise a broad spectrum of
HIV-1 isolates remains one of the major obstacles in B-cell vaccine research (Flynn et al., 2005;
Pitisuttithum et al., 2006). This is due to the HIV-1 hypervariability in its Env region and its
immune evasive mechanisms against host neutralizing antibody responses mentioned in 1.1.3.1
and 1.1.3.2. However, broadly neutralizing antibodies still exist in vivo in HIV-1 infected
patients (Burton et al., 1991; Ferrantelli et al., 2004b; Pantaleo et al., 1995). Amongst these,
only a small percentage of neutralizing antibodies alone or in combination, can neutralize virus
isolates from different clades in vitro (Binley et al., 2004; Ferrantelli et al., 2004a; Kitabwalla et
al., 2003; Walker et al., 2009; Xu et al., 2001). Nevertheless, this observation still provides
support for the possibility of eliciting broadly neutralizing antibody by vaccination.
Passive immunization of broadly neutralizing antibodies in macaques provided complete
protection against virulent SHIV challenges (Ferrantelli et al., 2004b; Ferrantelli et al., 2004a;
Mascola et al., 1999; Parren et al., 2001; Veazey et al., 2003). These results support the
importance of neutralizing antibodies to achieve complete protection against HIV-1 infection
and the possibility of discovering the protective epitopes by studying the targets of these broadly
neutralizing antibodies. The interactions between these antibodies and their target HIV-1
epitopes have provided important information that could improve antigen design for future HIV-











sites on gp120 and gp41. These include CD4 binding sites on gp120 recognized by neutralizing
antibody b12 and F105 (Posner et al., 1991; Saphire et al., 2001), mannose residue on gp120
recognized by neutralizing antibody 2G12 (Calarese et al., 2005) and membrane proximal
external region of gp41 recognized by neutralizing antibodies 4E10 and 2F5 (Cardoso et al.,
2005; Zwick et al., 2005). Functional constraints on these epitopes for receptor binding, may
prevent hypervariability in these regions.  However, some of these epitopes are hidden in their
normal protein configuration and are only transiently available after structural change during
binding and fusion to the target cells. This feature allows the virus to avoid immune surveillance
by the host (Kwong et al., 1998; Wei et al., 2003; Wyatt et al., 1998). Some neutralizing
antibodies have been demonstrated to be autoreactive to host protein such as cardiolipin (Haynes
et al., 2005). These observations may explain why HIV-1 specific neutralizing antibody
responses are not easily generated, neither through infection nor vaccination.
Different approaches have been investigated to try and improve the ability of B-cell vaccines to
elicit broadly neutralizing antibody responses. One of the approaches was to investigate the
protective epitopes targeted by broadly neutralizing antibodies. The technique of phage display
peptide libraries for the production of mimotopes that mimic HIV-1 env epitopes, has been used
as a high throughput screening method for elucidating the protective epitopes targeted by
neutralizing antibodies (Humbert et al., 2008). Mice primed with a DNA vaccine encoding HIV-
1 gp160 and boosted with phage expressing mimotopes targeted by neutralizing antibodies,
induced neutralizing antibodies and can neutralize both HIV-1 subtype B and subtype C isolates
(Humbert et al., 2008).  Another approach involves the generation of modified HIV-1 surface
molecules that are stable intermediate complexes that would expose the normally concealed
epitopes such as the CD4 binding sites on gp120 for antibody binding (Banerjee et al., 2009;
Bontjer et al., 2009; Douek et al., 2006; Wu et al., 2009) .
A role for non-neutralizing antibodies in the protective response against HIV-1 has also been
suggested (Hessell et al., 2007). Despite the absence of neutralizing activity against HIV-1
isolates in in vitro neutralization assays, the Fc region of these antibodies are required for the
antiviral responses against HIV-1, mediated through complement binding to Fc receptors to
induce lysis or phagocytosis of antibody-bound viruses (Banki et al., 2005; Huber et al., 2006;
Huber et al., 2008; Willey & asa-Chapman, 2008).
1.1.4.1.2 T-cell vaccines
The failure in HIV-1 vaccine research thus far to produce a successful B-cell vaccine that can
elicit HIV-1 specific broadly neutralising antibodies (Flynn et al., 2005; Pitisuttithum et al.,











viral load and disease progression in elite controllers (Buchbinder et al., 1994; Pereyra et al.,
2008), has provided the rationale for developing HIV-1 T-cell vaccines that are designed to
induce effective HIV-1 specific cellular immunity. T-cell vaccines may not be able to prevent
HIV-1 infection upon exposure, but ideally would be able to induce effective immune responses
to control the dissemination of HIV-1 and delay the disease progression of HIV-1 infected
individuals to AIDS. A decrease of only half a log of viral RNA results in a significant delay in
disease progression (Gupta et al., 2007). Even though T-cell vaccines may not prevent HIV-1
infection they should reduce the secondary transmission of HIV-1 to uninfected individuals. The
probability of HIV-1 secondary transmission is directly related to the chronic viral load level in
infected individuals. Studies have shown that sexual transmission from HIV-1 infected
individuals to their  HIV-1 negative partners is highly inefficient when their chronic plasma viral
load is below 1700 copies of viral RNA/ml (Gray et al., 2001; Quinn et al., 2000). A similar
observation was made in the case of vertical transmission from mother to child. Vertical
transmission failed when the mother’s plasma viral load was under 1000 viral RNA copies/ml
(Garcia et al., 1999). Therefore an HIV-1 T-cell vaccine that could elicit effective immune
control over acute and chronic viraemia would not only benefit the infected individuals by
delaying disease progression and the use of antiretroviral treatment, it would also have an
impact on the overall epidemic by limiting secondary transmission, even when the vaccine does
not provide sterile protection against HIV-1 infection.
There are many strategies that have been investigated for developing HIV-1 T-cell vaccines.
These vaccine candidates have provided partial protection and control of viral replication in
animal models (Barouch et al., 2000; Casimiro et al., 2005; Reynolds et al., 2008; Shiver et al.,
2002; Wilson et al., 2006). The combination of a DNA vaccine expressing SIV Gag and HIV-1
Env and a fusion protein consisting of IL2 and Fc portion of immunoglobulin, did not protect
the macaques from pathogenic SHIV89.6P infection, but was able to induce potent CTL
responses and reduce the viral set point and CD4+ T cell loss (Barouch et al., 2000). A prime
and boost combination with DNA and Adenovirus type 5 expressing SIV Gag, induced Gag-
specific cellular immunity, which was correlated to the short term control and reduction in viral
load in these macaques after SIV challenge (Casimiro et al., 2005). Macaques vaccinated with
attenuated SIV were able to reduce the initial viral replication by a level of 2 logs post challenge
with a pathogenic heterologous strain of SIV.  Furthermore, the transient depletion of CD8+ T
cells resulted in an increase in SIV replication, demonstrating that vaccine induced immune
control on SIV replication is CD8+ T cell related (Reynolds et al., 2008). The Merck adenovirus
type 5 vaccine expressing HIV-1 Gag, Nef and pol was the first T-cell vaccine candidate to be











However the trial was terminated due to the lack of efficacy in vaccinated individuals. There
were no significant differences in the level of plasma viral level between the vaccinated group
and the placebo control group. The vaccination also resulted in a higher risk of HIV-1 infection
in individuals that were positive for adenovirus type 5 before immunization, compared to the
placebo control group (Corey et al., 2009; McElrath et al., 2008). Although the outcome of the
trial was disappointing, it does not rule out the possibility of the development of a successful T-
cell vaccine.
Although the cellular immune correlation to the control of HIV-1 replication remains unclear,
there are several observations made in elite controllers that could provide clues for future T-cell
vaccine designs. Elite controllers exhibit increased frequency of polyfunctional HIV-1 specific
CD4+ and CD8+ T cells compared to progressors. These individuals have CD4+ and CD8+ T
cells that secrete multiple cytokines and chemokines, and degranulate simultaneously (Almeida
et al., 2007; Betts et al., 2006; Harari et al., 2007; Pereyra et al., 2008). The polyfunctionality of
the T cells are thought to be important for viremic control (Makedonas & Betts, 2006). CTL of
elite controllers preferentially target conserved epitopes in HIV-1 Gag, (Goepfert et al., 2008;
Makedonas & Betts, 2006; Miura et al., 2009; Pereyra et al., 2008; Streeck et al., 2007; Wang et
al., 2009); however, other conserved epitopes in Nef and Pol are also associated with protective
HLA allele restrictions (Wang et al., 2009).The level of protection observed in these controllers
was thought to be attributed to the strong CTL responses specific to escape variants,  which have
compromised viral fitness. Lower magnitude and fewer targeted epitopes of the HIV-1 specific
responses were observed in elite controllers compared to progressors (Pereyra et al., 2008),
indicating that a high magnitude of  HIV-1 specific CTL response is not essential for the control
of acute HIV-1 replication (Masemola et al., 2004; Pereyra et al., 2008).  The above results
suggest that an ideal HIV-1 T cell vaccine should elicit polyfunctional CTL responses specific to
conserved epitopes in Gag, although other conserved epitopes in Pol and Nef should also be
included in the vaccine to cover the HLA allele diversity in the population (Wang et al., 2009).
1.1.4.2 Different vaccine delivery systems
The protection provided by live attenuated SIV vaccination in NHPs against homologous or
heterologous strains of SIV challenge has been demonstrated to be the most promising
vaccination approach in NHPs thus far (Evans et al., 2005; Jia et al., 2009; Wyand et al., 1996;
Wyand et al., 1999). However this approach is unlikely to be adopted as a plausible strategy for
HIV-1 vaccination due to the safety concern of the attenuated HIV-1 reverting to a virulent strain,
which subsequently can cause persistent infection and disease in vaccinated individuals, as has











vaccine and challenge strains of SIV in macaques (Reynolds et al., 2008) . Other safer delivery
systems have been evaluated for the delivery of HIV-1 antigens to induce HIV-1 specific
immune responses. The different vaccine delivery systems have been extensively reviewed by
(Girard et al., 2006) and (Giri et al., 2004). These include DNA vaccines, Virus-like particles
(VLPs) (Chege et al., 2008; Chen et al., 2005; Doan et al., 2005; Hammonds et al., 2005;
Harvey et al., 2003; Zhang et al., 2004), subunit or protein vaccines (Banerjee et al., 2009;
Bontjer et al., 2009; Douek et al., 2006; Wu et al., 2009), and bacterial (Ami et al., 2005;
DeVico et al., 2002; Someya et al., 2005) and viral vector based vaccines. For the purpose of
this study, the emphasis is on DNA vaccines and recombinant viral vaccines, in particular,
poxviruses.
HIV-1 DNA vaccines are non-infectious DNA plasmid vectors expressing HIV-1 antigens. They
cannot replicate or produce additional undesirable proteins in vaccinated individuals, thus
providing a better safety profile compared to viral and bacterial vectors. DNA vaccines are
known to induce both humoral and cellular immune responses (Boyer et al., 1999; Boyer et al.,
2000; MacGregor et al., 2000). Early trials showed DNA vaccines induced only modest
immunogenicity (Lu et al., 2008; MacGregor et al., 1998; Wang et al., 1998). A DNA vaccine
expressing HIV-1 Env and Rev, was evaluated in a small group of asymptomatic HIV-1 infected
patients as a therapeutic vaccine. The vaccination did not have any effect on the plasma viral
load and CD4+ T cell count in these patients and only induced a small percentage of vaccine
elicited env-specific humoral or CTL responses (MacGregor et al., 1998; MacGregor et al.,
2000). Similar results were observed when DNA vaccination was tested in animal models. A
DNA vaccine expressing HIV-1 env, only induced a transient level of Env-specific antibodies in
mice (Lu et al., 1995). The limited immune response induced by DNA vaccines may be
attributed to the inefficiency of DNA vaccine uptake or to the low level of antigen expression
from DNA vectors (Giri et al., 2004). Increased levels of antigen expression from DNA vaccines
have been achieved by codon-optimising the antigen gene sequence, using codons commonly
used by the human transcriptional system (Andre et al., 1998; Barouch et al., 2000; Huang et al.,
2001; Van Harmelen et al., 2003; Williamson et al., 2003; zur Megede J. et al., 2000).
The co-expression of immune modulatory molecules, which act as a molecular adjuvant, has
improved the immunogenicity of DNA vaccines (Boyer et al., 2005; Moore et al., 2002a; Nayak
et al., 2006; Qiu et al., 2007; Xu et al., 2008). These molecular adjuvants include IL-2, IL-12,
IL-15 (Xin et al., 1999; Xu et al., 2008), granulocyte-macrophage colony stimulating factor
(GMCSF) ((Moore et al., 2002a; Qiu et al., 2007; Xu et al., 2008) and fms-like tyrosine kinase











encoding HIV-1 Env or Gag with IL-12, GMCSF or Flt-3L induced enhanced immunogenicity
to these HIV-1 antigens in mice. The percentage of polyfunctional CD8+ T cells was also
increased when DNA vaccines were co-administered with GMCSF (Xu et al., 2008).
The uptake of DNA can be improved using more efficient means of delivery (Babiuk et al.,
2002a; Babiuk et al., 2002b; Luckay et al., 2007; Tollefsen et al., 2002; Widera et al., 2000).
DNA vaccine was conventionally administered intramuscularly by needle injection or
intradermally using a gene gun. More recently, in vivo electroporation of the DNA vaccine into
macaques has been demonstrated to induce 10-40 times enhancement in HIV-1 specific cell
mediated immune responses compared to conventional needle administration (Luckay et al.,
2007).
Viral vectors have been evaluated as vaccine delivery vehicles for HIV-1 antigens. The
advantage of viral vectors over subunit vaccines is the ability of viral vectors to express HIV-1
antigens intracellularly, where they can be processed and presented through the MHC-class I
pathway to induce HIV-1 specific CTL responses. Viral vectors are also known to induce
humoral immune responses to the foreign antigen expressed. Recombinant Adenovirus serotype
5 (Ad5), has been the most immunogenic vector compared to DNA or recombinant poxvirus
vaccines (Casimiro et al., 2003; Santra et al., 2005). However, the immunogenicity in
preclinical and phase I studies did not translate to vaccine efficacy with respect to the reduction
of HIV-1 acquisition in the phase II trial (Buchbinder et al., 2008; Santra et al., 2005). Although
the vaccination regimen was immunogenic in humans and induced HIV-1 specific CD8+ T cells
in most of the vaccinees (Buchbinder et al., 2008; McElrath et al., 2008; Santra et al., 2005) the
vaccination failed to induce a significant reduction in HIV-1 infection. The observation of a
higher risk of HIV-1 acquisition in the vaccinated population with high pre-immunity to Ad5
compared to the placebo control group has raised concerns regarding the effect of vector pre-
immunity. Rare serotypes of human Adenovirus such as Ad35 and Ad11 (Lemckert et al., 2005;
Lemckert et al., 2006; Liu et al., 2008), and other viral vectors such as poxviruses (discussed in
1.2.2), are being evaluated to try and overcome the limitation of vector pre-immunity.
There are many different HIV-1 vaccination strategies, all of which, when used individually,
induce modest and short term HIV-1 specific immune responses. It is commonly accepted that
heterologous prime-boost combinations using serologically-distinct vectors induce enhanced
immune responses compared to single vaccination regimens and repeated inoculations using
homologous vaccine vectors. The use of different vectors for priming and boosting, such as











and human clinical trials (Lu, 2009; Ranasinghe & Ramshaw, 2009). Phase I clinical evaluation
of a Gag expressing DNA prime, MVA boost regimen demonstrated that Gag-specific
polyfunctional T cell responses were induced with the regimen in human subjects. Higher
percentages of responders were observed in the group vaccinated with DNA prime, MVA boost
regimen compared to the homologous MVA prime/boost regimen (Goonetilleke et al., 2006).
Similar immunogenicity results were observed when the DNA prime/ MVA boost regimen was
evaluated in animal models (Abaitua et al., 2006; Amara et al., 2002; Brave et al., 2007;
Burgers et al., 2009; Gherardi et al., 2004; Hanke et al., 2007; Smith et al., 2004). The DNA
prime/ adenovirus type 5 boost vaccination regimen could be a potential solution to overcome
the problem of the high percentage of adenovirus type 5 pre-immunity in the population. The
efficacy of the regimen was demonstrated in NHPs, where rhesus macaques vaccinated with a
SIV Gag- expressing DNA prime, followed by an adenovirus type 5 boost regimen, were able to
induce SIV Gag-specific immunity and reduce the viral load after pathogenic SIV challenge
(Casimiro et al., 2005). The heterologous prime/boost regimen was more efficacious in the level
of protection against pathogenic SIV, compared to the homologous prime/boost with adenovirus
type 5 (Casimiro et al., 2005; Cox et al., 2008). Analysis of the T cell profiles induced by the
two regimens showed differences in the diversity of the type of T cell responses and IL-2
secretion. The DNA prime/ adenovirus boost regimen elicited a more diverse phenotype of T
cell responses compared to the homologous prime/boost regimen with adenovirus type 5
(Casimiro et al., 2005; Cox et al., 2008). The combination of recombinant canarypoxvirus prime
and gp120 protein boost has recently been evaluated in a phase III clinical trial in Thailand
(Pitisuttithum et al., 2006). This regimen induced HIV-1 specific antibody mediated cellular
toxicity in the majority of individuals in the vaccinated group, and not in the placebo control
group (Karnasuta et al., 2005).  Preliminary results from the trial have shown that the prime-
boost vaccination regimen induced mild protection efficacy against HIV-1 infection (31%
reduction in infection in the vaccinated group compared to the group that received placebo)
(Berkhout & Paxton, 2009). The regimen did not induce a reduction in viral load in HIV-1
infected individuals in the vaccinated group (Berkhout & Paxton, 2009).
The heterologous prime/boost vaccination regimens are not limited to distinct classes of vectors,
such as poxviruses or adenoviruses. Similar but serologically distinct vectors can be used in
heterologous prime/boost regimens. Potential advantages of a specific class of vector may be
shared amongst members within the class, thus it could potentially have a positive effect on the
immunogenicity induced by the regimen. The prime-boost combination of adenovirus type 35
(Ad-35) and adenovirus type 11 (Ad-11) expressing SIV Gag induced significantly enhanced











Ad11 respectively. Heterologous Prime-boost combinations using diverse poxvirus vectors such
as MVA, vaccinia virus and fowlpox virus expressing HIV-1 Env and SIV Gag have induced
significantly higher magnitudes of SIV immune responses before challenge, containment of
viral replication after SHIV challenge and reduced levels of CD4+ T cell loss compared to
homologous prime-boost inoculations using MVA in macaques (Santra et al., 2007)
Interesting results were observed in mice vaccinated using a prime-boost-boost regimen with
three distinct vectors (Yu et al., 2008). The mice were primed with DNA expressing SIV-Gag
and boosted with recombinant adenovirus, followed by recombinant Sendai virus (murine
parainfluenza virus type 1), both expressing SIV Gag. The triple vaccination regimen induced
potent Gag specific responses, which were stronger than other double or single vaccination
regimens (Yu et al., 2008).
The benefit of the heterologous prime-boost vaccination strategy has provided the motivation
and rationale for the search for novel vaccine vectors that can be evaluated in such combinations.
1.2 Poxviruses
1.2.1 Life cycle
Vaccinia virus is the most well researched poxvirus due to its usefulness in the smallpox
eradication campaign. For this reason it has been used as a prototype virus for poxvirus research.
The fundamental knowledge of poxvirus replication, transcription and morphogenesis was
obtained from studying vaccinia virus. The details of this enormous field have been described in
several in-depth reviews (Broyles, 2003; Moss, 1996; Moss, 2006; Schramm & Locker, 2005;
Smith et al., 2002; Smith, 2007)
1.2.1.1 Virion structure and viral entry
The poxvirus virion is approximately 250 nm x 350 nm in size (Smith, 2007). There are two
types of poxvirus virion, intracellular mature virus (IMV) and extracellular enveloped virus
(EEV) which differ in their outer membranes. IMV is enveloped in a single layer of lipid
membrane (Dales & Siminovitch, 1961; Hollinshead et al., 1999), while EEV has an extra lipid
membrane compared to IMV (Schmelz et al., 1994; Tooze et al., 1993). The core of the virion is
surrounded by an 18 nm porous palisade layer (Hollinshead et al., 1999). Structural proteins, a
double-stranded viral DNA genome, and enzymes required for early transcription are enclosed











Poxvirus entry begins with attachment to the cell (Figure 1.5). The attachment of the virus is
facilitated by transmembrane proteins on the viral membrane of IMV. Several viral proteins and
cellular receptors have been implicated in virus attachment to the cells; such as poxvirus A27
(Hsiao et al., 1998), H3 (Lin et al., 2000), D8 (Hsiao et al., 1999) and A26 (Chiu et al., 2007)
which interact with cell surface glycosaminoglycan (GAG), heparan sulfate proteoglycan
(HSPG), chondroitin sulfate proteoglycan (CSPG), and extracellular matrix protein laminin
respectively. However none of these viral-cell protein interactions alone is essential for virus
attachment to the cells (Chiu et al., 2007; Hsiao et al., 1998; Hsiao et al., 1999; Rodriguez &
Smith, 1990). Possible alternative mechanisms could still allow attachment to take place.
Poxvirus core entry into the cell is achieved through fusion of the IMV membrane and the cell
plasma membrane (Figure 1.5). The fusion between the two membranes is facilitated by a multi-
viral protein entry/fusion complex (EFC), consisting of A21, A28, H2, L5, A16, G3, G9, and J5
(Senkevich et al., 2005). A21, A28, G3, H2 and L5 are proteins with N-terminal transmembrane
domains, while J5, A16 and G9 are proteins with C-terminal transmembrane domains
(Senkevich et al., 2005). Null mutant vaccinia viruses with all of the above genes
interrupted/deleted were still able to attach to the target cells, but not enter the cells, suggesting
a block in fusion between the viral and cell plasma membrane (Moss, 2006; Senkevich & Moss,
2005). Recent studies revealed that L1 and F9 proteins are also essential for the fusion process.
Like the EFC suppressed mutant vaccinia virus, L1 or F9 suppressed vaccinia mutants were able
to attach to the target cells but unable to enter the cell (Brown et al., 2006a; Foo et al., 2009).
The importance of these viral proteins in the poxvirus life cycle is evident from the conservation
of these genes across the different genera of poxviruses (Moss, 2006; Senkevich et al., 2005).
Because EEV has an extra membrane compared to IMV, additional mechanisms to disrupt the
external membrane are required before viral entry can take place (Figure 1.5). The disruption of
the outer membrane of EEV is achieved through a ligand-induced, non-fusogenic mechanism,
where the interaction of EEV surface proteins A34 and B5 to polyanionic glycosaminoglycans
on the cell plasma membrane, leads to the rupture of the EEV outer membrane (Law et al., 2006)
and exposes the IMV for entry through membrane fusion as described above. Even after its
disruption, the outer membrane of EEV still covers the IMV and shields it from IMV-specific
neutralizing antibodies (Smith, 2007).
After fusion of the IMV membrane with the target cell membrane, the core of the poxvirus is
introduced into the cytoplasm of the target cell and transported on microtubules to the











Figure 1.5 Poxvirus intracellular mature virus (IMV) and extracellular enveloped virus (EEV) entry mechanisms.
IMV attachment to the cell plasma membrane receptors facilitates the fusion of IMV and cellular membranes and
enables entry of the virus core into the cytoplasm. The disruption of the outer membrane on EEV is mediated
through glycosaminoglycan. The disruption of the outer membrane releases the internal IMV to enter the cell
cytoplasm as described above. The entered virus core is transported on microtubules to a perinuclear replication site.
The diagram is adapted from that published by (Smith, 2007).
1.2.1.2 Poxvirus replication, transcription and morphogenesis
The two strands of the poxvirus’s double stranded DNA genome are covalently linked by
terminal hair-pin loop structures into a single DNA molecule (Baroudy et al., 1982; Berns &
Silverman, 1970). Inverted terminal repeats (ITR)  are located adjacent to the hair-pin loops
(Goebel et al., 1990). The length of these repeated sequences varies between different
poxviruses from <0.1kb to 12.4kb,(Wittek et al., 1978). Within the ITR, shorter tandemly
repeated sequences and a highly conserved concatemer resolution motif can be found
(Merchlinsky, 1990; Merchlinsky & Moss, 1989). The motif is essential for the resolution of
concatemer DNA molecules during poxvirus DNA replication (Merchlinsky, 1990; Merchlinsky
& Moss, 1989).
The poxvirus genome contains open reading frames that are closely packed with little non-
coding intragenic sequences (Goebel et al., 1990). The central region of the poxvirus genome is
relatively conserved within the different genera (Gubser et al., 2004) and higher variability
occurs in the terminal regions of the virus genome (Gubser et al., 2004). Poxvirus genes can be
divided into three groups according to their time of expression in the virus life cycle - early,
intermediate or late (Broyles, 2003). The components required for early transcription, such as
viral DNA-dependent RNA polymerase, capping enzyme, polyA-polymerase and early
transcriptional initiation and termination factors are packed inside the viral core (Kates &
McAuslan, 1967; Shuman et al., 1987; Wei & Moss, 1974; Yuen et al., 1987). The presence of
the early transcriptional system allows poxvirus early genes to be independently transcribed of




























early genes code for proteins that are involved in viral DNA synthesis and defence against the
host immune response (Moss, 1996), and are under the control of early poxvirus promoters that
can only be recognized by poxvirus RNA polymerase (Davison & Moss, 1989).
Replication of Poxvirus DNA occurs within 2 hours post-infection (Salzman, 1960). It takes
place after early gene expression and uncoating of the viral core in cytoplasmic viral factories
(Cairns, 1960). DNA replication begins with a nick in one of the DNA strands near the terminal
hair-pin loop. This opens up the linked double strands and allows for self priming and
elongation of the viral DNA along the whole genome by a poxviral DNA polymerase. A
concatameric replicative intermediate is formed which, when nicked twice, is resolves into two
monomeric genomes (Eckert et al., 2005; Shuman & Moss, 1987). Parallel to DNA replication,
intermediate genes are expressed under the control of functionally distinct intermediate
promoters (Baldick, Jr. et al., 1992). These intermediate genes, A1L, A2L and G8R encode for
transcriptional factors required for late transcription (Keck et al., 1990; Kovacs et al., 1994;
Wright & Coroneos, 1993)
Late genes generally encode structural proteins for virion formation. Some of the late genes also
encode the enzymes and transcriptional factors required for early gene transcription mentioned
previously. Expression of the late genes are under the control of poxvirus late promoters (Rosel
et al., 1986). The initiation of poxvirus late transcription is dependent on poxvirus DNA
replication and the expression of late transcription factors encoded by the intermediate genes,
early gene H5L (Kovacs et al., 1994; Kovacs & Moss, 1996)and a host factor VLTF-X
(Gunasinghe et al., 1998; Wright et al., 1998).
After DNA replication and late gene expression, viral crescents, which are composed of viral
protein associated with a host derived single layer lipid membrane, are formed within viral
factories (Dales & Siminovitch, 1961) (Figure 1.6). The poxvirus DNA genome and viral
enzymes are packed into the viral crescents to form immature virions (IV), which mature into
IMV through proteolysis of the core capsid proteins (Moss & Rosenblum, 1973). IMV forms the
majority of the infectious poxvirus progeny and is released through lysis of infected cells (Smith
et al., 2002). Some IMV particles are transported away from the viral factories through
microtubules (Sanderson et al., 2000), and are further processed through the trans-Golgi  or
endosome, where they acquire an additional double-layered intracellular membrane and are
know as intracellular enveloped virus (IEV) (Hiller & Weber, 1985; Schmelz et al., 1994) . IEV
is transported through microtubules to the plasma membrane of the cell (Hollinshead et al.,











allows for export of IEV from the surface of the cell by exocytosis (Smith, 2007). The virion can
either remain attached to the cell (cell-associated enveloped virus, CEV) or be released as EEV.
The association of CEV with the cell induces actin tail formation which is important for cell to
cell spread of the virus (Frischknecht et al., 1999b; Frischknecht et al., 1999a; Smith et al., 2002)
(Figure 1.6).
Figure 1.6 Poxvirus morphogenesis pathways. Viral DNA, proteins and crescent membranes are synthesized in the
cytoplasmic viral factories. Viral DNA and protein are then packed with crescent membranes to form the immature
virus (IV). IV is then matured into intracellular mature virus (IMV) through proteolytic cleavage of the capsid
proteins and condensation. IMV is transported out of the viral factories on microtubules and is wrapped with a
double layered plasma membrane as it passes through the trans-Golgi network to form the intracellular enveloped
virus (IEV). IEV is transported to the cell plasma membrane and exits the cell surface by exocytosis. The virus can
stay associated with the cell as cell-associated enveloped virus (CEV) or released from the cell as extracellular
enveloped virus (EEV). CEV may induce actin tail formation in the cell cytoplasm that can aid the cell to cell
transmission of the virus. This figure is adapted from that published by (Smith, 2007).
1.2.2 Poxviruses as vaccine vectors
The successful eradication of smallpox in 1980 through vaccinia virus (VV) vaccination (WHO,
1980) provided evidence of the effectiveness of the eradication of an infectious disease through
vaccination. The success of vaccinia virus as a vaccine, along with the development of DNA
modification techniques for this virus, has led to the realization of the potential of poxviruses as
vaccine vectors for other infectious agents (Mackett et al., 1982; Mackett et al., 1984; WHO,
1980).  Vaccinia virus has several desirable properties as a vaccine vector. It can induce both




























1986; Graham et al., 1992; Nixon et al., 1988). Large inserts of foreign DNA can be
incorporated into the vaccinia virus genome without affecting the viral life cycle (Smith & Moss,
1983). Vaccinia virus can be used in human and veterinary vaccine applications because it has a
wide host range. The lack of viral DNA integration into the host genome and viral persistence
makes it a safe vector.  The use of recombinant vaccinia virus expressing the immunizing G
protein of rabies virus has demonstrated the effectiveness of vaccinia virus as a recombinant
vaccine vector. With the oral vaccination of  raccoons and foxes through bait, it has significantly
reduced the incident rate of wildlife rabies occurring in European countries and the United
States of America (Pastoret & Brochier, 1996; WHO, 1980).
Due to the HIV-1 pandemic, there is a significant part of the population that is or could be
potentially immunocompromised. Transfer of vaccinia virus could occur from vaccinated
individuals to non-vaccinated contacts. The possible dissemination of vaccinia virus in
immunocompromised individuals (Redfield et al., 1987) presents a great safety concern for its
application as a human vaccine vector. This undesirable feature of vaccinia virus has led to the
development of other safer poxvirus vectors such as highly attenuated, replication-deficient
modified vaccinia Ankara (MVA) and other host-range restricted poxviruses, such as
avipoxviruses and capripoxviruses (Aspden et al., 2003; Baxby & Paoletti, 1992; Bejon et al.,
2007; de Bruyn G. et al., 2004; Jentarra et al., 2008; Nitayaphan et al., 2004; Vijaysri et al.,
2008). Recently a number of studies have also evaluated several replication-competent vaccinia
viruses (Copenhagen, NYCBH, Western Reserve and vaccinia Tian Tan), attenuated through
deletion of virulence genes, as recombinant vaccine vectors (Huang et al., 2009; Jentarra et al.,
2008; Vijaysri et al., 2008). The efficacies of these attenuated replication-competent vaccinia
viruses  as vaccine vectors were demonstrated in mice (Huang et al., 2009; Jentarra et al., 2008;
Vijaysri et al., 2008) and their safety was demonstrated in immunocompromised mice (Jentarra
et al., 2008; Vijaysri et al., 2008).
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1.2.2.1 Modified Vaccinia Ankara (MVA)
MVA was derived from the Ankara strain of vaccinia virus. The attenuation was achieved  by
passaging the virus 572 times in chicken embryo fibroblasts (Meyer et al., 1991), during which
time approximately 30 kb DNA became deleted from the termini of the virus genome. The
attenuation led to the loss of the ability of the virus to replicate in most mammalian cell lines.
However MVA is able to replicate productively in the Syrian hamster kidney cell line, BHK-21
(Carroll & Moss, 1997) and, arguably, in the rat small intestinal epithelial cell line IEC-6 (Okeke
et al., 2006). MVA has been demonstrated to exhibit abortive replication in all other mammalian
cells (Zhang et al., 2007) and to be non-pathogenic in immunocompromised animals (Wyatt et
al., 2004). MVA was deployed as a smallpox vaccine during the later stage of the vaccination
campaign in Germany and the vaccination of humans with MVA did not result in any
complications (Stickl et al., 1974). The superior safety profile of MVA over vaccinia virus made
MVA an attractive and competitive vaccine vector against several infectious diseases.  A
recombinant MVA expressing mycobacterium tuberculosis 85A antigen (MVA85A) has been
developed as a promising Tuberculosis vaccine, which has been demonstrated to be both safe
and immunogenic in human clinical trials (Hawkridge et al., 2008; McShane, 2009; Sander et
al., 2009). Several studies and clinical trials have also demonstrated the protective
immunogenicity of recombinant MVA expressing the Plasmodium berghei circumsporozoite
protein of the malaria parasite (Hill et al., 2000; Hutchings et al., 2007; Moore & Hill, 2004;
Prieur et al., 2004).  MVA has attracted huge interest as a vaccine vector in the field of HIV-1
vaccine research (Burgers et al., 2009; Greenough et al., 2008; Im & Hanke, 2004; Sandstrom et
al., 2008), and is currently being evaluated in several clinical trials as a booster vaccine after
priming with DNA (HIV Vaccine Trials Network database and International AIDS vaccine
initiative trial database).
Poxviruses are known to induce long lasting anti-viral immunity in vaccinated individuals
(Amara et al., 2004; Hammarlund et al., 2003) and a significant percentage of the world
population was vaccinated with vaccinia virus during the smallpox eradication campaign. The
pre-existing anti-MVA immunity in vaccinia virus vaccinated individuals, due to cross-reactivity
between MVA and vaccinia virus, may reduce and hamper the effectiveness of MVA as a
vaccine delivery vector in these individuals (Baxby & Paoletti, 1992; Belyakov et al., 1999;
Gomez et al., 2008; Naito et al., 2007; Nigam et al., 2007). The possible large-scale deployment
of MVA as a smallpox vaccine (in the event of a threat of biological warfare) or as a vaccine
vector against a particular infectious agent, could lead to the presence of anti-MVA immunity in
vaccinated individuals and render the vector ineffective for subsequent vaccine development











competitiveness for the use of MVA as a vaccine vector, provide the rationale for the need for
additional antigenically distinct, nonpathogenic poxviruses as vaccine vectors.
1.2.2.2 Avipoxviruses
The Avipoxviruses, a genus in the subfamily Chordopoxviridae (Table 1.1), are host-restricted to
avian hosts and replication-deficient in most mammalian cells. They have been extensively
researched as veterinary and human vaccine vectors. The two most well known vectors in this
genus are fowlpoxvirus and canarypoxvirus (ALVAC) (Taylor et al., 1991b; Tulman et al.,
2004). The vaccine strains of these two poxviruses were initially evaluated and developed to
vaccinate birds against avian diseases (Boyle, 2007) such as avian influenza. Vaccination of
chickens with recombinant fowlpoxvirus expressing H5 hemagglutinin (HA) and N1
neuraminidase of the avian influenza virus could completely protect the birds from highly
pathogenic H5N1 avian influenza virus (Qiao et al., 2009; Qiao et al., 2003).  The
immunogenicity of recombinant avipoxviruses has also been demonstrated in a wide range of
non-avian species (Boyle, 2007). Recombinant Avipoxviruses have been evaluated as vaccines
against rabies, canine distemper, feline leukaemia and West Nile viruses and have been
demonstrated to protect against these mammalian diseases (Minke et al., 2004; Pardo et al.,
1997; Poulet et al., 2003; Taylor et al., 1991b). Recombinant canarypoxvirus expressing rabies
glycoprotein provided comparable levels of protection against rabies challenge in mice to that
of recombinant vaccinia virus expressing the same antigen (Taylor et al., 1991b). However the
recombinant fowlpoxvirus expressing rabies glycoprotein elicited only partial protection (Taylor
et al., 1991b).
Avipoxviruses have also been explored in the search for safer and more efficacious vaccine
vectors for HIV-1 vaccines. They have been shown to be immunogenic in prime/boost
combinations with DNA vaccine, protein subunit vaccines and MVA (Dale et al., 2004; Gupta et
al., 2002; Kent et al., 1998; Nitayaphan et al., 2004; Robinson et al., 1999; Russell et al., 2007;
Santra et al., 2007). Recombinant canarypoxvirus expressing HIV-1 subtypes B and E gp120
(ALVAC-HIV vCP1521) was deployed in prime-boost combination with gp120 protein in phase
I and II clinical trials and was shown to be safe and immunogenic in HIV-1 negative individuals
(Nitayaphan et al., 2004). The vaccination strategy has recently been evaluated in a phase III
clinical trial in Thailand. Preliminary result indicates a mild protective efficacy of 31% in the
vaccinated group (Berkhout & Paxton, 2009; Rerks-Ngarm et al., 2009).
Unlike MVA, the abortive steps of fowlpox virus and canarypox virus in non-permissive human











avipoxviruses were only able to transcribe early genes before DNA replication of the viral
genome was blocked. This early block in the virus replication process in non-permissive hosts
(non-avian) may limit the level and duration of foreign antigen expression from recombinant
avipoxviruses, and could be linked to the weak and limited immunogenicity induced in earlier
clinical trials (Russell et al., 2007).
1.2.2.3 Lumpy skin disease virus
Lumpy skin disease virus (LSDV) belongs to the Capripoxvirus genus of the Poxviridae family
(Alexander et al., 1957) (Table 1.1). Other members in the genus include sheeppox virus and
goatpox virus (Diallo & Viljoen, 2007). LSDV is the aetiologic agent of lumpy skin disease
(LSD) in cattle and was isolated from skin lesions of infected cattle in 1959 (Alexander et al.,
1957). The disease was first documented in Zambia in 1929 (Barnard et al., 1994) after which
the epidemic spread throughout southern Africa (Carn, 1993; Davies, 1991). Later, LSD spread
throughout the African continent (Diallo & Viljoen, 2007). There have  also been reports of LSD
in the middle-east in countries such as Israel and Saudi Arabia (Greth et al., 1992; Yeruham et
al., 1995).
The clinical symptoms of LSD include fever and the formation of necrotic skin nodules 4 to 11
days post infection (Weiss, 1968). Necrotic lesions in the respiratory tracts can lead to fatal
complications in infected cattle (Weiss, 1968). The mortality rate of LSD is approximately 40%
(Diallo & Viljoen, 2007; Henning, 1956). LSD can also affect milk production in infected cows,
and  infected bulls and cows could be permanently infertile (Diallo & Viljoen, 2007; Henning,
1956). The presence of nodules may permanently damage the hides of the cattle. These LSD
related factors have a significant negative economic impact on downstream industries.
The host-range of LSDV is restricted to ruminant animals; however, the virulence of the virus
appears to be restricted to cattle (Ali et al., 1990; Kitching et al., 1989). Infection of other
ruminant animals, such as buffaloes (Ali et al., 1990), which results in milder symptoms, has
been documented. A low prevalence of LSDV specific antibody was also detected in serological
surveys of  wild-life samples and by experimental inoculation of game animals with LSDV
(Davies, 1981; Young et al., 1970). The experimental inoculation of sheep with LSDV resulted
in a localised reaction at the site of inoculation, with no LSD-like symptoms (Kitching et al.,
1989). However some replication of LSDV is thought to take place as virus could be recovered
from inflamed lymph nodes (Barnard et al., 1994).  The transmission of LSDV through contact
of cattle is not efficient (Carn & Kitching, 1995). Transmission of LSDV is believed to occur via
biting insects (Carn & Kitching, 1995). This hypothesis has been supported by the successful











mechanical transmission of LSDV was observed for arthropod vectors (Carn & Kitching, 1995).
The transmission from infected cattle to naïve cattle failed in the absence of insects (Carn &
Kitching, 1995).
Because the transmission of LSDV is likely to be facilitated though biting insects, the control of
flying insects could be effective in the control of a LSD outbreak. However the control and
prevention of LSDV infection can also be achieved through vaccination. The LSDV vaccine was
developed by passaging the Neethling strain of LSDV in embryonated eggs and attenuating it
though multiple passages in lamb kidney cells and on chick chorio-allantoic membranes (CAM)
(van Rooyen et al., 1969). The passaging resulted in several insertions, deletions and frame shift
mutations in many of  the terminal variable genes and the central conserved genes (Kara et al.,
2003). The DNA modifications in these genes led to attenuation through impairment of DNA
replication and through the destruction of many immune evasive mechanisms (Kara et al.,
2003). Although the vaccine can effectively protect cattle from LSDV infection, adverse effects,
such as localized swelling at inoculation sites and reduction in milk production, could occur as a
result of vaccination (Diallo & Viljoen, 2007). Because LSDV, sheeppox virus and goatpox
virus are serologically identical (Kitching, 1986), sheeppoxvirus strains have been used as  an
alternative vaccine in areas such as Kenya, Egypt and Israel to control the outbreak of LSD in
these regions (Davies, 1991).
Similar to vaccinia virus and avipoxviruses, LSDV has a large DNA genome (151 kb) and large
inserts of DNA can be incorporated into the LSDV genome (Tulman et al., 2001). Genetically,
LSDV closely resembles the other members of the Chordopoxviradae, although it contains a
unique set of genes that correspond to its host range and virulence (Tulman et al., 2001).
The attenuated vaccine strain of LSDV (Neethling) has been shown to be a safe and efficacious
vaccine vector (Aspden et al., 2002; Aspden et al., 2003; Kitching et al., 1987; Wallace et al.,
2006; Wallace & Viljoen, 2005). The safety of LSDV (Neethling) has been demonstrated
through the vaccination of cattle against Lumpy skin disease (LSD) for many years without any
complications (Kitching et al., 1987). The restriction in the host-range of LSDV reduces the risk
of possible dissemination of LSDV in non-ruminant animals or humans.  LSDV does not
transmit horizontally from vaccinated to unvaccinated animals (Carn & Kitching, 1995;
Kitching & Mellor, 1986), which adds another desirable property to the safety profile of LSDV
as a vaccine vector.
1.2.2.3.1 LSDV as a vaccine vector











infectious diseases, namely, rinderpest virus, rabies virus and Ehrlichia ruminantium
Welgevonden infections (Aspden et al., 2002; Ngichabe et al., 2002; Pretorius et al., 2008;
Romero et al., 1993; Romero et al., 1994b; Wallace et al., 2006). Dual protection against LSD
and the pathogen of the recombinant antigen expressed, can be provided. Vaccination of cattle
with the recombinant LSDV, strain KS-1, expressing both the haemagglutinin and fusion
proteins of rinderpest virus, provided protection against lethal challenges of both rinderpest
virus and LSDV (Ngichabe et al., 1997; Romero et al., 1993; Romero et al., 1994a). Long-term
protective immunity induced by the recombinant LSDV against both viruses was also
demonstrated (Ngichabe et al., 2002). Two LSDV recombinants expressing Blue tongue virus
and peste-des-petits-ruminants virus antigens respectively have also been tested. These vaccines
induced partial protective immunities in goats and sheep against the respective pathogen
challenges (Berhe et al., 2003; Perrin et al., 2007).
The efficacy of LSDV as a replication-deficient viral vector has also been demonstrated in non-
ruminant hosts. A recombinant LSDV expressing the glycoprotein of rabies virus (Aspden et al.,
2002; Aspden et al., 2003) was found to elicit rabies glycoprotein specific antibodies in both
cattle (ruminant) (Aspden et al., 2002) and rabbits (non-ruminant) (Aspden et al., 2003). The
same recombinant LSDV did not induce a rabies glycoprotein specific antibody response in
mice; however, rabies-specific cellular immune responses were elicited in mice, rabbits and
cattle. The recombinant LSDV provided strong protection against high dose rabies virus
challenge, and complete protection against low-dose rabies virus challenge in mice (Aspden et
al., 2003). The protection provided by this recombinant LSDV was comparable to the protection
induced by a WHO approved commercial rabies vaccine Verorab (inactivated rabies virus) in
mice (Aspden et al., 2003).
A recombinant LSDV expressing the Rift Valley fever virus (RVFV) glycoprotein induced
neutralising antibodies against RVFV in mice and sheep and completely protected the
vaccinated animals against Rift Valley fever virus challenge (Wallace et al., 2006; Wallace &
Viljoen, 2005). The recombinant LSDV induced superior protective immune responses in mice
compared to the immune responses induced by purified Rift Valley fever virus glycoprotein or
DNA vaccine expressing the same glycoprotein (Wallace et al., 2006; Wallace & Viljoen, 2005).
The block in the life cycle of LSDV in a non-permissive cell line (CV-1) was shown to occur at
a late stage of the virus cycle, by infecting the cells with LSDV, transfecting with a plasmid
containing the lacZ gene under the control of the vaccinia virus p11 promoter and detecting lacZ











occurred once viral DNA replication had taken place.  The production of immature virions post
virus genome replication was also observed using electron microscopy (Aspden et al., 2003).
The duration and level of the foreign antigen expressed in recombinant LSDV could therefore
be superior to that of recombinant fowlpox and canarypox viruses,  due to a much earlier block
in the avipoxvirus replication cycle in non-permissive hosts (Taylor et al., 1995). We speculate
that the immunogenicity induced by recombinant LSDV will be superior to that induced by
recombinant fowlpox and canarypox viruses, but comparable to recombinant MVA, which also
progresses to the stage of forming immature virions (Sutter & Moss, 1992).
1.3 Project motivation
With the urgent need for a more efficacious HIV-1 vaccine and the limitations of the current
available vaccine vectors, it is important to evaluate novel vaccine vectors which may be
suitable for development into HIV-1 vaccines. Recombinant LSDV has been shown to be
immunogenic and efficacious in a number of animal infectious disease models (Aspden et al.,
2002; Ngichabe et al., 2002; Pretorius et al., 2008; Romero et al., 1993; Romero et al., 1994b;
Wallace et al., 2006). The aim of this study was to evaluate LSDV as a novel HIV-1 vaccine
vector. An important objective was to evaluate the safety of LSDV (Neethling) in an
immunocompromised setting. This was done by injecting LSDV into two groups of mice with
different immunodeficiency phenotypes and monitoring the weight loss, as an indication of
pathogenicity. The next objective was to construct a recombinant LSDV (rLSDV-Grttn)
expressing HIV-1 subtype C polyprotein Grttn (Gag, RT, Tat and Nef) and to evaluate it for
immunogenicity in BALB/C mice. rLSDV-Grttn was administered as a single vaccination and in
prime-boost combination with DNA or MVA vaccines expressing Grttn, in order to determine
the optimum  vaccination regimen. HIV-1 specific IFN-γ and IL-2 cytokine secretion was
measured, as were surface molecules CD107a/b (degranulation correlate) and CD44 (antigen
experienced status correlate) on the splenocytes of vaccinated mice. The presence of HIV-1
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2.1 DNA Procedures Employed in the Construction of Transfer Vectors
The cloning strategy followed in the construction of the transfer vector pYS-05 is described in
chapter 3, section 3.2, pages 64- 72 (Figures 3.4, 3.8 and 3.10).
2.1.1 Source of plasmids used in the project
pLW-51 (Wang et al., 2004) was kindly provided by Linda Wyatt (NIH, USA). HIV-1 subtype C
polyprotein gene Grttn (Gag, RT, Tat and Nef) (Burgers et al., 2006) with upstream Kozak
sequence cloned into pMOSBlue was provided by Dr J. van Harmelen (Medical Virology, UCT).
The plasmid pGPT07/14 (Boyle & Coupar, 1988), containing the E.coli xanthine-guanine
phosphoribosyl transferase gene (Gpt) with upstream VV P7.5 promoter cloned into the EcoRI
restriction enzyme site, was obtained as a gift from Dr Boyle (CSIRO, Australia) to Prof. Keith
Dumbell (former member of the department).
2.1.2 DNA preparation
Small scale plasmid DNA preparation was done using the High Pure Plasmid Isolation Kit
(Roche, Germany). Large-scale plasmid DNA preparation was carried out using the
NucleoBond® 500-Maxi Kit (Clontech Laboratories, USA). Endotoxin-free plasmid DNA was
prepared using the EndoFree Plasmid Maxi Kit (Qiagen, USA). DNA extraction from agarose
gels was done using the MinElute Gel Extraction Kit (Qiagen, Valencia, CA). PCR products
were purified using the MiniElute PCR purification kit (Qiagen, Valencia, CA). All kit
procedures were performed according to the manufacturers’ instructions and recommendations.
2.1.3 Polymerase chain reaction (PCR)
Oligonucleotide primers (Table 2.1) were ordered from the Synthetic DNA Laboratory in the
Department of Molecular and Cell Biology, University of Cape Town. For the polymerase chain
reaction (PCR), annealing temperatures were chosen approximately 50C below the melting
temperature of the primers and extension times were chosen according to the expected size of
the fragment to be amplified and the rate of polymerization of the DNA polymerase. The
following general PCR cycling conditions were employed using either Pfu polymerase
(Promega, USA) or GoTaq™ DNA Polymerase (Promega, USA): 95º C for 2 minutes, 30 cycles
of 95º C for 1 minute, 50-55º C for 30s and 73-74º C for 2-5 minutes, followed by a final











Table 2.1 PCR primer pairs used for DNA amplification of 5’ and 3’ end of LSDV RR fragments (LFI and LFII
respectively), HIV-1 Grttn (Grttn) and E.coli Gpt (Gpt).
2.1.4 Agarose gel electrophoresis
Electrophoresis of DNA was carried out through ethidium bromide (0.5 μg/ml) stained 1%
agarose gels (13 cm) prepared in Tris-acetate-EDTA (TAE, 0.04M Tris, 128 mM EDTA, 0.11%
Glacial acetic acid) buffer, under constant voltage (V) of 80 V for 1 hour. Gels were visualized
on an ultraviolet (UV) transilluminator.
2.1.5 Cloning
Restriction enzyme digestion and DNA cloning was performed according to standard procedures
(Sambrook et al., 1989). Ligation of DNA fragments was done using the Rapid DNA ligation kit
(Roche, Germany) as instructed by the manufacturer. Competent cells were prepared from E.coli
DH5α, using the CaCl2 treatment procedure described by (Dagert & Ehrlich, 1979). Competent
cells were transformed with plasmid DNA by incubating ligated DNA with thawed competent
cells (100μl) for 20 minutes on ice. The cells were then heat-shocked at 42˚C for 50 seconds
before adding 1 ml of 2X yeast-tryptone medium (2X YT, 1.6% Tryptone, 1% Yeast extract, 86
mM NaCl, pH 7) to the cells and incubating at 37˚C for 1 hour. The transformed cells were then
plated onto ampicillin (Sigma-Aldrich, USA) containing 2X YT agar plates (2 x YT with 15%
agar and 100μg/ml ampicillin) and further incubated at 37˚C overnight.
2.1.6 DNA sequencing
DNA sequencing was outsourced to the DNA sequencing unit in the Department of Molecular
and Cell Biology, University of Cape Town. The analysis of sequencing data was performed





LFI forward LFI 5’-GAATTCATGGTATAAAATAAAATGGAACC-3’
LFI reverse LFI 5’-GCGCGCCAAACGCTATTAATCGTTCTC-3’
LFII forward LFII 5’-CTGCAGTTGAGGGAATATTCTTTTCCGG-3’
LFII reverse LFII 5’-AAGCTTGGTTATTCAAGATAATTAACAAGAG-3’
Grttn forward Grttn 5’- ACCATGGCTGCTCGCGCATC -3’
Grttn reverse Grttn 5’- TCAGTCCTTGTAGTACTCGG -3’
Gpt forward Gpt 5’- ATTGCTCTTTCGGTGGCTGG -3’











2.2 Lumpy Skin Disease Virus (LSDV) Propagation
2.2.1 Viruses and cells
The Neethling strain of Lumpy Skin Disease Virus (LSDV), a bovine vaccine, was provided by
Onderstepoort Veterinary Institute. MVA was obtained from Therion Biologic. Recombinant
MVA expressing HIV-1 polyprotein Grttn under the control of VV mH5 promoter, inserted into
the delIII region of MVA, was constructed by Nicolette Johnston (former member of the
department). Propagation of LSDV was done in foetal bovine testes cells (FBT) as described
below (section 2.2.2). Madin-Darby bovine kidney epithelial (MDBK) cells were obtained from
the American Type Culture Collection (ATCC, CL-22) and used for LSDV titration.
2.2.2 Preparation of primary FBT cells from foetal bovine testes (Wallace, 1994)
LSDV grows optimally in foetal bovine primary cells. Primary foetal bovine testes cells were
isolated from foetal bovine testes obtained from the Maitland abattoir in Cape Town. The testes
were sliced open to remove the capsules, blood vessels and fat (Figure 2.1). The soft testes
tissue was removed and cut into smaller pieces. The tissue was washed with 25% trypsin (Gibco)
(in PBS) to rinse off the excess blood and then incubated with 1% trypsin at room temperature
for 30 minutes. The trypsinized mix was filtered through a steel mesh and collected in 50 ml
tubes (kept at 4˚C). Fresh 1% trypsin was added to the remaining tissue and the above process
was repeated for another two cycles. The trypsinized mixes were pooled and centrifuged at 1000
rpm for 10 minutes to pellet the cells. The supernatant fluid was discarded and the cell pellet
was resuspended in DMEM with 10% fetal calf serum (FCS, Gibco, USA). The resuspended
cells were placed into tissue culture flasks and incubated at 37˚C, 5% CO2 until the cells grew to
confluency.
Figure 2.1 The isolation procedure of FBT cells from foetal bovine testes. A) Single detached foetal bovine testis,












2.2.2.1 Trypsinization and storage of FBT cells
80-90 % confluent FBT cells were trypsinized using activated trypsin solution (Trypsin/EDTA
(Gibco, USA) diluted 1 in 10 with sterile PBS). The cells were washed with DMEM before
centrifuging the cell suspension at 1000 rpm for 10 minutes. The supernatant was discarded and
the cell pellet was resuspended in 1/10th of the original growth medium volume of FCS + 10%
DMSO. 1/2 and 1/10 dilutions of the cells were stained with Trypan Blue and counted using a
Neubauer cell counting chamber. The concentration of FBT cells was adjusted to 3 x 106 cells/
ml with FCS + 10% DMSO, and then stored in aliquots at -80˚C.
2.2.2.2 Thawing FBT cells from frozen vials
Frozen FBT cells were thawed at 37˚C and resuspended in 10 ml of pre-warmed (37˚C) DMEM.
The resuspended cells were centrifuged at 1000 rpm for 10 minutes, the cell pellet was
resuspended in DMEM + 10% FCS, seeded into tissue culture flasks and incubated in a
humidified incubator at 37˚C, 5% CO2 for 48 hours. These FBT cells could be further passaged
for 6-7 times before losing growth capability.
2.2.3. LSDV infection of primary FBT cells
2.2.3.1 Preparation of FBT cells
80-90 % confluent FBT cells were trypsinized as described in section 2.2.2.1, except the final
cell pellet was resuspended in 1/10th of the original growth medium volume of DMEM + 10%
FCS. The cells were counted and seeded at a concentration of 0.25 x 106 cells/ml. Volumes of
20 ml per tissue culture flask (175 cm2) and 4 ml per well of a 6-well plate were used. The cells
were incubated in a humidified incubator at 37˚C, 5% CO2 for 24 hours.
2.2.3.2 Infection of cells
LSDV was diluted in DMEM.  80-90 % confluent FBT cells in tissue culture flasks were
washed with PBS. Five milliliters of the diluted virus was adsorbed onto the cells for 1 hour at
37˚C, 5% CO2. Fresh growth medium (DMEM + 4% FCS) was added to the wild-type LSDV
infected FBT cells and selection medium (25 μg/ml mycophenolic acid, 250 μg/ml xanthine, 4%
FCS in DMEM) was added to rLSDV-Grttn- infected FBT cells. The virus-infected FBT cells
were incubated as before for a further 72 hours.
2.2.3.3 Large scale preparation of LSDV and rLSDV-Grttn
The titres of LSDV and rLSDV-Grttn were increased through repeated rounds of infection of











freezing and thawing. The cell suspensions were centrifuged at 2500 rpm for 5 minutes to pellet
the cell debris. The virus-containing supernatants were pooled in a 175 cm2 tissue culture flask
and 45 ml aliquots were transferred to 50 ml oakridge centrifuge tubes (NALGENE Labware,
Waltham, USA). 2 ml of 36% sucrose solution (in PBS) was slowly added to the bottom of each
tube. The tubes were centrifuged at 11000 rpm for 1 hour at 4˚C to pellet the virus.  The
supernatant fluid was discarded. The pellet was washed gently with 30 ml of sterile PBS (Gibco,
USA). The tubes were centrifuged as before for 30 minutes. The PBS was discarded and the
virus pellets were resuspended in a total volume of 1 ml of sterile PBS. The resuspended virus
was aliquotted into 50 μl aliquots in pyrogen-free Eppendorf tubes.
2.2.3.4 Titration of LSDV
The titre of LSDV was determined by counting foci of cytopathic effect (CPE) on the infected
cells. Wild-type LSDV was titrated by counting foci using a light microscope and recombinant
virus was titrated by immunostaining and counting brown foci, using a light microscope. The
titration procedures are described below.
80-90% confluent MDBK cells were prepared in six well tissue culture plates as previously
described for primary FBT cells (section 2.2.3.1). The virus to be titrated was diluted serially
10-fold (10-2 to 10-8) in DMEM. The MDBK cells were washed twice with 1 ml of PBS before
adding 300 μl of DMEM to each well. 200 μl of each virus dilution was vortexed and transferred
to a designated well. The virus was allowed to adsorb for 1 hour at 37˚C, 5% CO2. Medium was
added to the wells of MDBK cells without removing the virus inoculae to make the final volume
2 ml in each well. Virus infected cells were incubated for 48 hours. For wt LSDV foci were
counted directly using a light microscope. For recombinant LSDV the following staining
procedure was followed.
The medium in the wells was aspirated, the cells were washed with 1 ml of PBS three times,
PBS was completely aspirated from the wells and the cells were fixed with 1 ml of pre-cooled (-
20ºC) methanol and acetone mix (1:1) for 2 minutes. The fixative was then removed and cells
were washed three times with PBS as before. RT-specific sheep antibody was diluted 1 in 100 in
PBS + 3% FCS and 750 μl was added to each well of MDBK cells. The cells were incubated for
1 hour with gentle agitation and washed with PBS as before. Horseradish peroxidase conjugated
anti-sheep immunoglobulin (Dako, Denmark) was diluted in PBS + 3% FCS and 750 μl was
added to each well. The cells were incubated for 45 minutes before washing with PBS as before.
Substrate solution was prepared by adding 200 μl of o-Dianisidine (Sigma-Aldrich, USA)











The cells were incubated in substrate solution for 5-10 minutes. The colour development was
stopped by washing the cells in distilled water. Orange foci were counted when viewed using a
light microscope (400 X magnification).
The titre of rLSDV-Grttn was calculated by multiplying the counted RT positive foci by the
dilution factor and multiplying by 5 to finally express the titre as foci forming units per millilitre
(ffu/ml).
2.3 Transient Expression of HIV-1 Polyprotein Grttn and Reporter gene GUS
2.3.1 LSDV infection and pYS-05 transfection of FBT cells
Transient expression of the HIV-1 polyprotein Grttn and reporter gene GUS from the transfer
vector pYS-05 occurs when the plasmid is present in the same FBT cell in which LSDV
replication is taking place. pYS-05 was introduced into LSDV infected cells by transfection, as
described below.
80-90 % confluent FBT cells were seeded into a six well tissue culture plate as described in
section 2.2.3.1 The final volume seeded was 2 ml per well. Two wells of confluent FBT cells
were infected with LSDV at a m.o.i of 0.1 ffu/cell. The volume of the virus inoculae used was 1
ml per well. Two wells were left uninfected as negative controls. 5 hours post infection, 100 ng
of pYS-05 was transfected into one of the infected wells and one of the uninfected wells, using
Effectene from an Effectene transfection kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. The cells were incubated at 37˚C, 5% CO2 for 24 hours before
proceeding to the expression assays described below.
2.3.2 Detection of transient expression of reporter gene GUS from pYS-05 by substrate
staining (GUS Staining)
After infection and transfection of FBT cells as described above (section 2.3.1), the cells were
washed with 1 ml of DMEM per well, the medium was removed and 1 ml of staining overlay,
consisting of DMEM/Hams F12 with 4 % FCS, 0.2 mg/ml X-Gluc (Clonetech, USA) and 1%
low-melting point agarose, was added per well. The staining overlay was preheated at 45˚C
before adding to each well. The staining overlay was incubated at room temperature until the
agarose solidified. The cells were incubated at 37˚C, 5% CO2 for 6 hours, before observing the











2.3.3 Immunofluorescence staining for transient expression of HIV-1 p24 (Gag) from pYS-
05
Before seeding FBT cells into 6 well tissue culture plates, sterile round glass cover slips (1.2 cm
in diameter) were placed into each well. The cells were seeded as described above (2.2.3.1).
Confluent FBT cells on the cover slips were transferred to separate wells of a 24 well tissue
culture plate. The cells were left uninfected, infected, transfected, or both infected and
transfected. Infection was at a m.o.i. of 1 ffu/cell. One microgram of pYS-05 was transfected
into designated FBT cells as described in section 2.3.1. The plates were incubated at 37 C, 5%
CO2 for 24 hours.
After incubation, the cells were washed with PBS, fixed with pre-cooled acetone methanol mix
(1:1) at 4 C for 10 minutes, blocked with 5% bovine serum albumin (BSA) diluted with PBS
(500 μl per well) for 30 minutes at room temperature, washed twice with PBS for 10 minutes
per wash at room temperature and then incubated at 37 C for 1 hour with sheep anti-p24
antibody diluted 1/100 in 1.5% BSA (200 μl per well). The cells were then washed three times
with PBS for 10 minutes per wash at room temperature, before being incubated with FITC
conjugated donkey anti-sheep antibody (DAKO, Denmark) diluted 1/500 in 1.5% BSA. 200 μl
of the antibody dilution was added to each cover slip. The adsorption was carried out at 37 C for
1 hour after which the cells were washed with PBS as before. The cover slips were then rinsed
with distilled water, air dried, mounted on to glass slides with anti-fade mounting fluid (Sigma-
Aldrich, USA) and viewed using a fluorescent microscope.
2.3.4 Detection of transient expression of HIV-1 RT from pYS-05  by Western blot analysis
2.3.4.1 Protein sample preparation
FBT cells, seeded into a six well tissue culture plate, were infected with LSDV and transfected
with pYS-05 as described in section 2.3.1.
The FBT cells were washed with PBS and incubated with 200 μl of 1 x CAT lysis buffer (Roche,
Germany), 1 x Complete® protease inhibitor (Roche, Germany) for 30 minutes at room
temperature. The total protein concentration of each sample was determined using the Bio-Rad
DC Protein Assay kit II according to the manufacturer’s instructions. Sample absorbance











Fifty micrograms of sample was used in a total of 40 μl including loading buffer (50 mM Tris-
HCl; pH 6.8, 2% SDS, 10% Glycerol, 1% -Mercaptoethanol, 12.5 mM EDTA and 0.02%
Bromophenol Blue). The samples were heated at 100˚C for 10 minutes and centrifuged briefly
using a microfuge. 100 ng of RT protein and 10 μl of Precision Plus proteinTM Kaleidoscope
standard (Bio-Rad, USA) were also prepared for PAGE.
2.3.4.2  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
A 10% separating gel (Bio-Rad, USA) was prepared. The mix was poured into assembled glass
plates leaving 2 cm from the gel to the top of the plate. The gel was then topped up with 1 ml of
isopropanol to ensure polymerization in the absence of oxygen. After 20 minutes the
isopropanol was poured off and gel rinsed with distilled water. The remaining water droplet was
removed using Whatman paper.
The 5% stacking gel solution was prepared (Bio-Rad, USA) and poured between the plates to
the top. The comb was inserted into the unset stacking gel, which was left to polymerize for 45
minutes.
The plates were removed from the casting apparatus and clipped onto the electrophoresis
apparatus. 1 x SDS buffer was added to the apparatus until the top of the small plate was
covered. The comb was then removed from the gel and the wells were flushed with buffer to
remove excess acrylamide. The marker and the samples were loaded into the wells and
electrophoresis was carried out at 180 V for 45 minutes.
The gel was removed from the plates and soaked in transfer buffer (25 mM Tris and 192 mM
glycine) for 30 minutes. Hybond™-P membrane (Amersham, USA) and blotting paper was cut
to the same size as the gel. The pieces of blotting paper were soaked in transfer buffer until use.
The membrane was soaked in methanol for 2 minutes, washed in water for 5 minutes, soaked in
transfer buffer for 5 minutes and stored in transfer buffer until use. The transfer sandwich was
set up on a BioRad SD semi-dry Electroblotting apparatus in the following order: blotting paper,
gel, membrane and blotting paper. Air bubbles were removed before starting the electroblotting
procedure. Electro blotting was done at 25 V for 1 hour. After disassembling the blotting
sandwich the membrane was rinsed in 1 x TBS and stained with Ponceau S (0.1% Ponceau S,
5% acetic acid) for 2 minutes. The Ponceau S was then discarded and the membrane was rinsed
with water until protein bands were visible. The membrane was then soaked in blocking buffer











Sheep-anti RT antibody (1/2000 dilution) was prepared in a total of 20 ml blocking buffer. The
blocking buffer was removed from the membrane. The prepared antibody was added to the
membrane and left on a shaker to allow very gentle agitation for 2 hours. The blot was washed
four times with blocking buffer for 15 minutes per wash with high speed shaking. The blocking
buffer was then removed and anti sheep antibody conjugated with alkaline phosphatase, diluted
1 in 10000 (2 μl in 19.998 ml blocking buffer), was added to the membrane and left on a shaker
at room temperature for 1 hour with gentle agitation.
The membrane was washed four times as before and rinsed in 1 x TBS. The membrane was kept
in TBS until substrate solution was added. The substrate solution of alkaline phosphatase was
prepared by dissolving 1 NIP/BCIP tablet (Roche, Germany) in 10 ml of water. The substrate
solution was poured on to the membrane. The membrane was kept in the dark for 5-10 minutes
for colour development.
2.4 Construction and Purification of Recombinant LSDV Expressing HIV-1
Polyprotein Grttn (rLSDV-Grttn)
2.4.1 rLSDV-Grttn construction
Recombinant LSDV was generated from homologous recombination between the transfer vector,
pYS-05 and LSDV genomic DNA. pYS-05 was transfected into LSDV-infected FBT cells as
described in section 2.3.1. Recombinant LSDV was isolated after repeated passage of the
transfection lysate under Gpt selection conditions and detection of reporter gene, GUS,
expression. The procedures performed are detailed below.
FBT cells were seeded into six well tissue culture plates as described in section 2.2.3.1. The
cells were infected with LSDV diluted in 1ml DMEM, at a m.o.i of 0.1 ffu/ cell. Five hours post
infection, FBT cells were transfected with 0.4 μg of pYS-05 as described in 2.3.1. Twenty-four
hours post transfection, the FBT cells were washed with DMEM before adding selection
medium (25 μg/ml mycophenolic acid, 250 μg/ml xanthine, 4% FCS in DMEM). The FBT cells
were incubated as before for 72 hours. The virus was released from the FBT cells by freezing
and thawing three times.
The harvested cell lysate was used to infect 80-90% confluent FBT cells seeded in a 25 cm2
tissue culture flask. After one hour adsorption, the virus suspension was removed and selection











passaged in the same way four times before picking foci.
The virus suspension was diluted in serial 10 fold dilutions (10-2 to 10 -7). 80-90% confluent
FBT cells seeded in six well tissue culture plates were infected with different dilutions of the
virus. Seventy-two hours post infection GUS staining was performed on infected FBT cells as
described in section 2.3.2. Six hours after adding the staining overlay, the plate was viewed
using a light microscope at 100 x magnification. Blue foci were picked using p200 pipette tips
and inoculated into 500 μl of DMEM. Virus from these foci was released with three cycles of
freezing and thawing. Each picked focus was used to infected separate wells of 80-90%
confluent FBT cells and incubated as before in selection medium. The process of infection and
purification by focus picking was performed eight times until a pure recombinant LSDV
(rLSDV-Grttn) stock was obtained.
The pick purified recombinant LSDV was propagated by infecting 80-90% confluent FBT cells
in tissue culture flasks (Greiner, Germany) repeatedly. Virus infected cells were subjected to
three cycles of freezing and thawing. The cell lysate was then centrifuged at 2500 rpm for 5
minutes to pellet the lysed cell debris. The virus-containing supernatant was then used to infect
FBT cells in 10 flasks of 175 cm2. Seventy-two hours post infection the virus-containing
supernatant was purified as described in section 2.2.3.3 This propagation process of rLSDV-
Grttn was repeated five times to increase the titre of rLSDV-Grttn.
2.4.2 Identification of wild-type and recombinant LSDV by PCR analysis
The presence of wild-type LSDV carried over from each pick-purification step was monitored
by PCR. Three primers were designed: SQRR1, 5’-GTGGGCGTCAATGTTGAC-3’, binds
specifically to LSDV DNA sequences immediately upstream of the ribonucleotide reductase
gene (insertion site). SQGrttn3, 5’-GCTACTTCCCCGACTGGC-3’, binds specifically to
sequences within and towards the end of the Grttn gene. Anti-sense primer SQRR2, 5’-
CATAAAATCAGTACATGCATCC-3’, binds specifically to LSDV sequences immediately
downstream of the ribonucleotide reductase gene. The DNA fragments amplified from rLSDV-
Grttn or wild-type LSDV can be distinguished by size differences; the DNA fragments amplified
from rLSDV-Grttn and wild-type LSDV are 1.2 kb and 1.4 kb respectively. All three primers
were added to each PCR reaction to detect both wild-type and recombinant virus in a single
reaction.
Confluent monolayers of FBT cells in six well tissue culture plates were prepared as described











approximate m.o.i. of 0.05 ffu/cell and DMEM with 4 % FCS (no selection) was added after
viral adsorption. The plate was incubated at 37˚C, 5 % CO2 for 48 hours. The cells were
harvested by scraping into the growth medium and transferred to a 1.5 ml microfuge tube. The
cell suspension was centrifuged at 14000 rpm for 10 minutes. The pellet was resuspended in 50
μl lysis buffer A (100 mM KCl, 10 mM Tris-HCl pH 8.3 and 2.5 mM MgCl2). Fifty microlitres
of lysis buffer B (10 mM Tris-HCl pH 8.3, 2.5 mM MgCl2 and 1.5% Tween-20) was added to
the suspension, followed by Proteinase K (Roche, Germany) (1 mg/ml). The suspension was
incubated at 60˚C for 1 hour, followed by incubation at 90˚C for 10 minutes to inactivate the
Proteinase K. This DNA extraction method was taken from (Kellogg & Kwok, 1990).
PCR was performed on the lysates using Pfu polymerase (Promega, USA) according to the
manufacturer’s guidelines. The PCR was carried out with an initial denaturing step at 95˚C for 2
minutes, followed by 35 cycles of 95˚C for 1 minute, 55˚C for 30 s, 73˚C for 5 minutes and a
final elongation step of 73˚C for 7 minutes. The samples were then subjected to agarose gel
electrophoresis (section 2.1.4).
2.4.3 Confirmation of HIV-1 polyprotein Grttn expression by rLSDV-Grttn using western
blot analysis
The expression of full length Grttn by rLSDV-Grttn was confirmed using western blot analysis,
using HIV RT- and Gag- specific antibodies. 80-90% confluent FBT cells in a six well tissue
culture plate were 1) infected with rLSDV-Grttn (m.o.i of 0.01 ffu/cell), 2) infected with wild-
type LSDV (m.o.i of 0.01ffu/cell) or 3) left uninfected.
Forty-eight hours post infection, protein samples of infected and uninfected FBT cells were
prepared and subjected to SDS-PAGE and western blot analysis as described in section 2.3.4. A
positive control of a lysate of SAAVI-MVA (recombinant MVA expressing HIV-1 subtype C
Grttn and gp150 (Burgers et al., 2008; Shephard et al., 2008))-infected BHK-21 cells was
available within the department.
2.5 Mouse Immunizations
2.5.1 Other vaccines used in the immunization
pVRCgrttnC, a DNA vaccine which codes for the HIV-1 polyprotein Grttn, was constructed by
cloning Grttn with an enhancer intron A and a Kozak sequence, downstream of the











rMVA-Grttn, a recombinant MVA expressing the same HIV-1 polyprotein Grttn, expressed from
the same vaccinia virus H5 promoter as in rLSDV-Grttn, and also containing the reporter
gene -glucuronidase (GUS), was constructed by Nicolette Johnston (former member of the
department).  These genes were inserted into the deletion III region of the MVA genome.
2.5.2 Mice
All mouse procedures were done according to guidelines and approval of the University of Cape
Town Animal Research Ethics Committee. RAG mice (lacking both T-cells and B-cells) and
CD4 T cell knockout mice (6-8 weeks old) used for testing the safety of wild-type LSDV
(wtLSDV), were purchased from Prof. Frank Brombacher (Immunology, IIDMM, UCT) and
housed in a BSL-3 facility for the duration of the experiment. Female H-2d BALB/C mice
required for immunogenicity testing of rLSDV-grttn were purchased from South African
Vaccine Producers (Pty) Ltd (Johannesburg, South Africa) and housed in a BSL-2 facility at the
University of Cape Town Animal Unit. They were allowed to acclimatize for a minimum of 10
days prior to vaccinations.
2.5.3 Inoculation of immunocompromised mice with wild-type LSDV
Twenty RAG mice (4 groups) and 20 CD4 knockout mice (4 groups) were inoculated as
indicated in Table 2.2. Two different doses of wtLSDV (104 and 106 ffu per mouse) were tested.
Naïve mice and PBS vaccinated mice served as controls. The well-being of the mice (active and
inquisitive when disturbed with clean and groomed hair coat) was observed daily and their
weight recorded and plotted on a daily basis. On day 6, day 11 and day 30 post vaccination,
differences in weight from that prior to vaccination were calculated as a percentage of pre-
vaccination weight and presented as percentage weight change. This data for these days was
statistically analysed for all mouse groups using the one-way ANOVA test with 95% confidence











Table 2.2. Safety of LSDV in immunocompromised mice. Inoculation and sacrifice schedule for groups of CD4
knockout mice and RAG mice (five mice per group).
Mouse Group

























































































2.5.4 Immunogenicity of rLSDV-Grttn in combination with a DNA vaccine (pVRCgrttnC)
Forty-five 8-10 weeks old female BALB/C mice in 9 groups with 5 mice per group were
vaccinated as indicated in Table 2.3. The mice were pre-bled one week before the first
inoculation. Wild-type MVA (wtMVA) and wtLSDV served as control vaccines. The viruses
(106 ffu in 100 μl PBS) and the DNA vaccine pVRCgrttn (100 μg DNA in 100 μl PBS) were
injected by the intramuscular route, with 50 μl injected into each quadricep muscle. At the end
of the experiment on day 40, blood was collected from the mice by cardiac puncture followed by











Table 2.3 Immunogenicity of rLSDV-Grttn alone and when used as a booster vaccine after a prime with
pVRCgrttnC (DNA vaccine). Vaccination and sacrifice schedule for 9 groups of BALB/c mice (five mice per
group). wtMVA and wtLSDV were used as controls.
Mouse Group
with 5 mice per
group








































































































2.5.5 Immunogenicity of rLSDV-Grttn in combination with  rMVA-Grttn
2.5.5.1 Experiment A) Immunogenicity of the poxvirus prime/boost regimens
Forty-five 8-10 weeks old female BALB/C mice in 9 groups of 5 were vaccinated as indicated
in Table 2.4A. The mice were pre-bled one week before the first inoculation. For these
experiments wtMVA and wtLSDV served as control vaccines. The viruses (106 ffu in 100 μl
PBS) were injected by the intramuscular route, with 50 μl injected into each quadricep muscle.
At the end of the experiment on day 40, blood was collected from the mice by cardiac puncture
followed by cervical dislocation and harvest of the spleens (Table 2.4A).
2.5.5.2 Experiment B) Characterization of the immunogenicity of poxvirus prime/boost
regimens
Fifteen 8-10 weeks old female BALB/C mice in 3 groups of 5 were vaccinated as indicated in
Table 2.4B. The mice were pre-bled one week before the first inoculation. wtMVA and wtLSDV
served as control vaccines. The viruses (106 ffu in 100 μl PBS) were injected by the
intramuscular route, with 50 μl injected into each quadricep muscle. At the end of the
experiment on day 40, blood was collected from the mice by cardiac puncture, followed by











Table 2.4A Immunogenicity of rLSDV-Grttn alone and in homologous and heterologous and prime-boost
combinations with rMVA-Grttn. Vaccination and sacrifice schedule for 9 groups of BALB/c mice (five mice per
group). wtMVA and wtLSDV were used as controls.
Mouse Group
with 5 mice per
group










































































































Table 2.4B Characterization of the immunogenicity of heterologous poxvirus prime/boost regimens. Vaccination
and sacrifice schedule for 3 groups of BALB/c mice (five mice per group) in heterologous prime/ boost vaccination
regimens deploying rLSDV-Grttn and rMVA-Grttn.
2.6 Immunogenicity Assays
2.6.1 Isolation of mouse splenocytes
After the mice were sacrificed, spleens were harvested and pooled from 5 mice per group into
ice cold RPMI.
The pool of spleens from a group of mice was poured on to a cell strainer (pore size= 70µm)
with a sterile petri dish below. The spleens were meshed gently through the cell strainer with a
rubber plunger of a 2 ml syringe. The remaining cells were washed off the strainer with RPMI
into the collecting petri dish. The meshed spleens were transferred to sterile 50 ml conical tubes.
Collecting petri dishes were washed with RPMI and the solutions were transferred to the same
tube. The volume of the cell suspension in each tube was adjusted to 50 ml using RPMI. The
cells were pelleted by centrifuging the tubes at 400 g for 5 minutes. The supernatant was
decanted and the cell pellet was gently resuspended in 50 ml of RPMI. The cells were then
washed twice more by repeating these steps. After the last resuspension step, fibrin clots were
removed with a sterile Pasteur pipette. Cells were resuspended in 50 ml RPMI and cell number
and viability was determined by counting an aliquot of the cells in a Neubauer counting chamber
after staining them with trypan blue stain. Red blood cells (RBCs) were lysed by suspending
50x106 cells in 1ml of RBC lysis buffer (5 mM Tris-HCL, 140 mM NH4Cl, pH 7.3, Sigma-
















































minutes. The supernatant containing the lysed red cells was discarded and splenocytes were
resuspended in 5 ml RPMI and an aliquot of this suspension was stained with trypan blue and
counted in a Neubauer chamber. Cells were then suspended at a final concentration of 5 x 106
cells/ml in R10 medium (RPMI supplemented with 1% penicillin G/streptomycin, 10% FCS and
0.1% 2-mercaptoethanol). For the experiment detailed in Table 2.4B where the effect of FCS on
background responses in the IFN-γ ELISPOT was investigated the cells were resuspended at 5 x
106 cells/ml serum free medium (SFM; CTL TESTTM medium  from Cellular Technology Ltd,
Cleveland, Ohio) supplemented with 200 mM of L-glutamine (Sigma-Aldrich, USA)
2.6.2 ELISPOT Assays
The IFN-γ and IL-2 ELISPOT kits from BD Bioscience were used for the ELISPOT assays.
Instructions provided in the kit protocol were followed during the assay. The responses to each
of the stimulant peptides or controls were tested in triplicate for splenocytes from each group of
inoculated mice.
Twelve hours before the sacrifice of the inoculated mice, ELISPOT plate membranes were pre-
wetted with 15 μl of 35% ethanol for one minute. The membranes were then washed three times
with 200 μl of PBS. The PBS was discarded from the wells and the membranes were coated
overnight at 4 ºC with 100 μl of IFN-γ or IL-2 coating antibodies (5 μg/ml diluted in PBS) per
well.
The coating antibodies were then discarded and the membranes were washed once with R10 or
CTL TESTTM medium and then blocked with 200μl of complete medium or CTL TESTTM
medium for two hours at room temperature.
Splenocytes were stimulated with peptides corresponding to CD4+ and CD8+ T cell epitopes in
Gag and RT. An irrelevant peptide was included as a negative control (Table 2.5). Peptides were
used at 2 μg/ml in R10 or glutamine supplemented CTL TESTTM medium. The polyclonal
stimulus ConA (5 μg/ml) was included as a positive control (no data for this response is











Table 2.5 Control and peptide stimulants used in ELISPOT assays
Stimulant/ Control Description Peptide sequences
Con A






















RT MHC class II-restricted
peptide (CD4 peptide)
PKVKQWPLTEVKIKALTAI
After blocking, the R10 medium or CTL TESTTM medium in the wells was discarded. Stimulant
and control peptides and ConA were added to the allocated wells in triplicate for each group
(100 μl/well). 100 μl of R10 medium or CTL TESTTM medium were also included in triplicate
as a background control for the assay. This was followed by adding 100 μl of the splenocyte
suspensions into allocated wells on the plates. The plates were protected from light exposure by
covering them with foil, which also prevented evaporation. The plates were then incubated at
37oC, 5% CO2, humidified air incubator for 23 hours.
After the incubation, the cell suspensions were discarded from the plates and the membranes
were washed three times with deionised water. The water was removed from the wells, and the
membranes were washed three times with PBS+ 0.05% Tween 20 (Sigma-Aldrich, USA). The
PBS + 0.05% Tween 20 was then discarded and a volume of 100 μl of biotinylated anti- IFN-γ
or IL-2 detection antibody (2μg/ml in PBS with 10% FCS) was added to each well. The plates
were incubated at room temperature in the dark for two hours after which the antibodies were
discarded and the membranes washed three times with PBS+ 0.05% Tween 20. A volume of
100μl of avidin-horseradish peroxidase (Avidin-HRP) conjμgated anti- IFN-γ or IL-2 detection
antibodies (5 ug/ml in PBS with 10% FCS) was added to each well and the plates were
incubated at room temperature in the dark for one hour. The antibody was discarded and the
membranes were washed three times with PBS+ 0.05% Tween 20 then three times again with











water and a volume of 100 μl was added to each well. The plates were incubated at room
temperature in the dark for 5 minutes for spot development. The reaction was stopped by
washing five times with distilled water. The plates were dried in the dark before analysis.
The ELISPOT plates were scanned using an ImmunoSpot CTL Reader and the spots in each
well were counted using ImmunoSpot Software version 3.2. The software parameters indicated
in Table 2.6 were used to avoid the counting of spots due to debris or mechanical damage.
Table 2.6 ImmunoSpot Software parameters used for ELISPOT data acquisition
Parameters name Parameter status
Sensitivity 140
Minimum spot size 0.0025 mm2
Maximum spot size 0.2907 mm2
Oversized spots Estimated
Spot separation 1.00
Diffuse spot process On
Diffuseness 40
Gradient Off





Background balance On at 80
Fill holes Off
Audit spots Inactive
For each reaction, the mean number of spots from triplicate wells and the standard deviation
(SD) of this mean were calculated and adjusted to 1 x 106 splenocytes and expressed as spots
forming units per 1 x 106 splenocytes (SFU/106 splenocytes).The mean number of spots and its
SD in the absence of peptide for each group was used as the background response for the group.
Positive responses of the splenocytes to HIV-1 peptides in each group were considered to be
those greater than the background response plus two times the SD of this background response.
For all positive responses, the background responses of the group were subtracted from the HIV-











2.6.3 Quantification of antigen-specific cytokine production
Aliquots of the splenocytes pooled from 5 mice per group were also used to quantify the
cytokines released from the splenocytes during culture with Gag and RT peptides. Splenocytes
were adjusted to 15 x 106 splenocytes/ml with R10 medium and 100 μl of the splenocyte
suspension (1.5 x 106 splenocytes) was added to each well in a 96 well round-bottom micro-titer
plate followed by the addition of 100 μl of R10 medium, ConA or stimulant peptides (as
described in Table 2.5 and used in the ELISPOT assays). The plate was incubated at 37C, 5%
CO2 in a humidified air incubator for 48 hours after which 150 μl of the supernatant from each
well was harvested without disturbing the cell pellets. The supernatants were then stored at -
20C  until the cytokine content was determined using a BDTM cytometric bead array (CBA)
mouse Th1/Th2 cytokine kit (BD Biosciences, USA) that measures IFN-γ, TNF-α, IL-2, IL-5
and IL-4.
The CBA assay was carried out according to the kit protocol. Briefly, lyophilized mouse
Th1/Th2 standards were transferred to a FACS tube and reconstituted in 2 ml of assay diluent.
The reconstituted standards were allowed to equilibrate at room temperature for 15 minutes.
Serial dilutions (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256) of the reconstituted cytokine
standards were made in FACS tubes. Three hundred microlitres of assay diluent were first
pipetted into each of these tubes. A tube with assay diluent only was also prepared as a negative
control.
The number of assays including the standards and the controls were determined. Individual
capture beads (A1-A5, IL-2, IL-4, IL-5, IFN-γ and TNF-α capture beads respectively) were
vortexed vigorously before pooling specific volumes of capture beads together in a FACS tube
(10 μl of each type of capture bead per assay). The bead mixture was then mixed thoroμghly
again.
The assays were set up in FACS tubes. 50 μl of capture bead mixtures were added to each tube.
50 μl of each standard dilution were added into allocated tubes. 50 μl of test sample supernatants
were added into allocated tubes.
Fifty microlitres of Th1/Th2 PE detection reagents were then added into each of the tubes
containing standards and test samples. The tubes were incubated at room temperature for two
hours in the dark.











then centrifuged at 200 g for 5 minutes. The supernatants were carefully discarded and each
bead pellet was resuspended with 300 μl of wash buffer. The samples were then analyzed by
flow cytometry as recommend by the instructions in the kit.
2.6.4 Staining of splenocytes with MHC-1 H-2Dk pentameric peptide complexes
2.6.4.1 Staining strategy for HIV-1 specific, CD8 + and CD44+ T cells
HIV-1 Gag- or RT- specific CD8+ T cells in the spleens were detected by binding of pentameric
H-2Dk complexes folded with the Gag CD8+ or RT CD8+ peptide (see Table 2.5) conjugated to
APC (Proimmune, Oxford, UK) and binding of anti-CD8 antibody conjugated with PerCP
(Pharmingen). The antigen-experienced marker CD44 on these T cells was detected using an
anti-CD44 antibody conjugated to FITC (Pharmingen). Non-specific binding of the pentameric
complex to B-cells and monocytes was eliminated by gating on a CD45R/B220 and CD14
negative cell populations defined using CD45R/B220 and CD14 antibodies conjugated with PE
(Pharmingen).
3 x 106 splenocytes, isolated from groups of mice vaccinated according to Table 2.4B,
resuspended in CTL TESTTM medium, were aliquoted per FACS tube. 2 tubes were prepared for
each group (one tube for Gag pentameric complex binding, one tube for RT pentameric complex
staining). The aliquoted cells were centrifuged at 500 g for 5 minutes at 4ºC and the CTL
TESTTM medium was discarded. The cells were resuspended in residual volume in the tubes for
the staining process. A volume of 30 μl of Gag or RT pentameric complexes was added to the
designated tubes and mixed. The cells were then incubated for 10 minutes at room temperature,
shielded from light. During the incubation, an antibody mix solution containing anti-CD8-perCP,
anti-CD45R/B220-PE, anti-CD44-FITC and CD14-PE was prepared in FACS buffer (0.1%
Sodium Azide, 1% foetal calf serum in PBS) according to Table 2.7.
Table 2.7. Antibodies used in addition to the APC-conjugated Gag or RT pentameric complexes to select for Gag
or RT specific CD44+, CD8+ T cells.
Antibody-conjugated fluorochrome
Working concentration
















After 10 minutes incubation, 150 μl of the antibody mix solution was added to the cells. The
cells were incubated at 4ºC for 30 minutes, shielded from light, then washed with 1 ml of FACS
buffer, followed by an addition of 1 ml FACS lyse solution, then incubated at room temperature
for 10 minutes in the dark. The cells were then centrifuged as before. After discarding the
supernatant, the cells were washed twice with 1 ml FACS buffer. The cells were then
resuspended in 900 μl of FACS buffer per tube and analyzed by flow cytometry.  The gating
strategies used in flow cytometric analysis for Gag- or RT- specific/ CD44+/ CD8+ T cell
populations are illustrated in Figure 2.2.
Figure 2.2 Cell gating strategies used in flow cytometric analysis for Gag- or RT- specific/ CD44+/ CD8+ T cells.
Progressive gating: Lymphocytes (plot 1, R1), B-cells (plot 2, R2), CD8+ T cells (plot 3, R3), Pentameric H-2Dk
complexes folded with the Gag CD8+ or RT CD8+ peptide (pent)+/CD8+ T cells and pent+/CD44+/ CD8+ T cells
(Plot 5, UR).
2.6.4.2 Staining strategy for HIV-1 specific, CD8 + and CD107a/b+ T cells
Splenocytes (from groups of mice vaccinated as indicated in Table 2.4) in CTL TESTTM medium
were aliquoted at 3 x106 splenocytes per FACS tube. Four tubes were prepared for each group
(two tubes for Gag pentameric complex and RT pentameric complex staining with peptide
stimulations, two tubes for Gag pentameric and RT pentameric staining without peptide
stimulations).
3 tests of Gag or RT pentameric complexes (30 μl) were added to the designated tubes with the
splenocytes and mixed by pipetting. The cells were then incubated for 10 minutes at room
R1SSC
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Plot 3: CD8+ T cell gate
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temperature, shielded from light. The splenocytes were washed with 2 ml of CTL TESTTM
medium, and then centrifuged at 500 g for 5 minutes at 4ºC. The CTL TESTTM medium was
then discarded and the splenocytes were resuspended in 300μl of CTL TESTTM medium per tube.
Antibody mix solution described in Table 2.8 were prepared for stimulated splenocytes and
unstimulated splenocytes.






Volume (μl) Volume (μl)
CD107a-FITC 0.5 6.0 6.0
CD107b- FITC 0.5 3.0 3.0
Anti-CD28 1.0 1.2 1.2
Anti-CD49d 1.0 1.2 1.2
After a 10 minute incubation, the splenocytes were washed as before then resuspended in 300 μl
of CTL TESTTM medium per tube. The antibody described in Table 2.8 was added to the Gag or
RT pentameric complex stained splenocytes in designated tubes. In the stimulated splenocytes,
0.6 μl of Gag CD8 or RT CD8 peptide (4 μg/ml, Table 2.5) was added to the splenocytes in the
appropriate tubes. In the unstimulated splenocytes, 0.6 μl of CTL TESTTM medium was added to
splenocytes in each of the appropriate tubes. The volume in each tube was adjusted to 600μl
with CTL TESTTM medium and the tubes were incubated at 37˚C, 5% CO2 in a humidified air
incubator for 1.5 hours. BD GolgiStop™ containing monensin (1.2 μl, BD Bioscience, USAs)
was added to each tube and the incubation continued for a further 4.5 hours.
After the incubation the splenocytes were washed with 1 ml CTL TESTTM medium. Antibody
mix solution containing anti-CD8-perCP, anti-CD45R/B220-PE, and CD14-PE were prepared in











Table 2.9 Antibodies used in addition to the Gag or RT pentameric complexs and CD107a/b antibody in selecting
Gag or RT specific, CD107a/b+, CD8+ T cells
Volumes of 150 μl of the antibody mix solution described in Table 2.9 were added into each tube
of cells. The tubes were incubated at 4ºC for 30 minutes, shielded from light. The cells were
then washed with 1 ml of FACS buffer per tube, followed by an addition of 1 ml FACS lyse
solution. The cells were further incubated at room temperature for 10 minutes, shielded from
light. The cells were then centrifuged as before. After discarding the supernatant, the cells were
then washed with 1 ml FACS buffer per tube and centrifuged as before twice. The cells were
then resuspended in 900 μl of FACS buffer per tube and analysed by flow cytometry. The gating
strategies used in flow cytometric analysis for Gag- or RT- specific/ CD107a/b+/ CD8+ T cell
populations are illustrated in Figure 2.3.
Figure 2.3 Cell gating strategies used in flow cytometric analysis for Gag- or RT- specific/ CD107a/b+/ CD8+ T
cells. Progressive gating strategy: Lymphocytes (plot 1, R1), B-cells (plot 2, R2), CD8+ T cells (plot 3, R3),
Pentameric H-2Dk complexes folded with the Gag CD8+ or RT CD8+ peptide (pent)+/CD8+ T cells and
pent+/CD107a/b+/ CD8+ T cells (Plot 5, UR).
Antibody-conjugated fluorochrome










Plot 3: CD8+ T cell gate
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2.6.5 New LAV Blot assay
The New LAV blot Assay kit (Bio-Rad), a western blot based human HIV-1 specific antibody
detection kit, was used according to the manufacturer’s instructions. Briefly, the serum from the
vaccinated groups of mice described in Table 2.3 and 2.4A, obtained during pre-bleed and post
sacrifice were pooled separately within each group. The membrane strips were placed into each
well with the labeling number and reference mark facing upwards. Two millilitres of the diluted
wash buffer was added to each strip and incubated at room temperature for 5 minutes with
gentle shaking.
Twenty microlitres of the positive and negative control antibodies and 50 μl of each group of
pooled serum was added to the corresponding strips into the 2 ml buffer that was already in the
well. The strips were then incubated at room temperature for 2 hours with gentle shaking. After
the incubation, the buffer in the wells was aspirated. Two millilitres of wash buffer was added to
each well and removed immediately. Two millilitres of wash buffer was then added to each well
and incubated for 5 minutes at room temperature with shaking. The process was repeated for
another wash.
Because the kit was designed to detect human antibodies against HIV proteins, secondary
antibody specific for mouse immunoglobulin was used for the serum samples from mice. Two
millilitres of washing buffer was added to each of the strips 1-5. Four microlitres of alkaline
phosphatase conjugated goat anti mouse IGG (Dako) was added to the buffer in which the strips
probed with mice sera were. Two millilitres of the conjugate solution provided in the kit were
added to the well containing the controls. The strips were incubated at room temperature for 1
hour with gentle shaking. After incubation the strips were washed as before with wash/diluent
buffer three times.
Finally, the wash buffer was removed and 2 ml of development reagent was added to each strip
and incubated at room temperature for 5 minutes. The reaction was then stopped by washing the
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3.1.1 Construction of recombinant poxviruses
Technologies of recombinant poxvirus production have enabled the use of genetically modified
poxviruses for the molecular biology of the poxvirus, and also in recombinant poxvirus vaccine
vector research (Souza et al., 2005). Because the poxvirus genome is not transcribed by the host
cellular enzymes, the poxvirus DNA is not infectious. Therefore, direct modification of
extracted poxvirus DNA will not produce any infectious virion (Moss, 1996)
Recombinant poxviruses are generally constructed by insertion of foreign genes using a transfer
vector containing the genes of interest flanked by poxvirus sequences.  The latter allow for
homologous recombination into a specific site of the poxvirus genome. In order to produce a
recombinant poxvirus expressing foreign genes, it is essential to consider the unique properties
of the poxvirus transcription system when designing the transfer vectors. Poxvirus transcription
occurs in the cytoplasm of the infected cell and poxviral RNA polymerase is required for
transcription of viral genes.  Promoters are also specific for poxviruses. It is therefore essential
to have a poxvirus promoter sequence upstream of the inserted foreign gene (Schnierle et al.,
2007). The foreign gene should also have its own translation initiation codon (ATG) and stop
codon. There should be no poxvirus early transcription termination sequence (TTTTTNT) (Yuen
& Moss, 1987) within the inserted genes to ensure the correct and complete expression of the
genes.
The conventional approach to constructing a recombinant poxvirus is to introduce the foreign
genes into a non-essential region of the poxvirus genome by homologous DNA recombination
(Moss, 1996). This approach involves constructing an expression cassette on a transfer plasmid
(Figure 3.1). The expression cassette would consist of several foreign genes under the control of
upstream poxvirus promoters. These genes would include the antigen gene of interest if
constructing a recombinant poxvirus vaccine, and possibly a reporter gene and a positive
selection gene. The expression cassette has to be flanked by DNA sequences that are
homologous to the two ends of the poxvirus non-essential gene or non-coding region in which
the foreign DNA is to be inserted.  The thymidine kinase (TK) gene has been used as a common
non-essential target gene for foreign gene insertion into the poxvirus genome (Boyle & Coupar,
1988; Mackett et al., 1982; Wallace & Viljoen, 2005). The inactivation of TK  by foreign gene
insertion allows the recombinant poxvirus to be selected in TK deficient cell lines (Mackett et











active wild-type poxvirus. Other insertion sites have also been demonstrated to be non-
disruptive for the replication and growth of certain poxviruses, such as the Del III region of
MVA (Wang et al., 2004) and the ribonucleotide reductase (RR) gene of LSDV (Aspden et al.,
2002; Aspden et al., 2003). In this study, we have chosen the ribonucleotide reductase gene as
the insertion site for constructing a recombinant LSDV. The use of this gene as a site into which
to insert foreign DNA into the LSDV genome has previously been demonstrated to be successful
in our department (Aspden et al., 2002). Additionally, an antibiotic resistance gene and reporter
gene may be included in the expression cassette for the selection of recombinant poxviruses.
Figure 3.1 Production of recombinant poxvirus through DNA recombination between the viral genome and the
transfer plasmid. The transfer plasmid has an expression cassette which consists of a reporter gene, a positive
selection gene and the gene (s) of interest to be inserted into the poxvirus, all with suitable upstream poxvirus
promoters. These genes are flanked by DNA homologous to the insertion site in the poxvirus genome, usually a
non-essential gene. The transfer plasmid is transfected into poxvirus infected cells and homologous recombination
takes place between the poxvirus non-essential gene and flanking DNA in the transfer plasmid during poxvirus
DNA replication. The expression cassette in the transfer plasmid is inserted into the non-essential gene of the
poxvirus genome. The recombinant virus can be detected and selected for by means of reporter gene and positive
selection gene expression respectively. This figure is adapted and modified from (Schnierle et al., 2007).
The E.coli xanthine-guanine phosphoribosyltransferase (Gpt) gene has been demonstrated to be
a useful positive selection gene to be incorporated into the recombinant poxvirus (Boyle &



































dehydrogenase, an enzyme involved in guanine nucleoside synthesis. In the presence of MPA
and xanthine, Gpt can overcome the block in guanine nucleoside synthesis by utilizing xanthine
as an alternative substrate for synthesis of GMP (Figure 3.2).
Figure 3.2 De novo guanine nucleotide synthesis pathways and the rescue of guanine nucleotide synthesis from
mycophenolic acid inhibition by xanthine-guanine phosphoribosyltransferase (Gpt). Mycophenolic acid inhibits
inosine monophosphate dehydrogenase and prevents the conversion of inosine monophosphate (IMP) to xanthosine
monophosphate (XMP). Gpt utilizes xanthine as an alternative substrate to synthesize XMP, which subsequently
gets converted to Guanosine monophosphate (GMP), an important precursor for DNA and RNA synthesis (Falkner
& Moss, 1988; Stasolla & Thorpe, 2004)
Reporter genes such as E.coli β-galactosidase (β-gal) (An et al., 1982) and β-glucuronidase
(GUS) (Jefferson et al., 1986) can enable the selection of recombinant poxviruses by colour.
Staining the virus infected cells with colourless substrates of these enzymes results in a blue
colour change due to the activity of the enzymes, thus clearly distinguishing the recombinant
poxvirus infected cells from the wild-type virus infected cells.  Alternatively, a fluorescent
reporter gene such as the Green fluorescent protein (GFP) gene can also be used to distinguish
the recombinant from wild-type virus with the aid of a fluorescence microscope (Cheng et al.,
1996).
This chapter describes the construction of a recombinant LSDV, rLSDV-Grttn, expressing HIV-1
subtype C polyprotein Grttn (Gag, RT, Tat and Nef). The cloning procedures for constructing the
transfer vector carrying Grttn are shown in Figures 3.4, 3.8 and 3.10, and the sequence of events
in the construction of rLSDV-Grttn are depicted in Figure 3.3. Experiments were performed to
confirm the expression of Grttn and to assess the purity of the final recombinant LSDV. The
immunogenicity of rLSDV-Grttn was tested in mice and compared to that of DNA and






















vaccination regimens employed using DNA vaccine, rLSDV-Grttn and rMVA-Grttn.
Figure 3.3. Flow chart of experimental progression in the construction of rLSDV-Grttn.
1. Construction of transfer vector
pYS-04 containing Grttn + GUS
flanked by LSDV RR
3. Infection of FBT cells with
LSDV, transfection with pYS-04,
with intention of isolating
recombinant virus
4. Picking of blue foci
(expressing GUS)
5. Further passage - resulted in
colourless foci
6. Repetition of steps 3-5 eight
times. Virus from picked foci was
shown to be wild-type LSDV by
PCR.
8. Infection of FBT cells with
LSDV, transfection with
pYS-05
7. Cloning of Gpt gene into transfer
vector to allow for the positive
selection of recombinant virus;
construction of pYS-05
9. Propagation with selection (mycophenolic
acid + xanthine) for 4 passages
10. Recombinant LSDV isolation by reporter
gene expression (GUS staining)
11. Picking of blue foci and PCR analysis
12. PCR positive for both wild-type
and recombinant virus
13. Repetition of steps 10 and 11 seven times
14. Isolation of pure recombinant rLSDV-
Grttn
15. Large-scale preparation of rLSDV-Grttn
in primary FBT cells
16. Confirmation of Grttn expression by
western blot analysis and purity of the
virus by PCR
2. Expression of Gus and Grttn from












3.2 Construction of Transfer Vectors Required for the Construction of
rLSDV-Grttn
3.2.1 Construction of transfer vector pYS-03, containing GUS and VV mH5 promoter
flanked by LSDV RR sequences
The plamid pLW-51 (Wang et al., 2004) was used as a backbone for constructing a LSDV
transfer vector. The plasmid contains the β-lactamase gene, ampR, which confers ampicillin
resistance. It also contains the reporter gene, -glucuronidase (GUS) under the control of the
VV p11 late promoter which allows recombinant virus to be identified by X-gluc staining for
GUS expression (blue coloration). Cloning sites are located downstream of two VV promoters,
the strong late synthetic promoter Psyn II and the weaker early/late mH5 promoter. This allows
for foreign genes to be expressed from either of these promoters. The GUS gene and multiple
cloning sites are flanked by two MVA DNA sequences homologous to the Deletion III region of
MVA, MVA flank I and MVA flank II. These flanking regions allow for the insertion of the
foreign DNA into MVA genomic DNA by homologous recombination. To modify this plasmid
into a LSDV transfer vector, the MVA flanking sequences were replaced with LSDV flanking
sequences homologous to the non-essential LSDV ribonucleotide reductase gene. The cloning
steps involved are depicted in Figure 3.4.
The two LSDV flanking sequences, LSDV flank I (LFI, 508 bp) and LSDV flank II (LFII, 552
bp), were successfully amplified from LSDV genomic DNA by PCR (Figure 3.5) using the LFI
and LFII forward and reverse primers (Table 2.1). In the primer design, restriction enzyme sites
EcoRI and BssHII were included in the 5’ ends of LFI forward and LFI reverse primers
respectively. PstI and HindIII were included in the 5’ ends of LFII forward and LFII reverse
primers respectively. These restriction enzyme sites were included to allow for the cloning of












Figure 3.4 Schematic representation (not to scale) of the cloning procedures followed in the construction of pYS-
03. LSDV flanking sequences, LFI and LFII, homologous to LSDV ribonucleotide reductase gene, were amplified
from LSDV DNA and cloned into pUC19. MVA flank I and II sequences from pLW-51 were replaced sequentially











Figure 3.5 Agarose gel electrophoresis of PCR products amplified from LSDV genomic DNA, corresponding to
flanking sequences LFI (lane 2, 508 bp) and LFII (lane 3, 552 bp), homologous to  the ribonucleotide reductase
gene. DNA molecular weight marker VII (Roche, Germany) is in lane 1 with relevant sizes indicated to the left.
Purified LFI and LFII were successfully cloned into the SmaI site of pUC19 by blunt-end
ligation followed by transformation of competent cells. Recombinant plasmids containing LFI
(pYS-01) and LFII (pYS-02) were identified by restriction enzyme analysis and the sequences
of the inserts were confirmed by DNA sequencing using pUC universal primers (M13 forward
and reverse primer) (Figure 3.6A and B).
Figure 3.6 DNA sequences of LSDV flanking sequences LFI (A) and LFII (B). The restriction enzyme sites of
EcoRI + BssHII (in LFI) and PstI + HindIII (in LFII) required for subsequent cloning steps are indicated in red. LFI





























LF1, purified from pYS-01 as a BssHII-EcoRI restricted DNA fragment (508 bp), and LF2,
purified as a PstI-HindIII restricted DNA fragment (552 bp), were used in the next two cloning
experiments to replace the MVA flanking sequences in pLW-51 (see Figure 3.4). pLW-51
plasmid DNA was subjected to EcoRI and BssHII restriction enzyme digestion and the DNA
fragment (5554 bp) without the MVA flank I sequence was purified from an agarose gel. This
DNA fragment was ligated to the purified LFI DNA and used to transform competent cells. The
modified pLW-51 containing LFI (pYS-01a) was identified by restriction enzyme analysis. MVA
flank II was successfully removed from pYS-01a by PstI and HindIII restriction enzyme
digestion and the DNA fragment without MVA flank II (5538 bp) was purified from an agarose
gel. This DNA fragment was then ligated to the purified LFII DNA fragment and used to
transform competent cells. The recombinant plasmid containing LFI and LFII (pYS-03) was
identified by single and double restriction enzyme analysis using EcoRI, HindIII, SalI and
XmaCI restriction enzymes. Figure 3.7A is a schematic representation of pYS-03, showing the
expected size fragments from single and double restriction enzyme digestions. The expected size
DNA fragments were observed after restriction enzyme digestions (Figure 3.7B), confirming the
composition of the transfer vector and the presence of the restriction enzyme sites XmaCI and
SalI required for subsequent cloning of the HIV-1 polyprotein Grttn gene.
Figure 3.7 Agarose gel electrophoresis of single and double restriction enzyme analysis of pYS-03. (A) Restriction
enzyme map (not to scale) showing expected sizes of restriction enzyme digestion products. (B) Electrophoresis of
pYS-03 digested with SmaI (lane 2, isoschizomer of XmaCI), SalI (lane 3), EcoRI + HindIII  (lane 4), EcoRI + SalI
(lane 5) and HindIII + SalI (lane 6). The arrow on the right points to a faint band of 552bp in lane 6.  DNA











3.2.2 Construction of transfer vector pYS-05 containing HIV-1 polyprotein Grttn and
E.coli gpt inserted into pYS-03
3.2.2.1 Construction of pYS-04
In order to construct a recombinant LSDV expressing HIV-1 polyprotein Grttn, the DNA
encoding Grttn was cloned into the LSDV transfer vector pYS-03.  The DNA cloning procedure
is depicted in Figure 3.8. The DNA fragment containing Kozak-Grttn (3707bp) was successfully
excised from pMosBlueGrttn plasmid by SalI and XmaCI restriction enzyme digestion, purified
from an agarose gel and cloned into the SalI and XmaCI restriction enzyme sites of pYS-03,
downstream of the VV mH5 promoter. The resulting plasmid construct, pYS-04, containing the
DNA encoding Grttn under the control of the mH5 promoter, flanked by LFI and LFII, was
confirmed to be correct by restriction enzyme analysis (results not shown) and DNA sequencing
from the EcoRI site of LF1 to the HindIII site of LFII (Figure 3.9). The expression of GUS and
Grttn was confirmed using transient expression assays (results not shown).
pYS-04 was transfected into LSDV infected FBT cells in an attempt to produce recombinant
LSDV expressing Grttn. LSDV-induced foci exhibiting GUS activity (blue foci) were observed
and picked. However, upon further passaging in FBT cells, these foci reverted to being
colourless. The initial blue foci may have resulted from transient expression of GUS from
residual transfer plasmid in the virus-infected cells. After eight transfections with no recovery of
recombinant LSDV a positive selection system was employed for isolating recombinant LSDV.
Figure 3.8 Schematic representation (not to scale) of the cloning procedure followed in the construction of pYS-04.






















































































Figure 3.9 DNA sequence of pYS-04 from the EcoRI site of LFI to the HindIII site of LFII. Restriction enzyme
sites involved in the cloning steps are underlined. LFI (red), LFII (green), GUS (pink), and Grttn (blue) sequences
are colour-coded.
3.2.2.2 Cloning of Positive Selection Gene Gpt into pYS-04
Escherichia coli xanthine-guanine phosphoribosyl transferase (Gpt) was used as the positive
selection gene for recovery of recombinant LSDV. The DNA cloning procedure for introducing
gpt into the transfer vector is depicted in Figure 3.10.
The DNA fragment containing Gpt and the upstream p7.5 promoter (2.1 kb) was successfully
excised from pGPT07/14 plasmid DNA by EcoRI restriction enzyme digestion and purified
from an agarose gel. The Gpt fragment was blunt ended and cloned into the blunt ended Xho I
restriction enzyme site in pYS-04. The resulting plasmid pYS-05 was subjected to restriction
enzyme analysis, PCR and DNA sequencing. The presence of LSDV flanking sequences,
positive selection gene Gpt and HIV-1 polyprotein gene Grttn was successfully demonstrated by
PCR (Figure 3.11) using primer pairs listed in Table 2.1. The sequencing data revealed no




































Figure 3.10 Schematic representation (not to scale) of the cloning procedure in the construction of pYS-05. E.coli












Figure 3.11. Confirmation of composition of pYS-05 by PCR. A) Agarose gel electrophoresis of PCR products
amplified from pYS-05. LFI (lane 2, 508 bp), LFII (lane 3, 552 bp), Grttn (lane 4, approximately 3.6 kb) and Gpt
(lane 5, approximately 2.1 kb) were amplified from pYS-05 using primers listed in table 2.1. DNA molecular
weight marker VII (Roche, Germany) is in lane 1 with relevant sizes indicated to the left. B) Schematic
representation of pYS-05 (not to scale) showing expected sizes and positions of PCR products ( ).
3.3 Confirmation of VV Promoter Activity and HIV-1 Polyprotein Grttn
Expression from pYS-05
It was important to demonstrate the ability of LSDV to recognize the VV promoters in pYS-05
and express GUS and Grttn. Transient assays were performed to detect the expression of GUS
and Grttn from pYS-05 in LSDV infected FBT cells.
The transient expression of GUS was detected by a visible blue colour in the cells and agarose
overlay and was only detected in LSDV infected, pYS-05 transfected FBT cells (Figure 3.12A).
GUS expression was not detected in any of the negative controls which included LSDV infected
FBT cells (Fig 3.12B), pYS-05 transfected (uninfected) FBT cells (Figure 3.12 C) and untreated
FBT cells (Figure 3.12D). This shows that expression is only achieved in the presence of both











Figure 3.12 Transient expression of GUS. FBT cells were treated with X-gluc and visualized 6 hours later. A)
LSDV infected, pYS-05 transfected cells; B) LSDV infected cells; C) pYS-05 transfected cells; and D) uninfected
cells.
Transient expression of p24 (in the gag part of Grttn) under the control of the VV mH5 promoter
was detected by immunofluorescence using sheep anti-p24 antibodies and FITC-conjugated
anti-sheep immunoglobulin. The transient expression of p24 was only detected in LSDV
infected, pYS-05 transfected FBT cells (Fig 3.13A) and not in any of the negative controls. The
negative controls included LSDV infected FBT cells (Figure 3.13B), pYS-05 transfected FBT
cells (Figure 3.13C) and untreated FBT cells (Figure 3.13D). Again, this shows that expression
is specifically directed from the pox promoter (early/late mH5 promoter) in LSDV- infected
cells transfected with pYS-05.
The transient expression of full length Grttn (150 kDa) was confirmed by western blot analysis
and only detected in lysates from FBT cells both infected with LSDV as well as transfected with
pYS-05 (Figure 3.14, lane 4). The size (150 kDa) of the protein detected corresponded to the
protein expressed in the positive control, pTHgrttnC transfected HEK239 cells (Figure 3.14,
lane 2). Expression of the same protein was not detected in the negative controls which included












Figure 3.13. Immunofluorescence assay to detect transient expression of p24. FBT cells were treated with p24 (Gag)
specific sheep antibody, followed by FITC conjugated anti-sheep immunoglobulin. p24 expression was visualized
as green fluorescent signals. A) LSDV infected, pYS-05 transfected cells; B) LSDV infected FBT cells; C) pYS-05
transfected FBT cells; and D) uninfected FBT cells.
Figure 3.14 Western blot analysis on transient expression of Grttn. Western blot of lysates of pTHgrttnC transfected
HEK239 cells (lane 2), LSDV infected and pYS-05 transfected FBT cells (lane 4), LSDV infected FBT cells (lane
5), pYS-05 transfected FBT cells (lane 6) and uninfected FBT cells (lane 7), treated with RT specific sheep antibody,
followed by alkaline phosphatase conjugated anti-sheep immunoglobulin antibody. RT protein standard is in lane 3












3.4 Construction of rLSDV-Grttn
The recombinant LSDV expressing HIV-1 subtype C polyprotein Grttn was successfully
produced in the following way. FBT cells were infected with wild-type LSDV and then
transfected with plasmid pYS-05. Infected cells were harvested and the released virus was
passaged four times on fresh FBT cells in the presence of selection medium. This was to select
for recombinant LSDV expressing gpt and suppress the growth of wild-type LSDV with
mycophenolic acid.
Virus harvested from the lysed cells was serially diluted ten-fold and FBT cells were infected
with different dilutions of the virus isolated. In this way distinct foci could be dispersed for
picking. After GUS staining blue foci, representing recombinant virus, were picked. Figure 3.15
shows recombinant LSDV-infected FBT cells after GUS staining (A) and a single focus (400 x
magnification) produced by recombinant LSDV expressing GUS (B). Blue foci were plaque
purified eight times in FBT cells with selection medium, before a pure recombinant focus was
chosen for large scale preparation.
Figure 3.15 GUS expression in rLSDV-Grttn infected FBT cells. A) Cells with agarose overlay stained with X-gluc.
B) Focus of recombinant virus expressing GUS (400X).
3.5 Large Scale Preparation of rLSDV-Grttn and Titration
Recombinant LSDV (rLSDV-Grttn) was propagated in primary FBT cells under positive
selection (gpt) conditions. Although the growth of LSDV had been demonstrated to be better in
primary foetal bovine or lamb testes cells compared to bovine cell lines, it was still difficult to
propagate the rLSDV-Grttn to high titres for subsequent animal inoculations (107 to 108 ffu/ml).











to be seeded for further LSDV propagation. Sixteen to twenty (175 cm2) flasks of FBT cells
were prepared for each round of passage. Over the duration of the project, FBT primary cell
lines were prepared seven times due to the fast depletion of the frozen cell stock.
Although the preliminary growth curve experiment (result not shown) indicated that the titre of
the virus peaked at 72 hours post infection, and rLSDV-Grttn was harvested at this time point
after each passage, rLSDV-Grttn still had to be propagated in large volumes (virus infected cell
lysates reached 1-1.5 litres), before a high enough titre could be obtained for mice inoculations.
Mycophenolic acid in the selection medium might have had a negative effect on FBT cell
growth, and might have indirectly affected the growth of the recombinant LSDV. rLSDV-Grttn
was propagated, concentrated and purified from the cell debris by centrifugation through a 36%
sucrose cushion.
Although LSDV replicates better in primary FBT cells compared to MDBK cells (Wallace 1994),
LSDV-induced CPE on MDBK cells (ridges) were more visually distinct compared to the LSDV
induced foci in FBT cells. Therefore, the rLSDV-Grttn stock was titrated on MDBK cells. The
titre of rLSDV-Grttn was determined by immunostaining with anti-RT antibody. Figure 3.16A
shows a positive focus of infection. The virus titre from an initial volume of 1 litre of cell lysate
was determined to be 8 x 107 ffu which was concentrated to a final volume of 1.5 ml (5.3 x
107ffu/ml).
Figure 3.16 Titration of rLSDV-Grttn by immunostaining. rLSDV-Grttn (A) and wtLSDV (B) infected MDBK
cells  were treated with RT specific sheep antibody, followed by peroxidase conjugated anti-sheep antibody. The











3.6 Assessment of the Purity of rLSDV-Grttn
To ensure the rLSDV-Grttn isolated was free from any wild-type LSDV, PCR primers were
designed to amplify specific DNA fragments from rLSDV-Grttn and wild-type LSDV. The
positions of primer binding are schematically represented in Figure 3.17A. rLSDV-Grttn or
wild-type LSDV infected FBT cells were lysed and the lysates were used as the DNA template
in the PCR.  The simultaneous presence of both 1.2 and 1.4kb DNA products would indicate that
there was wild-type LSDV contamination in the rLSDV-Grttn stock. Both recombinant (1.2kb)
and wild-type (1.4kb) PCR products were detected in lysates of cells infected with an earlier
passage (passage 4) of rLSDV-Grttn, demonstrating that the PCR assay could effectively detect
wild-type and recombinant virus in a single reaction (Figure 3.19.B, lane 5). Only the
recombinant DNA product (1.2 kb) was amplified in the final rLSDV-Grttn stock (Fig 3.17B,
lane 4) indicating that the rLSDV-Grttn isolated was free from any wild-type LSDV.
Figure 3.17 Detection of wild-type LSDV and rLSDV-Grttn by PCR. A) Schematic representation of primer
binding sites and the respective sizes of the DNA products amplified from recombinant and wild-type LSDV. B)
Agarose gel showing PCR products from the lysates of FBT cells (lane 2), LSDV infected FBT cells (lane 3) and
rLSDV-Grttn infected FBT cells (lane 4). Lane 5 shows the products from an earlier passage of rLSDV-Grttn












3.7 Full Length HIV-1 Polyprotein Grttn Expression from rLSDV-Grttn
The expression of full length Grttn was confirmed using western blot analysis with HIV-1 Gag-
and RT-specific antibodies. FBT cells were infected with rLSDV-Grttn, wild-type LSDV or left
uninfected. These FBT cells were then lysed and subjected to PAGE and Western blot analysis.
Gag and RT protein standards and a lysate of BHK-21 cells infected with recombinant MVA
known to express Grttn and HIV-1 gp150 (SAAVI-MVA-C) were included as positive controls.
Expression of protein with a molecular weight of 150 kDa, corresponding to the size of Grttn
was detected in rLSDV-Grttn infected FBT cell lysates (Figure 3.18A, lane 4; Figure 3.18B, lane
3). Expression of Grttn was absent from wild-type LSDV infected FBT cell lysates (Figure
3.18A - lane 5; B – lane 4). This experiment confirmed that Grttn was expressed in its entirety
from rLSDV-Grtn.
Figure 3.18 In vivo expression of Grttn in rLSDV-Grttn infected FBT cells. Lysates were subjected to western Blot
analysis using RT-specific (A) or p24-specific (B) sheep antibody, followed by alkaline phosphatase conjugated
anti-sheep antibody. A). Western blot of lysates of SAAVI-MVA infected BHK-cells (lane 3), rLSDV-Grttn infected
FBT cells (lane 4) and WtLSDV infected FBT cells (lane 5). Lane 2 contains RT protein standard. Protein
molecular weight standards are in lane 1 with sizes indicated to the left  B) Western blot of lysates from rLSDV-
Grttn infected FBT cells (lane 3) and WtLSDV infected FBT cells (lane 4). Gag protein standard is in lane 2 and
Kaleidoscope Precision Plus Protein prestained standards (Bio-Rad, USA) is in lane 1 with sizes indicated to the
left.
3.8 Discussion
In this part of the study, a LSDV transfer vector containing genes encoding HIV-1 polyprotein
Grttn, reporter protein GUS and positive selection enzyme Gpt, all flanked by DNA sequences











to confirming the construction of the transfer plasmid by restriction enzyme analysis and DNA
sequencing, the expression of the foreign genes inserted was successfully confirmed using
transient expression and detection assays in LSDV infected, transfer plasmid transfected FBT
cells. The reporter gene, Gus, activity was confirmed through GUS staining and the expression
of Grttn was detected by immunofluorescence and western blot analysis.
Recombinant LSDV expressing the HIV-1 subtype C polyprotein Grttn (rLSDV-Grttn) was
successfully constructed. Although other recombinant poxviruses such as vaccinia virus and
MVA have been produced with relative ease (Mackett et al., 1982; Panicali et al., 1983), the
particular recombinant desired in this study was difficult to isolate. Initially the construction of
the rLSDV-Grttn was attempted without the aid of a positive selection gene. All attempts at
isolating the rLSDV with the aid of only the reporter gene GUS failed. The positive selection
gene, gpt, was introduced to suppress wild-type LSDV growth and increase the probability of
isolating the recombinant LSDV. This approach was successful and rLSDV-Grttn was
successfully constructed and isolated. However, it is acknowledged here that repeated sequences
should have been introduced into the transfer vector flanking the Gpt and Gus genes in order to
remove these genes from the final recombinant virus.
rLSDV-Grttn was viable in FBT cells and it could be propagated to the required experimental
titre (approximately 108 ffu/ml). The CPE induced by rLSDV-Grttn showed no difference from
that induced by the wild-type LSDV.  The construction of this recombinant affirms the ability to
use the ribonucleotide reductase gene as an insertion site for the generation of stable
recombinant LSDV (Aspden et al., 2002; Aspden et al., 2003). Expression of the full-length
Grttn protein from the VV mH5 promoter was demonstrated by western blot analysis. This
further supports the finding that promoter sequences are highly conserved within the
Chordopoxviridae subfamily (Boyle, 2007; Prideaux et al., 1990). Stable expression of Grttn
was detected after 17 passages of rLSDV-Grttn in FBT cells, under positive selection conditions.
The lack of contaminating wtLSDV in the rLSDV-Grttn stock was demonstrated by PCR.
rLSDV-Grttn was constructed as a potential HIV-1 vaccine candidate. Within our department a
recombinant MVA expressing Grttn (rMVA-Grttn) has been constructed (N. Johnson,
unpublished). The same promoter was used for the control of Grttn expression in the two
vaccine candidates. Ideally, for comparative purposes, it would be desirable to use the
equivalent sites of insertion for the two vaccine candidates. However, Grttn was inserted into the
Del III region of MVA and such a region is absent from the LSDV genome, so Grttn could not











vectors, rMVA-Grttn could have been reconstructed with Grttn inserted into the ribonucleotide
reductase gene of MVA, but this was beyond the scope of this project.
Another non-essential gene, the thymidine kinase gene, has been used for the insertion of
foreign genes into LSDV (Wallace et al., 2006; Wallace et al., 2007; Wallace & Viljoen, 2005).
Although these (TK and RR) insertion sites were demonstrated to be non-essential, there could
still be a difference in growth or fitness of the recombinant virus generated using different
insertion sites. The effect of disrupting the ribonucleotide reductase or the thymidine kinase
genes on LSDV growth or ability to express foreign protein has not been evaluated. However,
disruption of either of these genes in VV leads to mild attenuation in vivo (Buller et al., 1985;
Child et al., 1990; Taylor et al., 1991a).
Because our intention was to compare LSDV to MVA as a vaccine vector, we used the same
promoter (mH5) and antigen (Grttn) which was used in the construction of rMVA-Grttn. (Wyatt
et al., 2008) have shown that higher levels of in vitro antigen expression is positively correlated
with better immunogenicity of rMVA vaccine in mice. Therefore the immunogenicity of a
vaccine candidate is likely to be affected by the level of antigen expression in vaccinated
individuals. However, the use of a strong promoter may reduce the stability of the recombinant
poxvirus. Testing other poxvirus promoters could be considered to optimise the level of antigen
expression, without compromising the stability of the recombinant LSDV.
The HIV-1 antigens chosen in this study include important epitopes across HIV-1 subtype C
capsid protein, reverse transcriptase, Tat and Nef, however, the glycoprotein (Env) was missing
from rLSDV-Grttn. Because this is the first attempt to evaluate LSDV as a HIV-1 vaccine vector,
the study was designed to be a “proof of concept” evaluation of the potential of LSDV as a HIV-
1 subtype C vaccine vector. Future candidate rLSDV vaccines could include Env epitopes to
optimize the coverage across the HIV-1 subtype C genome. HIV-1 subtype C was chosen
because it is the predominant subtype found in Sub-Saharan Africa, which is also the region
worst affected by the HIV-1 pandemic. The use of LSDV as a vaccine vector in this area would
be considered acceptable because LSD is endemic in the area. In addition the LSDV strain used
is the vaccine strain given to cattle in the region (Kara et al., 2003). However the introduction
and use of LSDV in non-LSD affected or exposed regions (predominated by non-subtype C
HIV-1) may encounter resistance from local regulatory bodies.
rLSDV-Grttn constructed in this project is a valuable tool for evaluating the immunogenicity of











next chapter. Unfortunately, there are a number of drawbacks of this particular construct for use
in humans. It is not desirable to have reporter or selection genes in the final recombinant. The
deletion of undesirable foreign genes such as the reporter gene and positive selection gene could
be achieved by simply engineering into the transfer vector a repeated sequence flanking the
genes which need to be deleted.  After isolating a pure recombinant containing the marker gene,
this virus would then be further passaged in the absence of selection, and colourless foci could
be picked to select for a recombinant containing the foreign gene of interest, but no marker or
positive selection genes. The desired recombinant could be identified by PCR analysis.
A major concern is the lack of an approved cell line for manufacture of recombinant LSDV.  A
recombinant LSDV from a research lab would have to be remade in a GMP compliant facility
using approved cell lines and reagents. LSDV grows optimally in bovine primary cells (Wallace,
1994). However these primary cells isolated from bovine tissue have a limit to the number of
times that they can be passaged, and fresh cells need to be isolated regularly. The quality control
of the cells isolated cannot be maintained easily due to the genetic variability of individual
calves and the condition of tissue harvested each time. Most importantly, opportunistic
contaminants such as retroviruses and prions, such the causal agent of bovine spongiform
encephalopathy, (BSE), may be present in these primary bovine cells (Asher, 1999a; Asher,
1999b), necessitating the screening of cells after each primary cell isolation. Thus the primary
FBT cells are unlikely to be approved by the regulatory bodies for the production of rLSDV
intended for human use. The use of the ovine testis cell line OA3.Ts for the propagation of
capripoxviruses, including LSDV, has been shown to produce comparable titres of virus to that
of  primary cells (Babiuk et al., 2007). However the cell line will need to be evaluated for its
suitability and approved by regulatory agencies for human vaccine production. Propagation of
rLSDV in Vero cells, an acceptable cell line for human vaccine production (influenza) has also
been demonstrated (Babiuk et al., 2007); however the virus yield is about 100 times less
compared to OA3.Ts and primary cells (Babiuk et al., 2007).  LSDV can be propagated on the
chorioallantoic membranes (CAMs) of embryonated eggs, and this is partly how LSDV was
attenuated in the generation of the Neethling vaccine strain (van Rooyen et al., 1969).  Eggs are
commonly used for the production of vaccine for human use. However, like the Vero cell line, a
lower yield of LSDV was obtained in embryonated eggs compared to bovine primary cell lines
(Wallace, 1994). The use of animal cell lines and embryonated eggs should be further evaluated
and optimized as alternative means of rLSDV production. A recombinant could possibly be
made in Vero cells and then grown to high titres on the CAMs of embryonated eggs.










rLSDV could be reconstructed in a Bacterial artificial chromosome system (BAC) (Cottingham
et al., 2008; Domi & Moss, 2002). This will ensure the purity of the rLSDV vaccine stock
without numerous plaque purifications in tissue culture. The method involves the manipulation
of the poxvirus genome in a BAC system. The entire head to tail poxvirus DNA concatamer
intermediate is cloned into a BAC. This allows for the manipulation of poxvirus DNA in E.coli
through an efficient DNA homologous recombination technique directed by bacteriophage-
lambda enzyme (recombineering, http://recombineering.ncifcrf.gov).  Because poxvirus DNA is
not infectious alone, due to the absence of the early transcription system which is packaged into
the virion core of viral particles, transfected recombinant poxvirus genomic DNA will need to be
rescued by another poxvirus infecting the cells in order to grow the final construct in cell culture
(possibly Vero cells). This rescue virus provides the necessary enzymes to initiate early
transcription and replication but should not produce infectious progeny in the cell line which is
transfected with recombinant poxvirus DNA. Host range-restricted Avipoxviruses would be
suitable for the rescue of rLSDV. Once the desired recombinant LSDV is acquired, it could be
propagated to the titre required for vaccine production, possibly on CAMs of embryonated eggs.
In conclusion to this chapter, a viable recombinant LSDV expressing HIV-1 polyprotein Grttn,
rLSDV-Grttn, was constructed. The evaluation of the immunogenicity of this vaccine in
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The safety and efficacy of a new candidate vaccine are critical aspects which need to be
investigated prior to the advancement of the vaccine to clinical trials. Because of the high HIV-1
prevalence in regions such as Sub Saharan Africa (Luthy et al., 2006; Redfield et al., 1987;
Rivas et al., 2007; Wyatt et al., 2004) it is important to evaluate the safety of a potential HIV-1
vaccine in both immune-competent and immunocompromised hosts, especially if the vaccine
has the potential to be used as a therapeutic vaccine. The safety of MVA in an
immunocompromised setting was demonstrated in SCID mice (Wyatt et al., 2004). Previously,
the vaccine had been tested in humans and shown to be safe as a vaccine against smallpox
(Stickl et al., 1974; Wyatt et al., 2004). The Neethling strain of LSDV has been demonstrated to
be non-pathogenic in ruminant and non-ruminant animals, and shown to be host restricted in cell
culture (Aspden et al., 2002; Aspden et al., 2003). However, the safety of LSDV has not been
investigated in an immunocompromised setting. The present study has addressed this issue by
evaluating the safety of the Neethling strain of LSDV (wtLSDV) in two strains of
immunocompromised mice with different immunodeficiency phenotypes. CD4 knockout mice,
which are deficient in CD4 T cell production, and RAG mice, which are deficient in both mature
T and B cells, were vaccinated with wtLSDV and the well being and weight of the mice
recorded for 30 days after vaccination.
Pre-clinical evaluation of candidate HIV-1 vaccines relies on ex vivo immunogenicity assays,
which determine both cellular and humoral immune responses induced by the vaccine. These ex
vivo assays measure the frequency and functionality of the immune cells by evaluating factors
such as cytokine secretion and cell surface molecule expression (Ghanekar & Maecker, 2003;
Maecker & Maino, 2003; Zhang et al., 2009). Cytokines released from T cells function both
directly and indirectly on the immune activity of T cells (Bevan, 2004; Haynes et al., 1989;
Peters et al., 1991; Schroder et al., 2004; Sun et al., 2004). The Th1 cytokines IFN-γ and IL-2
are known to be associated with the activation and maintenance of CD4+ and CD8+ T cells
(Bevan, 2004; Boehm et al., 1997; Mach et al., 1996; Schroder et al., 2004; Sun et al., 2004)
and are associated with the induction and modulation of cellular immune responses (Abbas et al.,
1996; Mosmann et al., 1986), which are important for antiviral immunity (Barker et al., 1995;
Clerici et al., 1993; Maggi et al., 1987). IL-2 secretion by CD4+ T cells is known to be
associated with growth stimulation, differentiation and survival of antigen-specific cytotoxic T











used to evaluate the frequency of antigen–specific IFN-γ and IL-2 producing cells (Asmuth et
al., 2009; Burgers et al., 2009; Harro et al., 2009; Lalvani & Pareek, 2009; Sadagopal et al.,
2005; Shephard et al., 2008). The cytokines produced by antigen-stimulated immune cells are
captured by cytokine specific antibody coated onto membranes. Cytokine specific biotinylated
antibody is then added and subsequently probed with horse radish peroxidise (HRP) conjugated
with Avidin. Spots, which respresent cytokine producing cells, are visualized after HRP
substrate incubation. Enumeration of antigen specific cytokine producing cells can be achieved
by counting the spots.
Antigen specific cells in the immune cell population can be detected and counted using
flowcytometry after binding of fluorochrome conjugated pentramic MHC-peptide complexes to
complementary T cell receptors and suitable different fluorescent labeled antibodies (e.g. CD8)
to suface receptors. (Almeida et al., 2007; Arora, 2002; Betts et al., 2003; Bridgeman et al.,
2009; Brooimans et al., 2008; Chattopadhyay et al., 2008; Cottingham et al., 2006; Shephard et
al., 2008). CD44 expression on T cells has been shown to be up-regulated in response to
antigen-specific T cell activation (Budd et al., 1987; Haynes et al., 1989; Lesley et al., 1993).
High and intermediate levels of expression of CD44 on T cells are associated with a memory T
cell phenotype (Budd et al., 1987; Dutton et al., 1998). The effector function of cytotoxic T cells
is related to the capacity of these cells to degranulate lytic granules containing perforin and
granzymes. The membrane surfaces of these lytic granules are associated with lysosomal-
associated membrane proteins (LAMP) such as CD107a/b (Peters et al., 1991). The active
degranulation process exposes CD107a/b transiently on the membrane of activated cytotoxic T
cells (Peters et al., 1991), allowing CD107a/b to be a marker of degranulation activity of these T
cells (Betts et al., 2003; Betts & Koup, 2004; Peters et al., 1991).
This chapter addresses the immunogenicity of rLSDV-Grttn on its own and in different prime-
boost vaccination regimens with a DNA vaccine, pVRCgrttnC, and a recombinant MVA vaccine,
rMVA-Grttn, in BALB/c mice. Splenocytes from vaccinated mice were used to determine
cellular immune responses to Gag and RT. Initially IFN-γ and IL-2 ELISPOT assays were used
to enumerate Gag- and RT-specific CD8+ and CD4+ T cells secreting IFN-γ and IL-2. These
assays contained splenocytes and peptides with amino acid sequences matching BALB/c CD8
and CD4 T cell epitopes in Gag and RT as stimuli. The level of IFN-γ and IL-2 released into the
culture medium by these splenocytes during culture with the Gag and RT CD8+ and CD4+ T











H-2Dk complexes folded with the Gag peptide AMQMLKDTI and pentameric H-2Dd complexes
folded with the RT peptide VYYDPSKDLIA were used to enumerate total HIV-specific CD8+ T
cells generated by the heterologous poxvirus vaccination regimens. In addition the functional
capacity of the pentameric positive cells was assessed by expression of CD44 and CD107a/b.
The humoral responses induced by the heterologous vaccination regimens were evaluated by
detecting the presence of Gag- specific antibodies in the sera of immunized mice using a
LAVblot I assay.
4.2. Safety of LSDV in Immunocompromised Mice
LSDV has previously been demonstrated to be safe in mice and cattle. However the safety in
immunocompromised animals remains to be investigated.  Safety of wtLSDV (Neethling strain)
was evaluated in two strains of immunocompromised mice, CD4 knockout mice and RAG mice.
Two different doses of  wtLSDV (104 ffu and 106 ffu) were tested in each of these strains. Naïve
mice and mice vaccinated with PBS served as controls in the experiment. For all the mouse
groups no change in their well-being was observed up to 30 days after vaccination with
wtLSDV or PBS. They were active and inquisitive when disturbed and their hair coat remained
clean and groomed throughout the experiment, indicating no adverse affects of wtLSDV. Mice
weights were also recorded daily for 30 days as an indicator of possible pathogenicity of the
virus (Figure 4.1). A fluctuation in the weight of the individual mice in each group was observed
however a general increase in weight for all mouse groups was seen (Figure 4.1). Prior to the
experiment a decision was made to statistically analyse the effect of wtLSDV on mouse weight
on day 6, day 11 and day 30 post vaccination. These time points were chosen based on critical
times during the development of immune responses to rLSDV-grttn.  On these days the
percentage change in weight from that pre-vaccination for all mice in a group was calculated
(Figure 4.2). To determine any significant effect of wtLSDV vaccination on weight change this
data for each group on day 6, day 11 and day 30 was statistically analysed using one-way
ANOVA (Figure 4.2).
CD4 knockout mice vaccinated with 1 x104 ffu or 1 x 106 ffu of wtLSDV did not show any
significant changes in weight at days 6 (p= 0.79), 11 (p= 0.55) and 30 (p= 0.24) compared to
mice vaccinated with PBS or left unvaccinated (naïve) (Figure 4.2). Similar observations were
made with RAG mice at day 6 (p= 0.18) and day 30 (p= 0.16). The difference in percentage











groups and the negative control groups (PBS-inoculated and naïve RAG) were statistically
different (p= 0.04), however the percentage weight change (weight loss) did not occur in a
LSDV-titre dependent manner, which may indicate that the significance of differences between
the percentage weight change in these RAG mice was questionable (Figure 4.2).
Figure 4.1 Evaluation of the safety of LSDV in immunocompromised mice using daily weights as an indicator.
Immunocompromised CD4 knockout (1-4) and RAG (5-8) mice were inoculated with PBS (1 and 5), 104 ffu of
LSDV (2 and 6), 106 ffu of LSDV (3 and 7) or not vaccinated (naïve, 4 and 8). The weight recorded for the 5











Figure 4.2 Percentage weight change of CD4 knockout mice (A-C) and RAG mice (D-F) in response to vaccination.
Mice were vaccinated as indicated. On day 6 (A and D), day 11 (B and E) and day 30 (C and F) the difference in
mouse weight from that on day 0 was calculated as a percentage of weight on day 0 and plotted as percentage
weight change. A positive value indicates a gain in weight and a negative value indicates a loss in weight on a
particular date. A Statitical difference in the percentage weight change for each group was determined using the











4.3 Cellular Immune Responses to a DNA Prime and Poxvirus Boost
Vaccination
Immune responses to rLSDV-Grttn were evaluated in BALB/C mice given either as a single
vaccination or as a booster vaccination after a primary vaccination with pVRCgrttnC, a DNA
vaccine that encodes the identical antigen Grttn.  The immunogenicity of rLSDV-Grttn was
compared to another poxvirus vaccine, rMVA-Grttn, a recombinant MVA vaccine that expresses
Grttn, controlled by the same VV mH5 promoter. Nine groups of mice were vaccinated as
indicated in Chapter 2, Table 2.3, and as summarised in the vaccination and sacrifice time line
(Figure 4.3).
Figure 4.3 BALB/c mouse inoculation and sacrifice schedule to investigate immunogenicity of rLSDV-Grttn alone
and when used as a booster vaccine after a prime with pVRCgrttnC (DNA vaccine).
Cellular immune responses were evaluated using IFN-γ and IL-2 ELISPOT assays to enumerate
the frequencies of Gag and RT specific IFN-γ or IL-2 secreting CD8+ and CD4+ T cells in the
spleen (Figure 4.4A and 4.4B respectively). Considerable background responses in the absence
of peptides were detected in both ELISPOT assays (100-300 SFU/106 splenocytes) with
splenocytes from mice vaccinated with LSDV, (Figure 4.4A and 4.4B). This was seen after a
single vaccination or after a boost vaccination with LSDV (wtLSDV or rLSDV-Grttn). Minimal
background responses were detected in these assays for vaccination regimens without wtLSDV
or rLSDV-Grttn. Responses to an irrelevant peptide were similar to those in the absence of











responses to individual peptides deduced after background responses were taken into
consideration for all vaccination regimens are shown in Figure 4.4C and 4.4D. Cumulative
positive responses to the individual HIV peptides for each vaccination regimen is shown in
Figure 4.5.











Figure 4.4 IFN-γ and IL-2 ELISPOT analysis of HIV-1 Gag and RT-specific CD8+ and CD4+ T cell responses
induced in the spleen by the indicated vaccination regimens and described in Figure 4.3. At sacrifice splenocytes
were pooled from 5 mice per group then incubated in the absence of peptide (medium), stimulated with an
irrelevant peptide or stimulated with HIV-1 Gag and RT CD8+ and CD4+ T cell peptides in A) IFN-γ ELISPOT and
B) IL-2 ELISPOT assays. Bars are the mean number of spots of triplicate reactions in medium only (background)
or to an individual peptide for 106 splenocytes with indicated standard deviation (SD) of the mean.  For each
vaccination regimen positive responses to the HIV peptides were considered to be those greater than the
background response (response in peptide free medium) plus two times the standard deviation (SD) of this response.
C) The magnitude of positive IFN-γ ELISPOT responses and D) the positive IL-2 responses for each vaccination
regimen after the background response has been subtracted. The bars indicate the average net SFU ±SD from











Figure 4.5 Cumulative proportions of positive IFN-γ (A) and IL-2 (B) ELISPOT responses induced by the
indicated vaccination regimens and described in Figure 4.3. The individual sections of each bar indicate the average
net SFU ±SD from triplicate wells for 106 splenocytes to a individual CD8+ or CD4+ peptide in the IFN-γ
ELISPOT assay as shown in Figure 4.4 (C and D).
The data from these ELISPOT assays as displayed in Figure 4.4C and 4.4D, indicate wtLSDV
did not induce Gag-or RT-specific IFN-γ or IL-2 responses.  Vaccination with rLSDV-Grttn
induced only a low frequency of RT-specific CD8+ T cells producing IFN-γ (131 Net SFU/106
splenocytes) (Figure 4.4C). This is in contrast to a vaccination with rMVA-Grttn which induced











ELISPOT assay of 435 net SFU/106 splenocytes. The ability of these recombinant poxviruses to
boost a response induced by a primary pVRCgrttnC DNA vaccination was compared. No Gag or
RT responses were detected after the DNA prime (Figure 4.4). However the prime with
pVRCgrttnC must have been below the detection limit of the assay as a prime with pVRCgrttnC
and boost with rLSDV-Grttn induced a cumulative frequency of RT-specific CD8+ and CD4+ T
cells producing IFN-γ of 607 net SFU/106 splenocytes of which 78% were from responding RT-
specific CD8+ T cells (Figure 4.5A). This cumulative response is 4.6 fold higher than the
magnitude of the IFN-γ RT- specific CD8+ T cell response of mice vaccinated with just rLSDV-
Grttn.  In contrast, mice primed with pVRCgrttnC and boosted with rMVA-Grttn developed
responses to Gag and RT CD8+ and CD4+ T cell peptides with a cumulative frequency of 1529
net SFU/106 splenocytes (Figure 4.5A). Gag- and RT-specific CD8+ T cells contributed 73% to
this cumulative response which was 3.5 fold above that of the response to just rMVA-Grttn.
Such boosting of a DNA prime was not detected when the booster vaccines were wtLSDV or
wtMVA. These DNA prime-poxvirus boost vaccinations regimens were more potent than a
prime and boost with pVRCgrttnC (Figure 4.5A) which induced a cumulative magnitude to Gag
and RT CD8+ and CD4+ T peptides of 82 net SFU/106 splenocytes in the IFN-γ ELISPOT assay.
Vaccination with rLSDV-Grttn induced RT-specific CD4+ T cells that produced IL-2 (50 net
SFU/106 splenocytes). In contrast vaccination with rMVA-Grttn induced both Gag CD4+ and
RT CD4+ T cells that produced IL-2 (Figure 4.5A). A cumulative frequency of 171 net SFU/106
splenocytes was measured. No IL-2 producing cells could be detected in response to a prime
with pVRCgrttnC. However when mice were primed with pVRCgrttnC then boosted rLSDV-
Grttn, a 2 fold increase in IL-2 producing RT CD4+ T cells over that of rLSDV-Grttn only was
measured (Figure 4.5A). A boost of mice primed with pVRCgrttnC with rMVA-Grttn did not
change the frequency of RT CD4+ T cells producing IL-2 but increased the frequency of Gag
CD4 T cells producing IL-2 by a factor of 2 and induced RT CD8+ T cells producing IL-2 in the
ELISPOT assay over that of rMVA-Grttn only (Figure 4.5A).  The double vaccination with












4.4 Cellular Immune Responses to Poxvirus Prime and Boost Vaccination
Regimens
Immune responses of BALB/c mice to rLSDV-Grttn were evaluated after either homologous or
heterologous poxvirus prime/boost regimens with rMVA-Grttn. Nine groups of BALB/C mice
were vaccinated as indicated in (Table 2.4A) and as summarised in the vaccination and sacrifice
time line (Figure 4.6)
Figure 4.6 BALB/c mouse inoculation and sacrifice schedules to investigate immunogenicity of rLSDV-Grttn
alone and in homologous and heterologous and prime-boost combinations with rMVA-Grttn.
Cellular immune responses were evaluated using IFN-γ and IL-2 ELISPOT assays to enumerate
the frequencies of Gag and RT specific IFN-γ or IL-2 secreting CD8+ and CD4+ T cells in the
spleen (Figure 4.7A and 4.7B respectively). As we found in our previous experiments
considerable background responses in the absence of peptides were detected in both ELISPOT
assays of 80-370 SFU/106 splenocytes (Figure 4.7A and 4.7B) for splenocytes harvested from
mice vaccinated with LSDV. This occurred for both recombinant and wtLSDV, and after both a
single vaccination and when LSDV was used in prime/boost vaccination regimens. Minimal
background responses were detected in these assays for vaccination regimens without wtLSDV
or rLSDV-Grttn. Responses to an irrelevant peptide were similar to those in the absence of
peptide for all vaccination regimens (Figure 4.7A and 4.7B).  The magnitude of net positive
responses to individual peptides deduced after background responses were taken into
consideration for all vaccination regimens are shown in Figure 4.7C and 4.7D. Cumulative












In this set of experiments no response in the IFN-γ ELISPOT assay was detected for mice
vaccinated with rLSDV-Grttn alone. A single vaccination with rMVA-Grttn induced Gag and
RT-specific CD4+ and CD8+ T cell responses with a cumulative magnitude of 475 net SFU/106
splenocytes. When rLSDV-Grttn was used in a homologous prime/boost vaccination regimen,
only RT-specific CD8+ T cells with a magnitude of 477 net SFU/106 splenocytes were detected
in the IFN-γ ELISPOT assay (Figure 4.8A). The homologous prime/boost vaccination regimen
with rMVA-Grttn induced Gag and RT-specific CD4+ and CD8+ T cell responses with a
cumulative magnitude of 795 net SFU/106 splenocytes (Figure 4.8A), with 68% of the response
due to responding CD8+ T cells.  This cumulative response is 1.8 fold higher than the magnitude
of cumulative Gag and RT-specific response induced by rMVA-Grttn alone (475 net SFU/106
splenocytes).
The heterologous prime/boost vaccinations were more potent regimens compared to the
homologous vaccination regimens. After priming with rMVA-Grttn and boosting with rLSDV-
Grttn or priming with rMVA-Grttn and boosting with rLSDV-Grttn, high frequencies of IFN-γ
secreting Gag and RT specific CD8+ and CD4+ T cells  were induced (Figure 4.8A).
Cumulative frequencies of Gag and RT-specific CD4+ and CD8+ T cell producing IFN-γ of
3066 net SFU/106 splenocytes was induced by a rLSDV-Grttn prime/ rMVA-Grttn boost
vaccination regimen, with 72% of the response contributed by the CD8+ T cells. This
cumulative response is 6.5 fold higher than the magnitude of cumulative frequency induced by
rMVA-Grttn alone. The reverse vaccination regime induced a cumulative frequency of Gag and
RT-specific, CD4+ and CD8+ T cell producing IFN-γ of 2592 net SFU/106 splenocytes of,
which 65% was due to responding CD8+ T cells. This cumulative response is 5.5 fold higher
than the magnitude of cumulative frequency induced by rMVA-Grttn alone (Figure 4.8A).
IL-2 producing cells were detected in the IL-2 ELISPOT assay. A single vaccination of rLSDV-
Grttn induced a low frequency of RT-specific CD4+ T cells producing IL-2 of 52 net SFU/106
splenocytes.  Gag- and RT-specific CD4+ T cells producing IL-2 with a cumulative frequency of
221 net SFU/106 splenocytes were induced by a single vaccination of rMVA-Grttn.  However,
no detectable positive IL-2 ELISPOT responses were measure in mice vaccinated with a
homologous prime/boost vaccination regimen for either rLSDV-Grttn or rMVA-Grttn.  In
contrast, a prime with rLSDV-Grttn and boost with rMVA-Grttn resulted in a boost of both Gag
and RT-specific CD4+ T-cells to a cumulative magnitude of IL-2 producing cells of 450 net











SFU/106 splenocytes when mice were primed with rMVA-Grttn then boosted with rLSDV-Grttn
(Figure 4.8B). The rMVA-Grttn prime/ rLSDV-Grttn boost regimen induced a low IL-2
ELISPOT response specific for Gag CD4 (17) peptide (64 net SFU/106 splenocytes) (Figure
4.7D), which was absent in the reverse vaccination regimen (Figure 4.7D).











Figure 4.7 IFN-γ and IL-2 ELISPOT analysis of HIV-1 Gag and RT-specific CD8+ and CD4+ T cell responses
induced in the spleen by the indicated vaccination regimens and described in Figure 4.6. At sacrifice splenocytes
were pooled from 5 mice per group then incubated in the absence of peptide (medium), stimulated with an
irrelevant peptide or stimulated with HIV-1 Gag and RT CD8+ and CD4+ T cell peptides in A) IFN-γ ELISPOT and
B) IL-2 ELISPOT assays. Bars are the mean number of spots of triplicate reactions in medium only (background)
or to an individual peptide for 106 splenocytes with indicated standard deviation (SD) of the mean.  For each
vaccination regimen positive responses to the HIV peptides were considered to be those greater than the
background response (response in peptide free medium) plus two times the standard deviation (SD) of this response.
C) The magnitude of positive IFN-γ ELISPOT responses and D) the positive IL-2 responses for each vaccination
regimen after the background response has been subtracted. The bars indicate the average net SFU ±SD from
triplicate wells for 106 splenocytes. The magnitude of positive IL-2 ELISPOT responses of each group after












Figure 4.8 Cumulative proportions of positive IFN-γ (A) and IL-2 (B) ELISPOT responses induced by the
indicated vaccination regimens and described in Figure 4.6. The individual sections of each bar are the average net
SFU ±SD from triplicate wells for 106 splenocytes to an individual CD8+ or CD4+ peptide in the IFN-γ ELISPOT











4.5 Gag- and RT- specific IFN-γ Levels Induced by Poxvirus Prime/ Boost
Vaccination Regimens
The amount of IFN-γ secreted by the Gag- and RT-specific CD4+ and CD8+ T cells during
culture with the HIV peptides was also quantified (Figure 4.9).  Splenocytes harvested from
mice vaccinated according to the regimens indicated in Figure 4.6 were incubated for 48h with
the Gag- and RT- specific CD8+ and CD4+ T cell peptides and the level of  IFN-γ released into
the culture medium was quantified using a Cytometric Bead Array assay (BD Pharmingen) and
flow cytometric analysis.
Considerable background IFN-γ of 86-376 pg/106 splenocytes was released into the medium
when splenocytes were incubated in the absence of peptides for splenocytes harvested from
mice vaccinated with LSDV, both recombinant and wild-type, and after both a single
vaccination and when LSDV was used in prime/boost vaccination regimens (Figure 4.9A).
Minimal background IFN-γ was released by splenocytes from mice vaccinated with the other
vaccine regimens (Figure 4.9A). IFN-γ released by splenocytes to an irrelevant peptide was
similar to that in the absence of peptide for all vaccination regimens (Figure 4.9A).  The
magnitude of the net positive IFN-γ level produced by the splenocytes during culture with
individual CD8+ and CD4+ T cell peptides deduced after background responses were taken into
consideration are shown in Figure 4.9B for all vaccination regimens. The cumulative positive
IFN-γ level produced to the HIV peptides for the individual vaccination regimens is shown in
Figure 4.9C.
A low level of IFN-γ was released from RT-specific CD4+ T cells (57 pg/106 splenocytes) in
response to a rLSDV-Grttn vaccination even though we could not detect these cells in an IFN-γ
ELISPOT assay (Figure 4.7C). After a single vaccination with rMVA-Grttn, RT-specific CD4+ T
cells producing IFN-γ (267 pg/106 splenocytes) were detected (Figure 4.9C). WtLSDV and
WtMVA did not boost these HIV-1 specific IFN-γ levels. The level of IFN- γ produced by
splenocytes from homologous prime/boost vaccinations with rLSDV-Grttn or rMVA-Grttn was
similar to that of a single vaccination with rLSDV-Grttn or rMVA-Grttn. In contrast, splenocytes
from heterologous prime/boost vaccination regimens produced high levels of IFN-γ during
culture with Gag- and RT-specific peptides (Figure 4.9C). Splenocytes from mice primed with
rLSDV-Grttn and boosted with rMVA-Grttn produced a cumulative positive IFN-γ level of 1540
pg/106 splenocytes, with 52% of the IFN-γ produced by RT-specific CD4+ T cells (Figure 4.9C).











positive IFN-γ level of 2889 pg/106 splenocytes. 73% of this total IFN-γ was produced by RT-
specific CD4+ T cells (Figure 4.9C). Thus the difference in the level of IFN-γ produced by the
two heterologous prime/boost regimens was mainly attributed to a higher level of IFN-γ being
produced by the RT-specific CD4+ T cells. This data leads to the suggestion that a prime with
rMVA-Grttn and boost with rLSDV-Grttn is more potent than the reverse inoculation regimen
(Figure 4.9C). However, the data from the IFN-γ ELISPOT assay indicates only a small
difference in the frequencies of RT-specific CD4+ T cells (Figure 4.8A) for these two
heterologous prime boost vaccination regimens (Figure 4.8A). Thus the RT-specific CD4+ T
cells induced by the rMVA-Grttn prime/rLSDV-Grttn boost have a higher capacity to produce
IFN-γ per cell than the RT-specific CD4+ T cells induced by the rLSDV-Grttn prime/rMVA-
Grttn boost.











Figure 4.9 IFN-γ produced by Gag- and RT-specific CD8+ and CD4+ T cells during culture. Splenocytes was
harvested from mice vaccinated with the indicated regimens and described in Figure 4.6, and pooled from 5 mice
per group. They were then cultured in the absence of peptide (medium), an irrelevant peptide or with the individual
Gag- and RT-specific CD8+ and CD4+ T cell peptides for 48 h. Culture supernatants were collected and the level of
IFN-γ released into the medium (pg /106 splenocytes) was measured using a Cytokine Bead Array assay and flow
cytometric analysis.  A) IFN-γ level in the splenocyte culture medium. The individual bars represent the magnitude
of the IFN-γ level in the medium of splenocyte of vaccinated mice, cultured with individual peptides B) Magnitude
of positive IFN-γ produced in the culture medium. The level of IFN-γ in the culture medium was considered
positive when the level is higher than the IFN-γ level in medium of splenocytes cultured in the absence of peptide.
The individual bars represent the magnitude of the IFN-γ level in the medium of splenocyte of vaccinated mice,
cultured with individual peptides, after subtracting the IFN-γ level in medium of splenocytes cultured in the
absence of peptide from it. C) Cumulative proportions of positive Gag- and RT-specific CD4+ and CD8+ T cell
IFN- levels.  Individual bars represent the cumulative positive IFN-γ levels in the culture medium of splenocytes
of vaccinated mice. The contributions due to different peptide stimulations are colour coded as indicated.
4.6 Phenotype of Pentamer-positive HIV-1-specific CD8+ T cells Induced by
rLSDV-Grttn and rMVA-Grttn Vaccination Regimens
Total Gag- and RT- specific CD8+ T cells induced in the spleens of mice by the rLSDV-Grttn
prime/ rMVA-Grttn boost regimen and the reverse prime/ boost vaccination regimen were
enumerated. CD8+ T cells in the spleens of vaccinated mice that bound either a H-2Dk MHC class
I pentamer folded with the Gag CD8 peptide (AMQMLKDTI) or the RT CD8 peptide
(VYYDPSKDLIA) were analysed as a percentage of total CD8+ T cells by flow cytometry.
Expression of CD44 on these pentamer+ CD8+ T cells was also evaluated. For these studies mice










Figure 4.10 BALB/c mouse inoculation and sacrifice schedules to investigate phenotype of HIV-specific CD8+ T
cells induced by the vaccination regimens and investigate the effect of foetal calf serum on background responses in
the IFN-γ ELISPOT assay.
Flow cytometric analysis indicated that both vaccination regimens induced high frequencies of
HIV-specific CD8+ T cells while vaccination with wild-type virus induced low unspecific Gag
and RT pentameric complex binding of 0.5% and 0.7% of CD8+ T cells respectively (Figure
4.11A). The sum of Gag- and RT-specific CD8+ T cells was 6.9% of the total CD8+ T cells for
rLSDV-Grttn prime/ rMVA-Grttn boost vaccination regimen. This frequency was 4.6% of the
gated CD8+ T cells with the reverse vaccination regimen. For both regimens approximately 98%
of these HIV-specific CD8+ T cells expressed CD44 confirming these T cells to be antigen
experienced.
Figure 4.11.Expression of CD44 on Gag- and RT-specific CD8+ T cells. Mice were vaccinated as indicated and
according to the schedule described in Figure 4.10. At sacrifice splenocytes were pooled from 5 mice per group.
Vaccine elicited Gag- and RT- specific CD8+ T cells in the splenocyte population were detected by binding of a H-
2Dk MHC class I pentamer folded with either the Gag CD8 peptide (AMQMLKDTI) or the RT CD8 peptide
(VYYDPSKDLIA) to CD8+ T cells using flow cytometry. A) Data presented as the percentage of gated CD8+ T
cells that bound the pentamer B) Percentage of pentamer+/CD8+ T cells that expressed CD44 in the











4.7 Expression of Degranulation Marker CD107a/b on HIV-1 specific CD8+ T
cells
The expression of CD107a/b on the HIV-1 specific CD8+ T cells induced by the rLSDV-Grttn
prime/ rMVA-Grttn boost regimen and the reverse vaccination regimen in BALB/C mice was
evaluated as a further functional characteristic of these CD8+ T cells. The splenocytes from each
group of mice vaccinated as indicated in Figure 4.10 were stimulated with either Gag or RT
CD8 peptides or left unstimulated. Flow cytometry was used to enumerate the Gag- and RT-
specific CD8+ T cells that bound the H-2Dk MHC class I pentamer folded with either the Gag or
the RT CD8 peptide and then expression of CD107a/b on these pentamer+ CD8+ T cells .
Stimulation of splenocytes with Gag or RT CD8 peptides had no or little effect on the frequency
of H-2Dk MHC class I pentamer binding (Figure 4.12) and confirmed the high frequency of
HIV-1 specific CD8+ T cells induced by rLSDV-Grttn prime/ rMVA-Grttn boost regimen and
the reverse regimen as shown in Figure 4.11A and 4.11B. Also as previously found vaccination
with wild-type virus did not induce HIV-1 specific CD8+ T cells (Figure 4.11A). For both
vaccination regimens a high percentage (>61%) of these HIV-specific pentamer+ CD8+ T cells
were found to express CD107a/b after stimulation (Figure 4.12C and 4.12D). However, a large
percentage of the unstimulated HIV-1 specific CD8+ T cells from both regimens were also
positive for CD107a/b (57.2%-75.8%) (Figure 4.12C and 4.12D), indicating a large percentage
of these HIV-1 specific CD8+ T cells ex vivo may express CD107a/b before stimulation.
Alternatively, there is non-specific expression of this marker during culture in medium alone. To
address this, the experiment should have included the analysis of CD107a/b expression on the
splenocytes before the six hour peptide stimulation (time zero control).
4.8 Role of Foetal Bovine Serum on Background Responses in the IFN-γ
ELISPOT Assay
Background responses in the IFN-γ and IL-2 ELISPOT assays were abnormally high (Figure 4.4
and 4.7) for splenocytes from mice vaccinated with either wtLSDV or rLSDV-Grttn. There is a
possibility that these responses are a result of responses to components of the foetal bovine
serum in the culture medium used in the assays. This was investigated by performing the assays
in a serum free medium (SFM; CTL TESTTM medium, see Chapter 2 Methods and materials).
Splenocytes from mice vaccinated as indicated in Figure 4.10 were used in an IFN-γ ELISPOT











Figure 4.12. Expression of CD107a/b on Gag- and RT-specific CD8+ T cells. Mice were vaccinated as indicated
and according to the schedule described in Figure 4.10. At sacrifice splenocytes were pooled from 5 mice per group
then stimulated with either Gag or RT CD8 peptides or left unstimulated. A and B: Flow cytometry analysis if Gag-
and RT- specific CD8+ T cells binding of H-2Dk MHC class I pentamers folded with either the Gag CD8 peptide
(AMQMLKDTI) or the RT CD8 peptide (VYYDPSKDLIA). Data is presented as the percentage of gated CD8+ T
cells that bound the pentamer. C and D: Percentage of pentamer+/CD8+ T cells that expressed CD107a/b in the
pentamer+/CD8+ T cell gate.
Background responses in the IFN-γ ELISPOT assay for splenocytes in R10 for this set of
experiments (Figure 4.13) were 2.4 fold lower (rLSDV-Grttn primed/ rMVA-Grttn regimen) or
5.4 fold lower (rMVA-Grttn primed/ rLSDV-Grttn regimen) than reported in the previous IFN-γ
assays (see Figure 4.4 or 4.7). However, these background responses of 41-92 SFU/106
splenocytes obtained in this experiment are still considered higher than the background
responses for vaccination regimens where LSDV in not administered.  In the IFN-γ ELISPOT
assays with SFM, the background responses were found to range from 1-9 SFU/106 splenocytes
which is 10-41 fold reduced from that obtained in the IFN-γ ELISPOT with R10 (Figure 4.13).
However the Gag- and RT- specific IFN-γ ELISPOT responses to both poxvirus prime boost
regimens for the assay with R10 and SFM were comparable. This may suggest that the












Figure 4.13 Comparison of IFN-γ ELISPOT assays in R10 and SFM. Mice were vaccinated as indicated and
according to the schedule described in Figure 4.10. At sacrifice splenocytes were pooled from 5 mice per group
then used in an IFN-γ ELISPOT assay with either R10 culture medium or SFM as indicated without peptides
(medium) or the indicated HIV-1 Gag and RT CD8+ and CD4+ T cell peptides. Bars are the mean number of spots
of triplicate reactions in medium only (background) or to an individual peptide for 106 splenocytes with indicated
standard deviation (SD) of the mean.
4.9 Comparison of the Frequency of HIV-1 specific CD8+ T Cells Detected in
the IFN-γ ELISPOT Assay and by Pentameric H-2Dk Peptide Complex
Binding to HIV-specific CD8+ T Cells
The frequencies of Gag- and RT-specific CD8+ T cells detected in the IFN-γ ELISPOT assay
performed in SFM (Figure 4.13) were calculated as a percentage of the total CD8+ T cell
population in the spleen (Table 4.1). These figures were then compared with the percentage of
HIV-specific CD8+ T cells obtained using pentameric H-2Dk peptide complex binding (Table
4.1 and see Figure 4.11). For the rLSDV-Grttn prime/ rMVA-Grttn boost regimen the percentage
of Gag- or RT-specific CD8+ T cells detected in the IFN-γ ELISPOT assay was calculated to be
0.57% and 1.23% of the CD8+ T cell population in spleen respectively (Table 4.1). These
figures for the reverse regimen were calculated to be 0.73% and 0.68% of the CD8+ T cell
population in the spleen (Table 4.1). When this data is compared to the data obtained using
pentameric H-2Dk peptide complex binding to enumerate these HIV-specific CD8+ T cells it











Table 4.1 Comparison of frequencies of Gag- and RT- specific CD8+ T cells detected by IFN-γ ELISPOT or
pentameric H-2Dk peptide complex binding. Mice were vaccinated as indicated and according to the schedule
described in Figure 4.10. At sacrifice splenocytes were pooled from 5 mice per group. CD8+ T cells in the
splenocyte population was determined by flow cytometry and presented as percentage gated lymphocytes. Vaccine
elicited Gag- and RT- specific CD8+ T cells in the splenocyte population were detected using an IFN-γ ELISPOT
assay and data presented as SFU/106 splenocytes. Gag- and RT- specific CD8+ T cells in the splenocyte population
were also detected using binding of H-2Dk MHC class I pentamers folded with either the Gag CD8 peptide
(AMQMLKDTI) or the RT CD8 peptide (VYYDPSKDLIA) to CD8+ T cells and data is presented as the
percentage of gated CD8+ T cells that bound the pentamer as measured by flow cytometry.
4.10 Antibody Responses Induced by the Vaccination Regimens
The HIV-1 specific antibody responses induced by the various single and prime/boost
vaccination regimens as indicated in Figure 4.3 and 4.6 were evaluated using New LAV Blot I
Assay. BALB/C mice were pre-bled to determine background antibodies then at the end of the
experiment before spleens were harvested.
Figure 4.14 shows the sera incubated test strips of single and DNA prime /poxvirus boost
regimens. DNA prime/ rMVA-Grttn boost regimen elicited weak antibody response for Gag
(p25). No detectable HIV-1 specific antibody was induced by the other vaccination regimens.
Nonspecific antibodies binding to the test strip (position slightly above p68) were induced by































rLSDV+rMVA Gag 13.5 135000 765 765/135000 =
0.57%
1.19%
rLSDV+rMVA RT 13.5 135000 1663 1663/135000
= 1.23%
5.74%
rMVA+rLSDV Gag 13.8 138000 1014 1014/138000
= 0.73%
1.20%













Figure 4.14 HIV-1 specific antibody in sera of mice vaccinated with single vaccines or DNA prime/boost
vaccination regimens indicated in the Figure 4.3. On Day 40, sera were pooled from five mice per group. Sera
obtained from the prebleed prior vaccination was included as negative control. The presence of HIV-1 antibody in
these sera was detected using LAV Blot assay.
Figure 4.15 shows the sera incubated test strips of homologous and heterologous poxvirus prime
/poxvirus boost regimens. In the homologous poxvirus prime/poxvirus boost regimens, rLSDV-
Grttn prime/ rLSDV-Grttn boost regimen elicited antibody response for Gag (p55). rMVA-Grttn
prime/ rMVA-Grttn boost  regimen elicited antibody response for two Gag proteins (p55 and
p25).  In heterologous poxvirus prime/boost regimens, both rLSDV-Grttn prime/ rMVA-Grttn
boost and rMVA-Grttn prime/ rLSDV-Grttn boost elicited antibody response to two Gag protein
(p55 and p25), with relatively higher antibody responses (intensity of the band on test strips)
compared to responses induced by homologous poxviruses. The non-specific antibodies binding












Figure 4.15 HIV-1 specific antibody in sera of mice vaccinated with single or poxviruses prime/boost vaccination
regimens indicated in Figure 4.6. On day 40 sera were pooled from five mice per group. Sera obtained from the
prebleed prior vaccination was included as negative control. The presence of HIV-1 antibody in these sera was
detected using  New LAV Blot Assay.
4.11 Discussion
The present study evaluated the safety of the Neethling strain of LSDV and the immunogenicity
of rLSDV-Grttn. It has shown wtLSDV to be safe in two strains of immunocompromised mice
with different immunodeficiency phenotypes. Similar evaluations of safety have been
demonstrated for other poxvirus vectors, such as MVA in SCID mice (Hanke et al., 2005; Wyatt
et al., 2004). MVA, inoculated into SCID mice up to a dose of 1 x 109 pfu, did not induce weight
loss or other adverse effects (Wyatt et al., 2004). Due to the limited ability of LSDV to be grown
to high titres, it was not possible to use the equivalent dose of LSDV. Nevertheless, doses of 1 x
104 and 1 x 106 ffu of LSDV was not adverse to the well being of the mice and did not induce
significant changes in weight compared to naive mice and PBS inoculated mice. This
demonstrated that the vector is not pathogenic in these immunocompromised mice and suggests
that the vector would be safe in immunocompromised humans, although further non-human
primate and human clinical safety trials would be required to confirm this.











and compared to the immunogenicity of rMVA-Grttn. In addition rLSDV-Grttn was evaluated in
a DNA prime/poxvirus boost regimen and compared to the DNA prime/MVA boost regimen,
which has been regimens extensively evaluated in different pre-clinical studies and ongoing
clinical trials (Brave et al., 2007; Burgers et al., 2009; Goonetilleke et al., 2006;
Gudmundsdotter et al., 2009; Guimaraes-Walker et al., 2008; Hanke et al., 2007; Sandstrom et
al., 2008). rLSDV-Grttn was also evaluated in heterologous prime/boost vaccination regimens
with rMVA-Grttn to determine whether the dual poxvirus regimens were more efficacious than
the DNA prime/ poxvirus boost regimens.
In this study we found that a single vaccination of 106 ffu of rLSDV-Grttn alone in mice was
able to induce weak HIV-1 specific cellular responses in mice. A weak RT-specific CD8+ IFN-γ
response and a weak CD4+ IL-2 response was elicited in rLSDV-Grttn vaccinated mice. In
comparison, the same dose of rMVA-Grttn elicited broader and higher cellular immune
responses compared to rLSDV-Grttn. Both RT- and Gag- specific IFN-γ responses were elicited
in CD8+ and CD4+ T cells as well as IL-2 responses in CD4+ T cells. The DNA prime/poxvirus
boost regimens resulted in improved immunogenicity compared to the single poxvirus
vaccination regimens, as anticipated from the results of others (Hanke et al., 2007; Im et al.,
2006; Shephard et al., 2008). The cellular immune responses to the DNA prime were below the
detection limit. A boost with rLSDV-Grttn induced a cumulative RT-specific IFN-γ response
(607 net SFU/106 splenocytes) four times higher than that elicited by rLSDV-Grttn alone.
However, the DNA/ rLSDV-Grttn regimen did not show any improved cellular immunogenicity
over the DNA/ rMVA-Grttn regimen, which induced both Gag- and RT-specific IFN-γ responses
with a cumulative IFN-γ response of 1529 net SFU/106 splenocytes and a cumulative IL-2
response of 245 net SFU/106 splenocytes.
Although the results of the present study suggest rMVA-Grttn induces superior immune
responses to rLSDV-Grttn when used with a DNA prime, when rLSDV-Grttn and rMVA-Grttn
were used in combination with one another in prime and boost vaccination regimens the
magnitude of the cellular immune response was higher than that elicited by the DNA
prime/rMVA-Grttn boost regimen. This was concluded from the finding that rLSDV-Grttn
prime/rMVA-Grttn boost and the reverse regimen (rMVA-Grttn prime/rLSDV-Grttn boost)
elicited cumulative Gag- and RT-specific IFN-γ responses that were, respectively, 2.0 and 1.7
times higher than those of the DNA prime/rMVA-Grttn regimen. For the induction of IL-2
secreting cells, rLSDV-Grttn prime/rMVA-Grttn boost and the reverse regimen (rMVA-Grttn










respectively, 1.8 and 3.1 times higher than the cumulative Gag- and RT-specific IL-2 responses
elicited by DNA prime/rMVA-Grttn.
It was concerning that the presence of rLSDV-Grttn in the vaccination regimens induced high
non HIV-specific responses that could have contributed to the significantly better
immunogenicity elicited by heterologous poxvirus prime/boost regimens over the DNA
prime/rMVA-Grttn boost regimen. Since rLSDV-Grttn was propagated in bovine cells in the
presence foetal bovine serum, we hypothesized that the non-specific responses could have
resulted from mouse splenocytes responding to traces of bovine cellular molecules or foetal
bovine serum present in the rLSDV-Grttn inoculum. The parallel experiments comparing
ELISPOT assays done using foetal bovine serum containing medium (R10) and serum-free
nutrient defined medium certainly suggest some contribution of responses to foetal bovine to
high background responses as the high non-specific background responses observed in assays
using R10 medium were lower in assays carried out in the presence of serum-free media. We
have also shown in these parallel comparative experiments that, in the absence of high non-HIV
specific responses, using serum-free medium, Gag- and RT- specific IFN-γ responses elicited by
the rLSDV-Grttn prime/rMVA-Grttn boost and the reverse regimen did not diminish compared
to the parallel counterpart experiment using foetal bovine serum in the medium. This suggests
that the high immune responses elicited by the heterologous poxvirus prime/boost regimens
were not false positive responses due to the presence of high non-specific background responses.
Similar comparisons should be repeated for the DNA prime/ poxvirus boost regimens in order to
further confirm their immunogenicity; however, due to funding constraints, we could only repeat
the evaluation for the two most immunogenic regimens with the respective controls.
The comparisons between the different prime/ boost regimens evaluated in this study have
revealed that the heterologous poxvirus prime/boost regimens are more immunogenic than the
homologous poxvirus prime/boost regimens and the DNA prime/poxvirus boost regimens. The
breadth and magnitude of the HIV-specific IFN-γ and IL-2 ELISPOT responses were
comparable between the rLSDV-Grttn prime/rMVA-Grttn boost and the reverse regimen.
Further investigation into the cellular immune responses elicited by the two heterologous
prime/boost regimens revealed more detail and differences in their immunogenicity. The Gag-
and RT-Pentamer binding assay detected a RT dominant CD8+ T cell response elicited by
heterologous poxvirus prime-boost regimens, similar to the responses detected in IFN-γ
ELISPOT assays. However, the percentages of Gag- or RT-specific CD8+ T cells detected using
pentamer binding assays were 1.6-5 times higher than those of the HIV-specific CD8+ T cells
detected using IFN-γ ELISPOT assays (see Table 3.1).  Although the differences in the HIV-











indicate that the vaccination regimens elicited Gag and RT-specific CD8+ T cells, other than
IFN-γ producing CD8+ T cells. These may include other single or multiple cytokine producing
HIV-specific CD8+ T cells. Unfortunately, further investigation was hampered by funding
constraints. The evaluation of CD44 and CD107a/b expression on the surface of these Gag- and
RT-specific CD8+ T cells gave an indirect indication of the activation and functional status of
these cells. Over 98% of the Gag- or RT-specific CD8+ T cells elicited by the heterologous
poxvirus prime/boost regimens were antigen-experienced and activated (CD44 surface
expression). Over 70% of the Gag- or RT-specific CD8+ T cells elicited by the heterologous
poxvirus prime/boost regimens had the capacity for degranulation (CD107a/b surface
expression). An unexpected result was the lack of difference in surface expression of CD107a/b
on the (Gag or RT) peptide stimulated Gag- or RT-specific CD8+ T cells and the non-stimulated
Gag- or RT-specific CD8+ T cells. Further evaluation of the surface expression of CD107a/b on
these splenocytes before stimulation is required to determine the initial level of CD107a/b.
Again, this experiment was not repeated due to funding constraints. Although further
evaluations would confirm the activation and functional status of these HIV-1 specific CD8+ T
cells, the results from this study have given some insight into the potential activation and
functionality of these HIV-1 specific CD8 T cells elicited by the rLSDV-Grttn prime/ rMVA-
Grttn boost and the reverse regimen.
The use of different poxvirus vectors in prime/boost vaccination regimens have previously been
demonstrated to be effective vaccination strategies (Cottingham et al., 2006; Santra et al., 2007).
The order of the poxvirus vectors used in the prime/boost regimens affected the magnitude of
the responses (Cottingham et al., 2006). The observations made in the present study support the
published observations to a degree. Although the magnitude and breadth of the Gag- and RT-
specific cellular responses were comparable between the rLSDV-Grttn prime/ rMVA-Grttn boost
and the reverse regimen, there was a difference in the quality of the response with respect to the
level of IFN-γ production by the HIV-1 specific T cells in culture. The rMVA-Grttn
prime/rLSDV-Grttn boost regimen elicited RT-specific CD4+ T cells with a 2.7 times higher
capacity to produce IFN-γ compared to the RT-specific CD4+ T cells elicited by the reverse
regimen. This suggests that the rMVA-Grttn prime/ rLSDV-Grttn boost regimen may be more
immunogenic compared to the reverse regimen.
The association of non-neutralizing antibodies with the cellular immune response, through
mechanisms such as complement binding to Fc receptors, has been highlighted in several studies











2008). Although HIV-1 envelope protein was not included in the rLSDV-Grttn vaccine, antibody
specific to Grttn, or parts thereof, may be important in mediating HIV-1 specific cellular effector
responses. We have demonstrated in this study that the rLSDV-Grttn prime/rMVA-Grttn boost
regimen and the reverse regimen were able to induce Gag-specific antibody production.
In conclusion, the immunogenicity evaluation of rLSDV-Grttn in this study has revealed that
rLSDV-Grttn has the potential to be used in heterologous poxvirus prime/boost regimens to
induce a high magnitude and breadth of cellular immune responses, with the induction of
surface molecules associated with immune cell activation and function. HIV-1 capsid protein-
specific antibody was also produced. The rMVA-Grttn prime/rLSDV-Grttn boost regimen may
be the better regimen due to the higher cytokine production per splenocyte induced by the
regimen. The immunogenicity of the vaccination regimens should be further characterized to











Chapter 5: Final Discussion
The present study has evaluated LSDV as a potential vaccine vector for delivering HIV-1
antigens. We have demonstrated the Neethling strain of LSDV to be a safe, non-pathogenic live
viral vector in mice with immunodeficiency phenotypes. LSDV did not induce any mortality,
weight loss or other adverse effects in these immunocompromised mice. The non-pathogenicity
of the virus in immunodeficient mice was not surprising when considering previous in vitro
studies which showed that LSDV is replication-deficient in mammalian cells (Aspden et al.,
2003) and the fact that the host-restricted MVA is non-pathogenic in immunocompromised mice
(Wyatt et al., 2004). Our observations suggest that LSDV could be safely deployed in
immunocompromised individuals in the event of large scale vaccination or as a therapeutic
vaccine vector. Although further pre-clinical and clinical evaluations of LSDV in non-human
primates and humans are needed to confirm the safety of the vector in populations comprising a
high percentage of HIV-1 infected individuals, the encouraging pre-clinical safety data observed
in this study does provide the motivation for further evaluation and development of LSDV as a
vaccine vector.
The development of an effective HIV-1 vaccine is essential and a matter of urgency. It would be
ideal to develop a universal HIV-1 vaccine that is effective in preventing infections of all the
circulating HIV-1 strains in the world. However, the development of such a vaccine has proved
to be very challenging due to the hypervariability of HIV-1(Burton et al., 2004). It would be a
more realistic goal to develop a HIV-1 vaccine that does not completely prevent infection but
slows down the disease progression and minimises the chance of secondary infections. It is
within our reach to develop such a vaccine that targets the most prevalent strain in a specific
region to effectively control the epidemic in that region. rLSDV-Grttn constructed in this study
was based on such a hypothesis. HIV-1 subtype C Gag, RT, Tat and Nef were used in the
construction of Grttn (Burgers et al., 2006; Williamson et al., 2003), to produce a vaccine
construct that specifically targets the HIV-1 subtype C strain that is currently the prevalent HIV-
1 strain in Southern Africa. The vaccine antigens were selected to generate a broad HIV-1
specific cellular immune response. Gag-specific cellular immunity has been shown to correlate
with slower disease progression in infected individuals (Pereyra et al., 2008). Although immune
responses to HIV-l regulatory proteins, such as Tat and Nef were not evaluated in this study, Tat
and Nef were included in the vaccine antigen design to broaden the HIV-1 specific responses
induced by the rLSDV-Grttn. Highly variable envelope proteins were excluded from the antigen











In this study a recombinant LSDV that expresses HIV-1 subtype C polyprotein Grttn (rLSDV-
Grttn) was constructed. Stable expression of HIV-1 Grttn was detected from rLSDV-Grttn which
was passaged 17 times.
As mentioned in the first chapter, DNA prime/poxvirus boost vaccination regimens, especially
with MVA as a boost vaccination can induce high magnitudes of HIV-1 specific cellular
immunity (Abaitua et al., 2006; Amara et al., 2002; Brave et al., 2007; Burgers et al., 2009;
Gherardi et al., 2004; Hanke et al., 2007; Smith et al., 2004). However, results from the STEP
trial have highlighted the significance of pre-immunity to the Adenovirus vaccine vector and its
possible negative effect on the effectiveness of the vaccine regimen (Corey et al., 2009;
McElrath et al., 2008). Vaccination of individuals with pre-immunity to Adenovirus-5 vector
increased their risk of infection with HIV-1 (Corey et al., 2009; McElrath et al., 2008). Whether
pre-immunity to MVA/VV causes the equivalent increase in HIV-1 infection post recombinant
MVA vaccination is not known. There is a significant portion of the population with pre-
immunity to vaccinia virus or MVA, which could pose a potential problem to using MVA as a
vector if pre-immunity is a problem. Nevertheless, there is a high probability that, with all of its
advantages, MVA will be used in the future as a vector for a vaccine against an infectious
disease or cancer. LSDV, which does not cross-react immunologically with MVA, could serve as
an alternative vector. In this particular study, although rLSDV-Grttn was effective in boosting
the HIV-1 specific immune response in the DNA prime/ rLSDV-Grttn boost vaccination regimen,
rLSDV-Grttn failed to demonstrate superior immunogenicity to rMVA-Grttn in the comparative
DNA prime/ rMVA-Grttn boost vaccination regimen. rLSDV-Grttn was, however, shown to be
highly immunogenic when used in heterologous poxvirus prime/boost vaccination regimens
with rMVA-Grttn. rLSDV-Grttn prime/ rMVA-Grttn boost and the reverse regimen induced 1.6-
3.1 times higher magnitudes of HIV-1 Gag- and RT- specific immune responses compared to the
DNA prime /rMVA-Grttn boost regimen. Both HIV-1 Gag- and RT-specific CD4+ and CD8+ T
cell responses were induced by these vaccination regimens in mice. The HIV-1 specific
cytotoxic CD8+ T cell response has been shown to correlate with the control of HIV-1 viraemia
(Koup et al., 1994; Miura et al., 2009; Pereyra et al., 2008).  CD4+ T cell responses are
essential in the production of effector and memory CD8+ T cell responses (Bevan, 2004; Sun et
al., 2004). Further evaluation in this study on the quality of the HIV-1 Gag and RT specific
CD8+ T cell responses induced by these regimens indirectly demonstrated the activated,
antigen-experienced status and cytolytic functional status by the presence of correlative surface
molecules (CD44 and CD107a/b respectively) on these CD8+ T cells. HIV-1 Gag-specific











Preliminary evaluation of rLSDV-Grttn in a heterologous prime/boost vaccination regimen with
SAAVI MVA-C in non-human primates has been carried out by Dr Wendy Burgers and Dr
Gerald Chege in our department (unpublished results). Five rhesus macaques were vaccinated
twice with recombinant MVA based vaccine, SAAVI MVA-C (Burgers et al., 2008; Shephard et
al., 2008) expressing HIV-1 subtype C Grttn and envelope. After the priming of these animals
with SAAVI-MVA-C two out of five macaques developed moderate IFN-γ ELISPOT responses
directed to single HIV-1 genes. Sixty-six weeks after the second SAAVI-MVA prime macaques
were boosted with a single dose of 1 x 106 ffu of rLSDV-Grttn. rLSDV-Grttn was able to boost
HIV-1 specific IFN-γ ELISPOT responses in four out of five animals even though 3 of them had
undetectable HIV-1 IFN-γ ELISPOT responses after two inoculations of SAAVI-MVA-C.
Overall, both the magnitude and breadth of the IFN-γ ELISPOT responses were improved with
rLSDV-Grttn boosting.
Figure 5.1 Cumulative HIV-1 specific IFN-γ ELISPOT responses of SAAVI-MVA-C prime/rLSDV-Grttn boost
vaccination regimen in rhesus macaques. This figure shows responses after 2 inoculations of SAAVI-MVA-C
priming (Post MVA) and those after a rLSDV-Grttn boost 66 weeks later (Post LSDV).
These observations, together with the mouse immunogenicity data demonstrate that
heterologous prime/boost vaccination regimens using rLSDV-Grttn and rMVA-Grttn are
promising potential vaccination regimens to use for the induction of potent HIV-1 specific
cellular immune responses. Similar observations on the effectiveness of heterologous poxvirus






















prime/boost vaccination regimens in inducing HIV-1 specific cellular immunity have been
reported using fowlpoxvirus, MVA and vaccinia virus (Cottingham et al., 2006; Ranasinghe et
al., 2006; Santra et al., 2007).
The promising rMVA-Grttn prime/rLSDV-Grttn boost immunogenicity results in mice and non-
human primates suggest that future LSDV based HIV-1 vaccine candidates could be integrated
into existing prime-boost vaccination regimens. A vaccination regimen comprised of three
different vaccine vectors expressing a common antigen has been shown to induce potent and
long-lasting antigen-specific CD8+ T cells, especially CD8+ effector memory T cells (Masopust,
2009; Vezys et al., 2009). The study deployed vesicular stomatitis virus (VSV) New Jersey
strain, vaccinia virus and VSV Indiana strain in the regimen. The regimen induced antigen
specific CD8+ T cells that comprised 90% of the circulating CD8+ T cells. More than 60% of
the antigen-specific CD8+ T cells were retained 150 days post last vaccination (Masopust, 2009;
Vezys et al., 2009). However, a contrasting observation has been made by Vuola et al (2005) in
an evaluation of a malaria vaccine. This study showed that the regimen comprised of DNA,
MVA and fowlpox virus did not elicit an improved immune response in humans compared to
the dual regimens of DNA prime/ MVA boost and fowlpox virus prime/MVA boost (Vuola et al.,
2005). Currently the prime and boost regimen with SAAVI-DNA-C and SAAVI-MVA-C
((Burgers et al., 2008; Burgers et al., 2009; Shephard et al., 2008) is being evaluated in phase I
clinical trials (HVTN 073). Both of the vaccine vectors in this trial were engineered to express
HIV-1 subtype C Grttn and envelope protein. rLSDV-Grttn could be incorporated into this
existing vaccination regimen as a third vaccine to potentially improve the immunogenicity of the
present dual prime-boost regimen and induce a further broadening of the T cell repertoire. In the
light of the recent promising preliminary results of the RV144 trial (Berkhout & Paxton, 2009),
the importance of HIV-1 envelope protein in the protective efficacy against HIV-1 infection was
emphasized. rLSDV-Grttn would need to be engineered further to incorporate the identical HIV-
1 subtype C envelope gene to that of the HVTN 073 vaccines before it could be evaluated in a
three vector prime-boost-boost vaccination regimen.
One of the concerns of using LSDV as a vaccine vector is that it has been passaged extensively
in cells of bovine origin with bovine serum. Our immunogenicity data suggests that these
products may be problematic and mice seem to develop responses to them which interfere in the
assays used to measure specific responses. However most live attenuated viral vaccines are not
purified extensively and would likely exhibit the same problems.  For example the smallpox
virus vaccine was made on cattle or sheep with limited purification.  MVA based vaccines are











the prions associated with transmissible spongiform encephalopathies (TSEs) which are fatal
neurodegenerative disorders (Yokoyama & Mohri, 2008). However the risk may be extremely
low because there are stocks of LSDV vaccine which predate 1985 and BSE has not been
reported in South Africa. Of importance there are a number of approaches that can be
considered to reduce this risk. One of these involves cloning the poxviral DNA into a bacterium
and then grow the vaccine in eggs or even better in a cell line which has a low risk of prion
contamination.  The second is to do extensive passages in such a cell line. The third is to harvest
poxviral DNA and to rescue the DNA with another poxvirus after transfection into an acceptable
cell line. The growth of LSDV in eggs was not investigated in this thesis. This would be worth
investigating in the future.
However we can confidently conclude from the data presented that we have proved the
hypothesis that LSDV has the potential to be a novel HIV-1 vaccine vector. It is safe in
immunocompromised settings and rLSDV-Grttn has been demonstrated to be immunogenic in
mice, especially in combination with rMVA-Grttn in prime-boost vaccination strategies. These
observations provide motivation for the further optimization of LSDV virus production and the
development of improved recombinant LSDV HIV-1 vaccines. Ultimately, it is conceivable that
LSDV could be used in combination with other vectors as part of a dual or multi vaccine
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